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CHAPTER 1: INTRODUCTION 
 
1.1 General Introduction 
  The  sanglifehrins  (Figure  1.1),  a  novel  class  of  macrolides,  were  initially 
discovered in a soil sample from Dembo-Bridge in Malawi by scientists at Novartis
1 in 
1997. Produced by Streptomyces sp A92-308110, sanglifehrins, especially sanglifehrin 
A (SFA, 1), possess impressive biological properties.
2, 3 These include strong binding 
to  cyclophilin  A  (CypA)  which  leads  to  inhibition  of  both  B-cell  and  T-cell 
proliferation. 
  The  structures  of  sanglifehrins  A-D  have  been  fully  elucidated  by 
spectroscopic  and  X-ray  crystallographic  techniques
4  and  are  shown  in  Figure  1.1. 
Key  features  of  sanglifehrins  include  a  novel,  highly  substituted  [5,5]spirolactam 
moiety and a 22-membered macrocycle containing a peptidic backbone characterized 
by an unusual β−substituted (S)-piperazic acid and a (S)-m-hydroxyphenylalanine unit. 
Sanglifehrin  A  (SFA,  1)  is  the  most  abundant  natural  product  from  this 
microbial strain and has the highest affinity for cyclophilins A, B and C. Its capacity 
for  inhibiting  mitogen-induced  B-cell  proliferation  without  influencing  T-cell 
receptor-mediated cytokine production is also notable.
5 The striking properties of SFA 
have  attracted  the  interest  of  many  research  groups.  Thus,  the  first  synthesis  was 
achieved by Nicolaou
6 and coworkers in 1999 and a second synthesis was completed 
by the Paquette
7 research team in 2002.   
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Figure 1.1 Sanglifehrins A-D 
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1.2 Isolation and Structural Assignment to Sanglifehrins 
  The sanglifehrins were found during screening of actinomycete strains with a 
cyclophilin-binding assay.
2 They were isolated and purified by extraction and several 
chromatographic,  activity-guided  steps.  The  chemical  structure  and  absolute 
configuration  of  sanglifehrins  A,  B,  C,  and  D  were  determined  unambiguously  by 
NMR  techniques  and  by  X-ray  crystallography  of  the  complex  formed  with 
cyclophilin A.
4 Sanglifegrins A and B are true natural products according to analytical 
HPLC  survey  during  the  fermentation  process,  whereas  sanglifehrins  C  and  D  are 
artifacts  formed  from  sanglifehrin  A  and  B,  respectively,  during  isolation  in  the 
presence of methanol.  
  The molecular formulas of the sanglifehrins were established by FAB-MS and 
elemental  analysis  to  be  C60H91N5O13  (m/z  1096,  [M+Li]
+)  for  sanglifehrin  A, 
C60H89N5O12 (m/z 1078, [M+Li]
+) for B, C61H93N5O13 (m/z 1110, [M+Li]
+) for C, and 
C61H91N5O12  (m/z  1092,  [M+Li]
+)  for  D.  The  UV  and  IR  spectra  of  the  four 
compounds  resembled  each  other,  suggesting  their  structural  similarity.  The 
characteristic, strong absorption band in the IR spectra of sanglifehrins at 1645 – 1650 
cm
-1 indicated the presence of several amide linkages. NMR data collected by Fehr 
and  co-workers  revealed  that  the  sanglifehrins  were  constituted  of  three  main 
segments,  specifically  a  22  membered  macrolide  (C1-C23),  a  linker  subunit (C24-
C32), and a unique spirolactam system (C33-N42) (Figure 1.2).   
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Figure 1.2 Carbon numbering of sanglifehrins A-D 
A tripeptide embedded in the macrolide consisting of valine, m-tyrosine, and 
1,2-piperazine-3-carboxylic acid was recognized using sequential NOE’s. An inverse 
1H-
15N-HSQC experiment confirmed the presence of the hydrazide group of the 1,2-
piperazine-3-carboxylic  acid  moiety  from  the 
15N  shift  of  NH-6′  to  high  field  (83 
ppm); all other NH’s have typical amide chemical shifts in the range 115-130 ppm. 
The disappearance of the C15-OH proton and an upfield shift of C53 from 208.1 to 
98.6 ppm, along with the presence of methoxy methyl protons at C65, established that 
cyclic ketal formation had occurred in sanglifehrins C and D.  
The C24-C32 linker connecting the macrolide with the spirolactam system was 
shown to contain a methyl-substituted conjugated (E,E)-diene and an aliphatic portion  
 
5 
 
(C28-C32)  which  bears  vicinal  methyl  and  hydroxyl  substituents  (C30  and  C31, 
respectively). This linker unit appears in all four sanglifehrins. 
The spirolactam subunit was shown to consist of two 6-membered rings fused 
at  C37;  this  carbon  signal  appeared  at  86.9  ppm  in  the 
13C-NMR  spectrum  of 
sanglifehrin A. One of these spiro fused rings is a tetrahydropyran and the other is a δ-
lactam. Sanglifehrins A and C have the tetrahydropyran ring of the spirolactam in a 
chair conformation with two equatorial methyl groups and an axial OH group, whereas 
the corresponding ring in sanglifehrins B and D possesses a C35-C36 double bond 
which probably arises from dehydration of the C35 hydroxyl of sanglifehrins A and C, 
respectively.  It  was  shown  that  the  lactam  ring  in  SFA  is  in  a  boat  conformation 
presumably to allow the methyl group at C38 and the ethyl group at C40 to assume an 
equatorial orientation.  
The  absolute  configuration  of  sanglifehrin  A  was  confirmed  by  an  X-ray 
crystallographic  analysis  of  the  cyclophilin  A/sanglifehrin  A  complex  at  1.6  Å 
resolution. The absolute configurations of sanglifehrins B, C, and D were deduced by 
spectroscopic and chemical correlation with sanglifehrin A. 
1.3 Biological Activity of the Sanglifehrins 
  Sanglifehrins  A  and  B  were  shown  to  bind  very  tightly  to  cyclophilin  A 
(CyPA).  Their  affinities  were  approximately  twenty  times  higher  than  that  of 
cyclosporine A (CsA).
2 Sanglifehrin A showed the strongest binding to cyclophilins  
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A,  B  and  C,  with  an  IC50  of  0.05-0.09  for  all  three  cyclophilins  (Table  1.1). 
Sanglifehrins C and D containing a cyclic acetal showed a more than 10-fold decrease 
in binding to CypA and possessed an affinity in the same range as that of CsA. 
Table 1.1 Relative IC50 values of sanglifehrins for binding to cyclophilins A, B and C 
 
Compound 
 
CYP-A  CYP-B  CYP-C 
 
Sanglifehrin A 
 
0.05±0.02  0.09±0.02  0.07±0.03 
Sanglifehrin B 
  0.05±0.01  0.56±0.23  0.12±0.03 
Sanglifehrin C 
  0.61±0.19  2.69±0.74  0.33±0.01 
Sanglifehrin D 
  0.71±0.14  2.63±0.62  0.62±0.03 
 
  The  immunosuppressive  activities  of  sanglifehrins  A,  B,  C  and  D  were 
assessed in two-way MLR (Mixed Lymphocyte Reaction) experiments. The results are 
shown in Table 1.2. Sanglifehrins A and B showed IC50 values of 170 nM and 102 
nM, respectively. Although both compounds showed affinity for cyclophilin A at a 
level 20-fold higher than that of CsA, their immunosuppressive activity in the MLR 
experiment was approximately 10-fold lower. 
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Table 1.2 Activity of sanglifehrins A, B, C and D and cyclosporine A in the murine 
mixed-lymphocyte reaction. 
 
 
Compound 
 
Mean IC50 [nM]
a  Relative IC50
b 
 
Sanglifehrin A 
 
170 ± 15  16 
Sanglifehrin B 
  102 ± 7  10 
Sanglifehrin C 
  1200 ± 104  113 
Sanglifehrin D 
  630 ± 87  60 
Cyclosporin A 
  10.6 ± 0.8  1 
a  Results  are  expressed  as  a  mean  ±  SEM  of  IC50  values  in  nM;  results  of  3∼4 
independent experiments. (SEM = Standard Error of Mean) 
b Ratio of the IC50 values of sanglifehrin and cyclosporine A 
1.4 References 
1.  Fehr, T.; Oberer, L.; Ouesniaux Ryffel, V.; Sanglier, J.-J.; Schuler, W.; 
Sedrani, R. Macrolides with immunosuppressant and antiinflammatory 
properties. 1997. 
 
2.  Sanglier, J. J.; Quesniaux, V.; Fehr, T.; Hofmann, H.; Mahnke, M.; Memmert, 
K.; Schuler, W.; Zenke, G.; Gschwind, L.; Maurer, C.; Schilling, W., J. 
Antibiot. 1999, 52 (5), 466-473. 
 
3.  Zhang, L. H.; Liu, J. O., Journal of Immunology 2001, 166 (9), 5611-5618. 
 
4.  Fehr, T.; Kallen, J.; Oberer, L.; Sanglier, J. J.; Schilling, W., J. Antibiot. 1999, 
52 (5), 474-479. 
 
5.  Cabrejas, L. M. M.; Rohrbach, S.; Wagner, D.; Kallen, J.; Zenke, G.; Wagner, 
J., Angew. Chem. Int. Ed. 1999, 38 (16), 2443-2446. 
 
6.  Nicolaou, K. C.; Murphy, F.; Barluenga, S.; Ohshima, T.; Wei, H.; Xu, J.; 
Gray, D. L. F.; Baudoin, O., J. Am. Chem. Soc. 2000, 122 (16), 3830-3838. 
 
7.  Paquette, L. A.; Duan, M. S.; Konetzki, I.; Kempmann, C., J. Am. Chem. Soc. 
2002, 124 (16), 4257-4270.  
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CHAPTER 2: PREVIOUS SYNTHETIC STUDIES OF 
SANGLIFEHRIN A 
 
  There have been two completed syntheses of sanglifehrin A to date. The first 
total synthesis was reported in 2000 by Nicolaou and coworkers, about three years 
after  its  isolation.
1  The  second  synthesis  was  published  in  2002  by  the  Paquette 
research  group.
2  Many  syntheses  of  fragments  of  sanglifehrin  A  have  also  been 
reported.
3-11 
2.1 Nicolaou’s Total Synthesis of Sanglifehrin A (2000) 
  2.1.1 Synthesis of the C13-C19 Acetylenic Ketal Portion 
  Nicolaou’s route to sanglifehrin A commenced with the synthesis of aldehyde 
14 as shown in Scheme 2.1. The known α,β-unsaturated ester 5
12 was converted to 
triisopropylsilyl ether 6 which was reduced with diisobutylaluminum hydride to give 
allylic alcohol 7. Epoxidation of allylic alcohol 7 with m-chloroperoxybenzoic acid 
furnished epoxide 8 in quantitative yield and good selectivity (β:α epoxide ratio ∼6:1). 
Regiospecific ring opening
13 of the epoxide with 3-butenylmagnesium bromide
14 in 
the presence of copper(I) iodide afforded olefinic diol 9, which was chemoselectively 
converted to the primary pivaloate 10. After removal of the triisopropylsilyl protecting 
group from 10 with tetra-n-butylammonium fluoride to give diol 11, Wacker oxidation 
of  the  terminal  alkene  followed  by  acid-induced  internal  ketalization  of  the 
intermediate methyl ketone provided ketal 12 in excellent yield. The benzyl protecting  
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group in 12 was removed by palladium-catalyzed hydrogenolysis to produce primary 
alcohol  13  which  was  oxidized  to  aldehyde  14  using  tetrapropylammonium 
perruthenate  in  the  presence  of  N-methylmorpholine-N-oxide.
15  Aldehyde  14  was 
subjected to homologation using Ohira-Bestmann reagent (15)
16 in the presence of 
potassium  carbonate  to  deliver  acetylenic  ketal  16.  The  pivaloate  group  was  also 
removed during this process when an excess of potassium carbonate was added. 
BnO
OR O
OEt BnO
OTIPS
OH
BnO
OTIPS
OH
O
BnO
TIPSO
OH
OH
BnO
RO
OPiv
OH
O
O
15
RO
PivO
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60 ºC, 95%
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O
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Scheme 2.1 Nicolaou’s synthesis of actylenic ketal 16 (32% yield, 11 steps)  
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  2.1.2 Alternative Synthesis of the C13-C19 Acetylenic Ketal 
  A subsequent synthesis of the C13-C19 acetylenic ketal 16 by Nicolaou and 
coworkers  which  had  the  advantage  of  one  less  step  but  no  increase  in  yield  is 
depicted  in  Scheme  2.2.  Subjection  of  propagylic  aldehyde  17
17  to  asymmetric 
crotylboration
18  with  18  gave  alcohol  19  which  was  protected  as  tert-
butyldimethylsilyl ether 20.  After  oxidative  cleavage of  alkene 20 with  ozone, the 
resulting  aldehyde  21  was  converted  to  α,β-unsaturated  ester  23  via  Horner-
Wadsworth-Emmons  olefination  with  phosphonate  22.  Reduction  of  ester  23  with 
diisobutylaluminum hydride furnished allylic alcohol 24 which was epoxidized with 
m-chloroperoxybenzoic  acid  to  give  epoxide  25  with  a  β:α  ratio  of  ∼79:21. 
Regioselective opening of 25 with Grignard reagent 26
19 gave diol 27 in which the 
primary  hydroxyl  group  was  protected  as  pivaloate  ester  28.  Removal  of  the  tert-
butyldimethylsilyl  group  from  28  with  hydrofluoric  acid  was  accompanied  by 
transketalization  and  furnished  ketal  29.  The  triethylsilyl  and  pivaloyl  protecting 
groups were removed  with potassium carbonate  to complete a  second sequence to 
alkyne 16.  
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Scheme 2.2 Nicolaou’s second synthesis of alkyne 16  
(25% yield, 10 steps) 
 
  2.1.3  Synthesis  of  the  Tripeptide  Fragment  44  via  Enantioselective 
Hydrogenation and Peptide Coupling 
  Nicolaou’s synthesis of tripeptide fragment 44 began with the stereoselective 
assembly of the intermediate dipeptide carboxylic acid derivative 36 as depicted in 
Scheme 2.3. Enantioselective hydrogenation of the α,β-dehydroamino acid derivative 
32  was  the  key  to  construction  of  the  stereocenter  at  C8.  Thus,  N-
benzyloxycarbonylglycine  phosphonate  31  was  condensed  with  m- 
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hydroxybenzaldehyde  (30)  in  the  presence  of  1,8-diazabicyclo[5.4.0]undec-7-ene  
(DBU) to provide (Z)-32 in excellent yield.
20 Ester 32 was subjected to asymmetric 
hydrogenation
21 in the presence of rhodium(I) catalyst to afford amino acid derivative 
33 with excellent enantiomeric excess and yield. The carbobenzyloxy protecting group 
in 33 was removed by palladium(0)-catalyzed hydrogenolysis to yield 34 which was 
coupled  with  N-(tert-butoxycarbonyl)-L-valine  in  the  presence  of  1-hydroxyl-7-
azabenzotriazole to give dipeptide derivative 35. Finally, hydrolysis of 35 by treatment 
with  lithium  hydroxide  furnished  dipeptide  carboxylic  acid  derivative  36  in  good 
yield. 
CHO
OH
OMe
(MeO)2P
NHCbz
O O
OH
NHCbz
O
MeO
OH
NHR
O
MeO
OH
H
N
O
RO
O
NHBoc
DBU, DCM
25 ºC, 90%
[(S,S)-Et-DuP-Rh]+TfO-
(0.7 mol%)
H2 (60 psi)
98%, ee 90%
33: R = Cbz
34: R = H
H2, 10% Pd/C
MeOH, 25 ºC, 96%
Boc-Val-OH
EDC, HOAt, DCM
0 ºC        25 ºC, 78%
35: R = Me
36: R = H
LiOH, THF/H2O
(3:1), 0        25 ºC, 78%
30
(31)
32
8 8
8
12
 
Scheme 2.3 Nicolaou’s synthesis of dipeptide 36 via enantioselective hydrogenation 
(52% yield, 5 steps) 
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  The next task was to prepare diiododiene 39 from known iodo aldehyde 37
22 as 
shown  in  Scheme  2.4.  A  chromium(II)-mediated  Takai  reaction
23  was  used  for 
stereoselective  introduction  of  the  C20-C21  (E)-vinyl  iodide,  after  which  the  tert-
butyldimethylsilyl ether at C23 of the resulting iodide 38 was unmasked with tetra-n-
butylammonium fluoride to produce secondary alcohol 39. Coupling of 39 with N,N,-
di-tert-butoxycarbonylpiperazic acid derivative 40
24 in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide and 4-pyrrolidinopyridine provided ester 41, from 
which  both  tert-butoxycarbonyl  groups  were  removed  upon  treatment  with 
trifluoroacetic  acid  to  afford  ester  42.  Regioselective  amide  formation  of  42  with 
dipeptide carboxylic acid derivative 36 in the presence of 1-ethyl-3-(3-dimethylamino 
propyl)carbodiimide and 1-hydroxyl-7-azabenzotriazole delivered tripeptide ester 43 
which was deprotected with trifluoroacetic acid to furnish tripeptide fragment 44. 
I O
OTBS
I
OR
I
NBoc
Boc
N HO2C
NR
R
N
O
O
I
I
H
N
O
O
NHR N
H
N
O
O
I
I
HO
CrCl2, CHI3
Dioxane/THF (9:1)
0        25 ºC, 57%
38: R = TBS
39: R = H
TBAF, THF
0        25 ºC, 88%
EDC, PPy, iPr2NEt
DCM, 0        25 ºC, 64%
41: R = Boc
42: R = H·CF3CO2H
TFA/DCM (1:1)
0        25 ºC
HOAt, iPr2NEt, EDC
DCM, 0        25 ºC
66% 2 steps
OH
H
N
O
HO
O
NHBoc
TFA:DCM (1:10)
0        25ºC
43: R = Boc
44: R = H
(36)
37
(40)
8
12
8
12
1
1
1
25
25 21
21
21
25
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Scheme 2.4 Nicolaou’s route to tripeptide fragment 44 (19% yield, 6 steps)  
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  2.1.4 Synthesis of the SFA Macrocyclic Core 48 via Intramolecular Stille 
Coupling 
  Nicolaou’s  synthesis  of  the  fully  functionalized  macrocyclic  core  of 
sanglifehrin A (1) commenced with the synthesis of vinylstannane 46 from alkyne 16 
in  three  steps  as  outlined  in  Scheme  2.5.  Thus,  alkyne  16  was  subjected  to 
palladium(0)-mediated  hydrostannylation
25  to  give  vinylstannane  45  which  was 
oxidized in two steps to carboxylic acid 46. Peptide coupling of 46 with tripeptide 44 
provided  the  precursor  47  for  macrocyclization.  Synthesis  of  macrocycle  48  was 
completed by treatment of 47 with a palladium(0) catalyst in the presence of Hunig’s 
base to give 48. 
I O
O O
N
NH O
NH
O HN
O
O
HO
I O
O O
N
NH O
NH
O HN
O
O
HO
I
Bu3Sn
O
O
HO
Bu3Sn
O
O
HO2C
19
13
15
Bu3Sn
O
O
19
15
HO
nBu3SnH, PdCl2(PhCN)2
P(o-tol)3, iPr2NEt, DCM
-20 ºC, 80%
1) TPAP, NMO, 4 A MS
    DCM, 25 ºC
2) NaClO2, NaH2PO4
    2-methyl-2-butene
    tBuOH:H2O (5:1)
44, HATU, iPr2NEt,
DMF, 0        25 ºC
50% 3 steps
Pd2(dba)3·CHCl3
AsPh3, iPr2NEt, DMF
25 ºC, 62%
13
19
13
15
1
19
13
23
20
25
23
20
19
1
13
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Scheme 2.5 Nicolaou’s synthesis of macrocycle 48 (25% yield, 5 steps) 
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  2.1.5 Synthesis of the Spirolactam Fragment 77 of SFA: Elaboration of the 
C31-N42 Fragment to Complete the Western Subunit of SFA 
  Nicolaou’s synthesis of the spirolactam 77 began with assembly of the key 
C31-N42 fragment, amide 59 (Scheme 2.6), which possesses six of the requisite seven 
stereocenters  (C37  alcohol  stereochemistry  was  inconsequential  since  a  ketone 
functional  group  was  introduced  at  this  carbon  in  a  later  step).  Asymmetric  aldol 
methodology
26 and substrate-controlled hydroboration were used to install the array of 
alternating oxygenated and methyl substituted carbons on the C33-C38 backbone, and 
an Ireland-Claisen rearrangement
27 was employed to introduce the C40 stereocenter. 
Thus,  subjection  of  diethyl  ketone  49  to  (+)-diisopinocampheylboron  triflate  and 
Hunig’s  base  to  generate  the  corresponding  (Z)-boron  enolate
28  followed  by  aldol 
reaction  with  methacrolein  provided  secondary  alcohol  50.  Protection  of  50  as  its 
triethylsilyl ether furnished ketone 51 which underwent a second asymmetric aldol 
reaction with 3-benzyloxypropanal in the presence of chlorodicyclohexylborane and 
triethylamine to give an intermediate that was reduced in situ by lithium borohydride 
to deliver diol 52. The requisite Ireland-Claisen precursor, ester 54, was prepared in 
two steps from diol 52 by protection as its acetonide with 2,2-dimethoxypropane in the 
presence of camphorsulfonic acid, a process that was accompanied by unmasking of 
the C37-hydroxyl group to furnish hydroxyacetonide 53. Acylation of 53 with butyric 
anhydride in the presence of triethylamine gave 54. Ester 54 underwent enolization 
and silylation to generate ketene acetal 55 which upon thermolysis in toluene followed 
by hydrolysis of the resulting silyl ester afforded carboxylic acid 56 in excellent yield  
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and  as  a  single  diastereoisomer.  Carboxylic  acid  56  was  subjected  to  substrated-
controlled hydroboration followed by an oxidative workup to provide a ∼5:1 mixture 
of diastereomeric diols in favor of the desired stereoisomer 57. The configurational 
assignments to C37 and C38 were based on Houk’s transition-state model
29 in which 
the largest group on the chiral center flanking the double bond in 56 is placed anti to 
the attacking borane so that allylic 1,3-strain is minimized, as illustrated in transition 
state  60.  Oxidation  of  diol  57  with  tetrapropylammonium  perruthenate  and  N-
methylmorpholine-N-oxide 
15  led  to  lactone  58,  and  final  treatment  of  58  with 
dimethylaluminum amide
30 afforded acetonide amide 59.  
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Scheme 2.6 Nicolaou’s synthesis of C31-N42 amide fragment 59 
(19% yield, 9 steps) 
 
  With subunit 59 completed, Nicolaou’s next task was elaboration of this amide 
into spirolactam 64. Two routes to 64 were pursued and are depicted in Scheme 2.7. In 
the first approach, 59 was converted to keto amide 61 by oxidation with pyridinium 
dichromate. Hydrolysis of acetonide 61 by hydrofluoric acid in aqueous acetonitrile  
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was  accompanied by  spirocyclization  to provide  spirolactam  62 in  excellent  yield; 
palladium-catalyzed  hydrogenolysis  of  benzyl  ether  62  then  led  to  diol  63. 
Chemoselective oxidation of the primary hydroxyl group of 63 with oxygen in the 
presence  of  a  ruthenium(II)  catalyst
31  afforded  aldehyde  64.  In  a  shorter  sequence 
leading to 64, the benzyl ether of 59 was cleaved by catalytic hydrogenolysis and this 
was followed by oxidation of the resulting diol 65 with Dess-Martin periodinane
32 to 
give  keto  aldehyde  66.  Acid-induced  spirocyclization  of  66  then  delivered  64  in 
excellent yield. 
OBn O O
H2N
OH
40 31
O OBn O O
H2N
O O
OH O O
H2N
OH O
O O O
H2N
O
42
38
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HO OR
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HO O
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25 ºC, 76%
MeCN/HF/H2O
(20:1:1), 25 ºC
95 % H2, 20% Pd(OH)2/C
EtOH, 25 ºC, 99%
62: R = Bn
63: R = H
H2, 20% Pd(OH)2/C
EtOH, 25 ºC, 100%
DMP, py, DCM
25 ºC, 55%
RuCl2(PPh3)3, air
PhH, 25 ºC, 83%
MeCN/HF/H2O
(20:1:1), 25 ºC
95 %
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Scheme 2.7 Nicolaou’s two approaches to spirolactam aldehyde 64 
(Left 52% yield, 3 steps; Right 60% yield, 4 steps)  
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  Completion of Nicolaou’s synthesis of the fully functionalized western portion 
of sanglifehrin A is depicted in Scheme 2.8. Crotylboration of spirolactam aldehyde 
64 with 67 furnished homoallylic alcohol 68 as a 7:3 mixture of diastereoisomers. 
Treatment of 68 with tert-butyldimethylsilyl trifluoromethanesulfonate in the presence 
of 2,6-lutidine gave 69 which was ozonolyzed to provide aldehyde 70. A two-carbon 
homologation of 70 to aldehyde 73 was achieved by treatment of the former with the 
lithio derivative of silyl aldimine 71
33 to give 72, after which the double bond of 72 
was hydrogenated using Lindlar’s catalyst.
34 Aldehyde 73 was transformed into alkyne 
74 in excellent yield with Ohira’s reagent 15 and subsequent desilylation of both silyl 
ethers in 74 with tetra-n-butylammonium fluoride gave diol 75. The terminal alkyne of 
75 was converted to alkynyl bromide 76 with N-bromosuccinimide in the presence of 
silver nitrate,
35 and treatment of 76 with tri-n-butyltin hydride in the presence of in 
situ-generated catalytic tetrakis(triphenylphosphine)palladium(0) led to vinylstannane 
77.   
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Scheme 2.8 Nicolaou’s synthesis of vinylstannane 77 
(10% yield, 9 steps) 
 
  2.1.6 Completion of Nicolaou’s Synthesis  of Sanglifehrin A Using  Stille 
Coupling to Connect Eastern and Western Segments 
  Completion  of  Nicolaou’s  total  synthesis  of  SFA  is  shown  in  Scheme  2.9. 
Treatment  of  a  mixture  of  vinylstannane  77  and  vinyl  iodide  48  with  a  catalytic 
amount  of  in  situ-generated  tris(triphenylarsine)palladium(0)
36
  in  N,N-
dimethylformamide at 40 °C delivered sanglifehrin A internal ketal 78 which upon  
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exposure to aqueous sulfuric acid provided 1. Nicolaou’s synthesis of sanglifehrin A 
required 49 steps with the longest linear sequence being 23 steps. 
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sanglifehrin A (1)
26
31
40
23
20
19
1
13
8
23
20
19
1
13
8
26
31
40
+
77
48
78
 
Scheme 2.9 Completion of Nicolaou’s synthesis of sanglifehrin A (15% yield, 2 steps) 
2.2 Paquette’s Total Synthesis of Sanglifehrin A (2002) 
  2.2.1 Synthesis of the C13-C16 Fragment via Asymmetric Acylation 
  Paquette’s  synthesis  of  the  C13-C16  fragment  is  depicted  in  Scheme  2.10. 
Wacker  oxidation  of  the  enantiopure  oxazolidinone  79
37  led  to  regiospecific 
introduction  of  a  ketone  group  in  80,  which  was  converted  into  dithioketal 82  by 
treatment with 1,3-propanedithiol (81) in the presence of p-toluenesulfonic acid. The 
propionyl substituent in 84 was installed by kinetically controlled attack on the lithium  
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enolate  of  82  with  propionyl  chloride.  This  process  proceeded  with  high 
diastereoselectivity to give principally 84 in combination with O-acylation product 83. 
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Scheme 2.10 Paquette’s synthesis of oxazolidinone 84 (54% yield, 3 steps) 
2.2.2 Synthesis of the C13-C25 Fragment 95 via Diastereoselective Anti-
Aldol Reaction 
  Paquette’s synthesis of the C13-C25 fragment 95 began with homologation of 
known aldehyde 37
22 with phosphonate 85 which led to α,β,γ,δ-unsaturated ester 86 as 
shown in scheme 2.11. Thus, coupling of 37 with the lithium salt of 85 installed the 
dienyl ester functionality of 86 as a 9:1 mixture in favor of the desired (E,E)-isomer 
86.  Subsequent  reduction  of  the  ester  moiety  to  a  primary  alcohol  with 
diisobutylaluminum hydride provided allylic alcohol 87 which upon oxidation with 
manganese dioxide furnished aldehyde 88. Subjection  of aldehyde 88 and the (E)-
boron enolate of 84 to an asymmetric anti-aldol coupling
38 gave ketone 89 which was 
reduced  stereoselectively  with  tetramethylammonium  triacetoxyborohydride  in  the  
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presence of acetic acid to afford diol 90. Removal of the dithioacetal protecting group 
from  90  with  [bis(trifluoroacetoxy)iodo]benzene  was  accompanied  by  internal 
ketalization to yield 91. Reductive cleavage of the oxazolidinone of 91 with sodium 
borohydride in aqueous tetrahydrofuran gave alcohol 92;
39 Dess-Martin oxidation of 
this  alcohol  then  gave  aldehyde  93  which  was  further  oxidized  using  Pinnick’s 
conditions to provide carboxylic acid 94. Finally, the C23-hydroxyl group of 94 was 
unmasked with tetra-n-butylammonium fluoride to afford hydroxy carboxylic acid 95. 
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Scheme 2.11 Paquette’s synthesis of hydroxy carboxylic acid 95 
(13% yield, 10 steps)  
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  2.2.3 Paquette’s First Generation Approach to Macrocycle 48 
  Paquette’s initial route to the macrocyclic core 48 of SFA commenced with the 
synthesis  of  piperazic  acid  derivative  99  as  outlined  in  Scheme  2.12.  The  2-
(trimethylsilyl)ethoxylcarbonyl  (Teoc)  protecting  group
40  was  installed  on  the  two 
piperazic  acid  nitrogen  atoms  in  the  known  compound  96.
41  Thus,  both  tert-
butoxycarbonyl protecting groups were removed from 96 under acidic conditions to 
give  97  and  the  free  diamine  97  was  then  re-protected  with  2-(trimethylsilyl) 
ethoxycarbonyl chloride in the presence of 4-dimethylaminopyridine to afford 98. The 
oxazolidinone chiral auxiliary in 98 was removed under basic conditions, leading to 
the required piperazic acid derivative 99. Paquette’s reasoning for exchanging the tert-
butoxycarbonyl groups in 96 for 2-(trimethylsilyl)ethoxycarbonyl protecting groups in 
99 was that eventual removal of the latter would be more facile, as has been proven in 
peptide  chemistry
42,  43  and  in  other  settings  involving  highly  functionalized, 
structurally complex intermediates.
44, 45 
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Scheme 2.12 Paquette’s synthesis of piperazic acid derivative 99 
(73% yield, 3 steps)  
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The  next  synthetic  operation  was  enantioselective  synthesis  of  m-
hydroxyphenylalanine  derivative  103,  as  shown  in  Scheme  2.13.  Commercially 
available  oxazinone  100  was  subjected  to  stereoselective  alkylation  with  benzyl 
bromide  101  in  the  presence  of  hexamethylphosphoramide  to  deliver  102,  which 
underwent hydrogenolysis in the presence of dichloropalladium(II) to liberate amino 
and carboxyl groups and furnish O-Boc-hydroxyphenylalanine 103. Protection of the 
free amino group in 103 with N-(benzyloxycarbonyloxy)succinimide to give 104 was 
followed by esterification with trimethylsilylethanol in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)  carbodiimide  to  produce  105  in  moderate  yield.  The  amino 
group was unmasked by hydrogenolysis and amino ester 106 was coupled with N-
carboxybenzyl-L-valine in the presence of N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-
1-yl)uronium  hexafluorophosphate  to  yield  dipeptide  107.  Dipeptide  107  was 
transformed  into  vinyl  iodide  109  in  two  steps  that  included  deprotection  of  the 
carboxybenzyl  group  to  give  108  and  coupling  of  108  with  carboxylic  acid  95. 
Alcohol 109 was esterified with piperazic acid derivative 99
46 in the presence of 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide  and  4-pyrrolidinopyridine
47  to  deliver 
110.  However,  attempts  at  removal  of  the  2-(trimethylsilyl)ethoxycarbonyl  and  2-
(trimethylsilyl)ethyl groups gave uncharacterizable products and this route to 111 was 
therefore abandoned.   
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Scheme 2.13 Synthesis of macrocyclization precursor 110 
(6% yield, 9 steps) 
 
  2.2.3 Paquette’s Second Generation Approach to Macrocycle 48 
Paquette’s  failure  to  remove  protecting  groups  from  110  led  to  a  second 
approach route to macrolactone 48 depicted in Scheme 2.14. In this approach, the 
focus was on macrolactonization to close hydroxy acid 121. This plan required access 
to tripeptide 119, for which known oxazolidinone 96
41 was again the starting point. 
The latter was transformed into piperazic methyl ester 113 in three steps according to  
 
27 
 
Hale’s procedure. First, 96 was cleaved to carboxylic acid 40 which was treated with 
diazomethane  to  give  methyl  ester  112.  The  tert-butoxylcarbonyl  groups  were 
removed  from  112  by  treatment  with  trifluoroacetic  acid  to  provide  113.  Peptide 
coupling of 113 with m-tyrosine derivative 114 produced dipeptide 115 in which the 
phenolic  hydroxyl  group  was protected  with tert-butoxycarbonyl anhydride  to give 
116.  The  primary  amino  group  of  116  was  unmasked  by  palladium-catalyzed 
hydrogenolysis to form dipeptide 117 which was coupled with N-carbobenzyloxy-L-
valine  in  the  presence  of  N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)uronium 
hexafluorophosphate to deliver tripeptide 118. The latter was converted to hydroxy 
ester  120  in  two  steps  involving  hydrogenolytic  cleavage  of  the  carbobenzyloxy 
protecting group at the N-terminus of the tripeptide and then amide formation of the 
liberated amino group in 119 with carboxylic acid 95 to construct the N12-C13 bond 
of  SFA.  The  methyl  ester  in  120  was  hydrolyzed  under  basic  conditions  to  give 
hydroxy carboxylic acid 121, the precursor for macrolactonization. Although lactone 
122 was produced in low yield when treated with 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide in the presence of 4-pyrrolidinopyridine, the phenolic hydroxyl group of 
122 was  unmasked  with  trimethylsilyl  triflate  and  2,6-lutidine  to provide  a  usable 
quantity of macrocycle 48. The latter bears a terminal iodoalkene moiety ready for 
linkage with the western segment of sanglifehrin A.  
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Scheme 2.14 Paquette’s synthesis of macrolactone 48 (6% yield, 12 steps) 
2.2.4 Elaboration of the C26-N42 Spirolactam 
Paquette’s synthesis of the C26-N42 spirolactam portion of SFA commenced 
with asymmetric allylation of known (R)-acyloxazolidinone 123 with allyl bromide to 
produce 124 as shown in Scheme 2.15. The chiral auxiliary was removed from 124 
with lithium borohydride in wet ether to furnish alcohol 125 which was protected as 
its tert-butyldiphenylsilyl ether 126. This alkene was converted to primary alcohol 127  
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by hydroboration with 9-borabicyclo[3.3.1]nonane followed by oxidation with basic 
hydrogen  peroxide.  Further  oxidation  of  127  with  pyridinium  dichromate  gave 
aldehyde 128 which was subjected to Pinnick oxidation to provide carboxylic acid 
129. The acid was advanced to oxazolidinone 132 through adaptation of an activated 
anhydride protocol
48, 49 in which 129 was transformed into 130 and then condensed 
with  131  in  the  presence  of  lithium  chloride.  Enantioselective  methylation  of  the 
enolate of 132 with methyl iodide gave 133, after which reductive cleavage of the 
chiral auxiliary with lithium borohydride led to alcohol 134. Swern oxidation of 134 
afforded aldehyde 135 which was condensed with the tin(II) enolate of 136
50-52  to 
yield a 92:8 mixture favoring syn,anti diastereomer 137 resulting from Felkin attack. 
Synthesis of diol 138 was completed by a hydroxyl-directed reduction of 137 with 
tetramethylammonium triacetoxyborohydride
53   
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Scheme 2.15 Paquette’s synthesis of diol 138 (19% yield, 13 steps) 
  Advancing  from  diol  138,  Paquette  prepared  aldehyde  142  required  for 
extension of the carbon framework that would lead to the C26-C41 portion of SFA. 
Thus, 138 was transformed into terminal p-methoxyphenyl acetal 139
54 in which the 
remaining hydroxyl group was protected as its triethylsilyl ether 140 (Scheme 2.16). 
Regioselective  reduction  of  140  with  diisobutylaluminum  hydride
55  gave  primary 
alcohol 141 and a subsequent Swern oxidation led to aldehyde 142.   
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Scheme 2.16 Paquette’s synthesis of aldehyde 142 (70% yield, 4 steps) 
  A seven-carbon chain extension of 142 in the direction of C26-C32 of SFA 
commenced  with  oxidation  of  alcohol  143  with  pyridinium  chlorochromate,
56 
activation  of  the  resulting  carboxylic  acid  144  with  pivaloyl  chloride,  and 
condensation of the mixed anhydride with oxazolidinone 131 to provide alkyne 145 
(Scheme 2.17). Stereoselective methylation of 145 gave 146 from which the chiral 
auxiliary was cleaved with lithium borohydride in wet ether. This led to alcohol 147 
which was oxidized under Swern conditions to aldehyde 148. A Grignard reaction of 
148  with  methylmagnesium  bromide  delivered  secondary  alcohol  149  which  was 
oxidized  to  methyl  ketone  150.  Linkage  of  142  with  150  was  effected  via  an 
asymmetric aldol reaction employing the chiral enolate of 150 prepared with Lewis-
acidic (+)-B-chlorodiisopinocampheylborane (DIPCl) in the presence of triethylamine. 
The ketone of aldol adduct 151 was reduced to give diol 152 by means of a 1,3-anti-
selective reduction with tetramethylammonium triacetoxyborohydride in acetic acid.  
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The 1,3-diol in 152 was protected as its acetonide 153 and the three silyl protecting 
groups  in  153  were  removed  in  a  single  operation  with  tetra-n-butylammonium 
fluoride to furnish diol 154. 
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Scheme 2.17 Paquette’s synthesis of diol 154 (12% yield, 11 steps) 
  In order to differentiate the two hydroxyl groups in 154, the primary alcohol 
was first protected as pivaloate and the remaining hydroxyl group in 155 was then 
masked  as  a  triethylsilyl  ether  to  produce  156  (Scheme  2.18).  Reduction  of  the 
primary pivaloate ester in 156 afforded alcohol 157 which was converted to carboxylic  
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acid 159 via a two-step oxidative sequence through aldehyde 158. The carboxyl group 
in 159 was converted to a methyl ester and treatment of 160 with freshly prepared 
dimethylaluminum amide in dichloromethane at reflux yielded amide 161.
30 Cleavage 
of triethylsilyl  ether 161 with  tetra-n-butylammonium fluoride  then led  to hydroxy 
amide 162. 
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Scheme 2.18 Paquette’s route to hydroxy amide 162 (47% yield, 8 steps) 
  With 162  in  hand,  Paquette  and  co-workers  advanced  toward  the C26-N42 
spirolactam 77 with oxidation of the C37 hydroxyl group to keto amide 163 (Scheme 
2.19). Treatment of 163 with camphorsulfonic acid produced mainly spirolactam 164 
along  with  its  spiro  (C37)  epimer  in  a  7:1  ratio.  After  deprotection  of  the  p-
methoxybenzyl  ether  in  164,  the  resulting  alkyne  75  was  reacted  with  N-
bromosuccinimide in the presence of silver nitrate
35 to provide bromoalkyne 76. The 
bromoalkyne was reduced to vinylstannane 77 by reaction with tri-n-butyltinhydride,  
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triphenylphosphine  and  dipalladium-tris(dibenzylideneacetone)chloroform  complex 
following a protocol due to Guibé.
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Scheme 2.19 Paquette’s synthesis of spirolactam 77 (53% yield, 5 steps) 
  A palladium-catalyzed Stille coupling was chosen for linking C1-C25 subunit 
48  with  C26-N42  moiety  77  as  shown  in  Scheme  2.20.  Thus,  treatment  of 
vinylstannane  77  and  vinyl  iodide  48  with  bis(acetonitrile)dichloropalladium(II)  in 
dimethylformamide furnished sanglifehrin A derivative 78. Finally, the cyclic ketal of 
78  was  hydrolyzed  with  p-toluenesulfonic  acid  and  boric  acid  to  complete  the 
synthesis of sanglifehrin A. Paquette’s synthesis of sanglifehrin A required 68 steps 
with a longest linear sequence of 35 steps.  
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Scheme 2.20 Completion of Paquette’s synthesis of sanglifehrin A 
(13% yield, 2 steps) 
 
2.3 Metternich’s Synthesis of the C13-C19 Segment of SFA (1999) 
  Metternich’s  synthesis  of  the  C13-C19  unit  of  SFA  commenced  with  the 
synthesis  of  alcohol  171,  for  which  a  boron-mediated  anti-aldol  condensation  was 
employed  as  a  key  step.  As  depicted  in  Scheme  2.21,  commercially  available  5-
ketohexanoic acid (165) was activated as its pivaloyl anhydride which was condensed 
with lithium enolate 166 to give acyl oxazolidinone 167.
49 Protection of the keto group 
of  167  with  ethane-1,2-dithiol  in  the  presence  of  titanium(IV)  chloride  furnished 
dithioketal  168  which  was  subjected  to  stereoselective  acylation  with  propionyl 
chloride to yield β-ketoimide 169 as a single diastereomer. Treatment of 169 with  
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chlorodicyclohexylborane  in  the  presence  of  ethyldimethylamine  generated  the  E-
boron enolate of 169 which was condensed with propagylic aldehyde 170 to afford a 
93:7 mixture of diastereomers in favor of 171 over 172.  
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Scheme 2.21 Metternich’s synthesis of alcohol 171 (36% yield, 4 steps) 
  Metternich’s elaboration of the C13-C19 unit 171 is shown in Scheme 2.22. 
Stereoselective  reduction  of  the  C15-carbonyl  group  of  171  with 
tetramethylammonium  triacetoxyborohydride  gave  1,3-anti  diol  173,  after  which 
removal  of  the  chiral  auxiliary  in  173  with  methylmagnesium  bromide  in 
methanol/dichloromethane followed by transketalization with 2,2-dimethoxypropane 
in the presence of camphorsulfonic acid yielded acetonide 174. The methyl ester of 
174 was cleaved with sodium hydrogen telluride in N,N-dimethylformamide
57 to give 
carboxylic acid 175, and peptide coupling of 175 with L-valine methyl ester mediated  
 
37 
 
by  1-ethyl-3-(3-dimethylaminopropyl)carbodiimide  and  1-hydroxybenzotriazole 
delivered amide 176. This last step was apparently intended as a model for coupling of 
175 with the intact C1-N12 tripeptide of SFA. Metternich’s synthesis of the tripeptide 
187 is described in Section 2.4 below. 
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Scheme 2.22 Metternich’s synthesis of amide 176 (30 %, 4 steps) 
2.4 Metternich’s Synthesis of the C1-N12 Tripeptide Subunit of SFA 
(1999) 
  Synthesis of the C1-N12 tripeptide component of SFA in Metternich’s hands 
commenced  with  selective  hydrogenation  of  commercially  available  3-
hydroxycinnamic acid 177 to give carboxylic acid 178. The phenolic hydroxy group of 
178 was protected with benzyl chloride under basic conditions to yield benzyl ether 
179 (Scheme 2.23), and a benzyl oxazolidinone chiral auxiliary was appended to 179  
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with lithium enolate 166 using the pivaloyl mixed anhydride method
49 to afford acyl 
oxazolidinone  180.  The  latter  underwent  stereoselective  azide  introduction  with 
triisopropylbenzenesulfonyl azide (181) to afford azide 182.
58 Palladium(0)-catalyzed 
hydrogenation  of  azide  182  in  the  presence  of  barium  sulfate  and  di-tert-butyl 
dicarbonate gave the protected amine 183. By contrast, catalytic reduction of 182 in 
the  absence  of  di-tert-butyl  dicarbonate  led  to  attack  on  the  oxazolidinone  by  the 
liberated amine to produce a hydantoin, as illustrated in Scheme 2.24. Removal of the 
tert-butoxycarbonyl group from 183 with trifluoroacetic acid provided amine salt 184 
which  was  coupled  with  N-tert-butoxycarbonyl-L-valine  using  1-
hydroxybenzotriazole and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
59, 60 in the 
presence  of N-methylmorpholine  to  give  the  C7-N12  sector  of  SFA, 185. Lithium 
peroxide  hydrolysis
61  of  185  in  wet  tetrahydrofuran  delivered  carboxylic  acid  186  
without epimerization of the C7 stereocenter.  
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Scheme 2.23 Metternich’s synthesis of dipeptide 186 (22% yield, 8 steps) 
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Scheme 2.24 Formation of a hydantoin from oxazolidinone 184 
  With 186 in hand, Metternich coupled the dipeptide with known piperazic acid 
derivative 113
41 to give 187, the C1-N12 portion of SFA, as shown in Scheme 2.27. 
First, carboxylic acid 40 was converted to methyl ester 112 and then the pair of tert-
butoxycarbonyl groups was removed with trifluoroacetic acid to form piperazic acid 
methyl  ester  113.  Peptide  coupling  of  113  with  186  in  the  presence  of  N- 
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methylmorpholine yielded tripeptide 187. However, no further progress from 175 or 
187 towards SFA has been reported from the Metternich laboratory. 
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Scheme 2.25 Metternich’s synthesis of tripeptide 187 (81% yield, 3 steps) 
2.5 Gurjar’s Synthesis of the C13-C18 Segment of SFA (2002) 
  Gurjar’s  synthetic  route  to  the  C13-C18  portion  of  SFA  began  with  a 
stereoselective C-C bond forming reaction through radical mediated coupling of (5R)-
5-chloro-5-deoxy-glucurono-6,3-lactone derivative 188
62 with allyltributyltin (189), as 
illustrated  in  Scheme  2.23.  Treatment  of  188  with  189  in  the  presence  of 
azobisisobutyronitrile furnished lactone 190 which was reduced with lithium aluminun 
hydride to 1,4-diol 191. Transketalization of 191 with 2,2-dimethoxypropane in the 
presence of p-toluenesulfonic acid afforded acetonide 192, and this was subjected to a 
hydroboration-oxidation sequence to produce primary alcohol 193. Oxidation of 193 
under  Swern  conditions  provided  aldehyde  194  which  was  reacted  with 
methylmagnesium iodide to give secondary alcohol 195 as a single diastereomer. The  
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configuration of the new stereo center in 195 was inconsequential as it would later be 
transformed into a ketone. The secondary hydroxyl group in 195 was protected with 
benzyl bromide to yield benzyl ether 196 in which the cyclic ketal moiety was cleaved 
with dilute sulfuric acid to give diol 197. Silylation of the primary hydroxyl group in 
197 with tert-butyldimethylsilyl chloride in the presence of imidazole led to 198. 
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Scheme 2.26 Gurjar’s synthesis of alcohol 198 (20% yield, 9 steps) 
  Gurjar’s  next  plan  was  to  invert  C15  configuration  in  198,  for  which 
elimination of the C16 hydroxyl group to give a dihydrofuran followed by facially 
selective oxidation, as depicted in Scheme 2.24, was programmed. Thus, alcohol 198 
was treated with trifluoromethanesulfonic anhydride in the presence of pyridine and  
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then with 1,8-diazabicyclo[5.4.0]undec-7-ene to give 199. Oxidative hydroboration of 
dihydrofuran 199 yielded alcohol 200 in which attack by borane had occurred at the 
exo face of the alkene (opposite the acetonide) to give reversed stereochemistry at 
C15. Oxidation of the secondary alcohol in 200 under Swern conditions furnished 
ketone  201  which  was  subjected  to  Wittig  olefination  to  afford  exo-methylene 
derivative 202. A hydroboration-oxidation sequence was employed to construct the 
primary  alcohol  of  203  and  set  in  place  the  desired  C16  stereochemistry.  Thus, 
reaction  of  202  with  borane-dimethylsulfide  complex  led  to  203  which  was 
transformed  into  dithiocarbonate  204  in  the  presence  of  sodium  hydride,  carbon 
disulfide and methyl iodide. Subjection of 204 to Barton radical deoxygenation
63 with 
tributyltin hydride and azobisisobutyronitrile gave 205, after which desilylation with 
tetra-n-butylammonium  fluoride  provided  primary  alcohol  206.  Ruthenium(III)-
mediated  oxidation  of  the  primary  alcohol  in  206  to  a  carboxylic  acid  was 
accompanied  by  oxidation  of  the  benzyl  group  to  give  benzoate  207.  Although 
carboxylic acid 207 bears all of the functionality needed for the C13-C18 fragment of 
SFA, Gurjar has not continued his route from this point.  
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Scheme 2.27 Gurjar’s synthesis of carboxylic acid 207 (11% yield, 9 steps) 
2.6 Dias’ Synthesis of the C29-C39 Subunit of SFA (2006) 
  Dias’ approach to the C29-C39 portion of SFA began with asymmetric aldol 
addition  of  the  boron  enolate  derived  from  N-propionyloxazolidinone  208  to 
methacrolein.  This  gave  syn-aldol  adduct  209,
64-66  after  which  the  new  secondary 
alcohol  was  protected  with  tert-butyldimethylsilyl  triflate  in  the  presence  of  2,6-
lutidine  to  yield  acyl  oxazolidinone  210  (Scheme  2.28).  Subjection  of  210  to  a 
hydroboration-oxidation  sequence  with  9-borabicyclo(3.3.1)nonane  resulted  in  
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cleavage of the chiral auxiliary and led to lactone 211. Treatment of 211 with N,O-
dimethylhydroxylamine hydrochloride in the presence of dimethylaluminum chloride 
gave Weinreb amide 212
30, 67, 68 in which the primary alcohol was masked with tert-
butyldimethylsilyl  chloride  to  afford  amide  213.  After  reduction  with 
diisobutylaluminum hydride at low temperature, 213 provided aldehyde 214. Horner-
Wadsworth-Emmons olefination
69 of 214 with phosphonate 22 gave α,β-unsaturated 
ester 215 which was reduced with diisobutylaluminum hydride to yield allylic alcohol 
216. Diastereoselective epoxidation of 216 with m-chloroperoxybenzoic acid delivered 
epoxide 217
70 which underwent opening with lithium dimethylcopper(I) cyanide to 
give 1,3-diol 218.
71 
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Scheme 2.28 Dias’s synthesis of diol 218 (43% yield, 10 steps)  
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  Elaboration  of  218  by  Dias  into  the  C29-C39  subunit  226  began  with 
acetalization of the diol with p-methoxybenzaldehyde dimethyl acetal (219) catalyzed 
by  pyridinium  p-toluenesulfonate.  This  afforded  acetal  220
72  which  was  reduced 
regioselectively  with  diisobutylaluminum  hydride  to  yield  primary  alcohol  221 
(Scheme 2.29). Swern oxidation of 221 gave aldehyde 222 which was reacted with 
methyllithium at low temperature to give secondary alcohol 223. Oxidation of 223 
under Swern conditions led to methyl ketone 224 and this was subjected to a boron-
mediated  aldol  rection
73  with  aldehyde  225
74  to  furnish  syn  product  226  and  thus 
complete synthesis of the C29-C39 portion of SFA. No further report towards the 
synthesis of SFA has appeared from the Dias group. 
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Scheme 2.29 Dias’ synthesis of the C29-C39 subunit of SFA (43% yield, 6 steps)  
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2.7 Wagner’s Synthesis of the C1-C23 Macrolide Analogue of SFA by 
Ring-Closing Metathesis (2000) 
  A Novartis group led by Wagner designed a simple macrocyclic analogue of 
SFA in which the sanglifehrin tripeptide is bridged across its termini by an eleven-
carbon dienoic acid to form lactam and lactone connections. The synthesis of this C1-
C23  macrolide  analogue  237  commenced  with  construction  of  C1-N12  tripeptide 
subunit 229, as depicted in Scheme 2.30. Thus, the piperazic acid derivative 112 was 
treated  with  trifluoroacetic  acid  to  give  113  which  was  coupled  with  N-tert-
butoxycarbonyl-L-phenylalanine  in  the  presence  of  1-ethyl-3-(3-dimethylamino 
propyl)carbodiimide  and  N-methylmorpholine  to  form  dipeptide  227.  Treatment  of 
227  with  trifluoroacetic  acid  furnished  amine  228  which  was  linked  to  N-tert-
butoxycarbonyl-L-valine using a standard carbodiimide-based coupling procedure to 
give tripeptide 229. 
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Scheme 2.30 Wagner’s synthesis of tripeptide 229 (49% yield, 4 steps)  
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  The key step used to complete the C1-C23 macrocycle 237 was ring-closing 
metathesis  as  shown  in  Scheme  2.31.  First,  the  N-tert-butoxycarbonyl  group  was 
removed from tripeptide 229 by treatment with trifluoroacetic acid and the resultant 
amine 230 was acylated with 6-heptenoic acid (231) to give amide 232. Cleavage of 
the methyl ester from 232 with lithium hydroxide yielded carboxylic acid 233 which 
was esterified with E-3,5-hexadienol (234)
75 under Mitsunobu conditions
76 to produce 
triene  235.  Subjection  of  the  triene  to  ring-closing  metathesis  with  Grubbs 
ruthenium(II) carbenoid complex 236
77  in reflux dichloromethane gave  macrocycle 
237  in  moderate  yield.  There  has  been  no  report  from  the  Novartis  laboratory  of 
biological activity associated with this SFA analogue. 
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Scheme 2.31 Wagner’s synthesis of the C1-C23 macrolide analogue of SFA 
(21% yield, 5 steps)  
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CHAPTER 3: SYNTHESIS OF THE C13-C19 SUBUNIT 
OF SANGLIFEHRIN A 
 
Featuring  a  highly  substituted  [5,5]-spirolactam  moiety  as  well  as  a  22-
membered  macrocycle  containing  a  peptidic  backbone  characterized  by  unusual 
β−substituted (S)-piperazic acid and (S)-m-hydroxyphenylalanine units, sanglifehrin A 
(1)  presents  a  challenging  target  from  the  viewpoint  of  synthesis.  Synthesis  of  a 
molecule of this complexity provides an opportunity to develop new strategies and 
methodologies which can be applied to other complex targets. 
3.1 Retrosynthetic Analysis 
Our approach to sanglifehrin A (1) relies on the assembly of two principal 
subunits separated by the C25-C26 bond of the exocyclic E,E-diene. This plan leads to 
a disconnection involving E-vinylstannane 238 and E-vinyl iodide 239, assembly of 
which would use a palladium-mediated Stille coupling
1 as outlined in Scheme 3.1.  
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Scheme 3.1 Retrosynthetic analysis of Sanglifehrin A (1) 
Our approach to the macrocyclic core of 239 involves intramolecular Suzuki 
coupling
2  with  macrocyclization,
3  carbodiimide  assisted  esterification  at  C1,  and 
racemization-free amide bond formation between tripeptide 241 and carboxylic acid 
242  (Scheme  3.2).  Sequential  disconnection  of  the  C19-C20,  N12-C13,  and  C1-O 
bonds  reveals  alcohol  240,  tripeptide  241,  and  carboxylic  acid  242  as  our  key 
intermediates for assembling macrocycle 239.  
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Scheme 3.2 Retrosynthetic analysis of macrocycle 239 
Scheme 3.3 outlines our retrosynthetic analysis of vinyl boronate 240 which 
would be prepared by Takai olefination
4 of aldehyde 37
5 with boronate 243.
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Scheme 3.3 Retrosynthetic analysis of vinyl boronate 240  
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In  planning  the  synthesis  of  tripeptide  241,  (S)-piperazic  acid  methyl  ester 
113,
7  (S)-m-hydroxyphenylalanine  derivative  244,  and  commercially  available  N- 
carboxybenzyl-L-valine 245 are required for a properly sequenced peptide coupling. 
First,  we  focused  our  attention  on  enantioselective  synthesis  of  (S)-m-
hydroxyphenylalanine derivative 244 using a phase-transfer catalytic method,
8 while 
anticipating that (S)-piperazic acid methyl ester 113 would be acquired via a protocol 
due to Hale
7 (Scheme 3.4). 
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Scheme 3.4 Retrosynthetic analysis of tripeptide 241 
  Synthesis of carboxylic acid 242 was initially envisioned from a Paterson anti-
aldol reaction
9 of aldehyde 246 and thioester 247, as illustrated in Scheme 3.5, but this 
plan subsequently changed to one employing a Masamune anti-aldol coupling.  
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Scheme 3.5 Retrosynthetic analysis of carboxylic acid 242 
It was envisaged that spirolactam 238 could be constructed through oxidative 
hydroboration  of  alkene  248  followed  by  nucleophilic  substitution  of  the 
corresponding  activated  alcohol  with  organo-copper  species  249
10  (Scheme  3.6). 
Alkene  248  was  anticipated  from  aldehyde  250  via  asymmetric  crotylation.
11  The 
C31-N42 framework in 250 was programmed via cyclization of carboxylic acid 251 
which  would  be  generated  via  an  Ireland-Claisen  rearrangement
12  of  ester  252. 
Finally, ester 252 would be obtained in a straightforward sequence from aldehyde 253.  
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Scheme 3.6 Retrosynthetic analysis of spirolactam 238 
3.2 Synthesis of the C13-C19 Vinyl Iodide 242 
  3.2.1 First Generation Approach: Construction of the C13-C19 Segment 
via Paterson Anti-Aldol Condensation 
  Our  initial  approach  to  vinyl  iodide  242  commenced  with  the  synthesis  of 
known allylic alcohol 259.
13 As depicted in Scheme 3.7, protection of commercially 
available (R)-methyl 3-hydroxy-2-methylpropanoate (254) with tert-butyldiphenylsilyl 
chloride gave silyl ether 255 which was reduced with diisobutylaluminum hydride at  
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low temperature to aldehyde 256. Subjection of 256 to olefination with commercially 
available  Wittig  reagent 257 in  refluxing  tetrahydrofuran  delivered  α,β-unsaturated 
ester 258 which was reduced with diisobutylaluminum hydride to allylic alcohol 259. 
Sharpless  asymmetric  epoxidation
14  of  259  in  the  presence  of  (−)-diethyl  tartrate 
furnished oxirane 260 in high diastereomeric purity, and subsequent conversion of the 
free hydroxyl group in 260 to chloride 261 was achieved under standard conditions. 
Based-induced double elimination was employed to convert epoxy chloride 261 to 
alkyne 262, as depicted in Figure 3.1. Thus, treatment of 261 with 3.5 equivalents of 
lithium  diisopropylamide  generated  carbanion  265  which  underwent  simultaneous 
epoxide opening to yield alkoxide 266. Deprotonation of the C18 hydrogen from 266 
with a second equivalent of lithium diisopropylamide led to alkenyl anion 267 which 
expelled  chloride  ion;  aqueous  workup  then  provided  alkyne  262.
15,  16  A  p-
methoxybenzyl group was chosen to mask propargylic alcohol 262 due to its stability 
and its easy removal with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone. Treatment of 
262 with p-methoxybenzyl bromide under basic conditions at room temperature was 
investigated  first  (Table  3.1,  entries  1-3)  but  only  recovered  starting  material  was 
observed.  At  a  higher  reaction  temperature  (40  °C,  12  h,  entry  3),  262  was 
decomposed.  Treatment  of  alcohol  262  with  p-methoxybenzyl  acetimidate  under 
acidic conditions
17 was also investigated (Table 3.1, entries 4-7), and in the presence 
of  10  mol%  pyridinium  p-toluenesulfonate  or  10  mol%  camphorsulfonic  acid  the 
reaction gave p-methoxybenzyl ether 263 in good yield. The primary silyl ether in 263 
was unmasked with tetra-n-butylammonium fluoride and the resulting alcohol 264 was  
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oxidized with Dess-Martin periodinane to aldehyde 246 in good overall yield for the 
nine steps from 254. 
MeO2C
OR
OTBDPS
R OTBDPS R
O
OR1
OR2
DIBAL-H, DCM
-78 ºC, 86%
EtO
PPh3
O
256
OTBDPS H
O
(257)
OPMB
O
246
254: R = H
255: R = TBDPS
TBDPSCl, DMAP
Imid., DCM, rt, 90%
THF, reflux, 88%
258: R = CO2Et
259: R = CH2OH
DIBAL-H, -78 ºC
DCM, 98%
260: R = OH
261: R = Cl
Ph3P, NCS, DCM
reflux, 89%
Ti(Oi-Pr)4, 4 A MS
(-)-diethyl tartrate
TBHP, -20 ºC
DCM, 90%
(d.r. > 20:1)
LDA, THF
-35 ºC, 88%
262: R1 = H, R2 = TBDPS
263: R1 = PMB, R2 = TBDPS
264: R1 = PMB, R2 = H TBAF, THF, 90%
DMP, DCM
NaHCO3, 92%
PMBOC(NH)CCl3
CSA (10 mol%), DCM, rt, 92%
19
15
19
15
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15
15 15
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Scheme 3.7 Synthesis of aldehyde 246 (36% yield, 9 steps) 
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Figure 3.1 Mechanism for base-induced double elimination of 261 
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Table 3.1 p-Methoxybenzyl protection of alcohol 262 under various conditions 
OH
OTBDPS
262
19
15
OPMB
OTBDPS
263
19
15
conditions
 
 
Entry 
 
Conditions  Yield of 263 (%) 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
 
NaH, PMBCl, TBAI, THF, rt, 3 h 
 
NaH, PMBCl, TBAI, THF, rt, 12 h 
 
NaH, PMBCl, TBAI, THF, 40 °C, 12 h 
 
PPTS (10 mol%), PMBOC(NH)CCl3, DCM, rt 
 
TfOH (20 mol%), PMBOC(NH)CCl3, Et2O, rt 
 
TFA (20 mol%), PMBOC(NH)CCl3, Et2O, rt 
 
CSA (10 mol%), PMBOC(NH)CCl3, DCM, rt 
 
No reaction 
 
No reaction 
 
Decomposition 
 
80 
 
Decomposition 
 
No reaction 
 
92 
 
  Our next task was preparation of thioester 247 required for its aldol coupling
9 
with aldehyde 246. As shown in Scheme 3.8, thioester 247 was prepared in three steps 
from commercially available 5-oxohexanoic acid 165. First, carboxylic acid 165 was 
transformed into its methyl ester 268, after which the ketone was reacted with ethylene 
glycol in the presence of p-toluenesulfonic acid to give cyclic ketal 269. Thioester 
formation  by  displacement  of  methyl  esters  with  tert-butyldimethyl  aluminum, 
generated in situ from trimethylaluminum and tert-butylthiol in dichloromethane has 
been  reported  by  Weinreb
18  but  treatment  of  ester  269  with  tert-
butyldimethylaluminum resulted only in decomposition of the starting material. This 
result, which is probably a consequence of the incompatibility of the ketal function of 
269 with strong Lewis acid, forced us to reroute the synthesis of thioester 247 by first  
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removing the methyl ester from 269 to give carboxylic acid 270. Treatment of the 
latter with N,N-dicyclohexylcarbodiimide in the presence of 4-dimethylaminopyridine 
followed by addition of tert-butyl mercaptan
19 led to thioester 247 in excellent yield. 
RO
O O
HOCH2CH2OH, 
p-TsOH, PhH, reflux
93%
DCC, DMAP;
then tBuSH
DCM, rt, 85%
RO
O O O
S
O O O
165: R = H
268: R = Me
MeOH, H2SO4 (cat.)
rt, 87%
269: R = Me
270: R = H
LiOH, THF-H2O (1:1)
rt, quant.
247
14
14 14
 
Scheme 3.8 Synthesis of thioester 247 (69% yield, 4 steps) 
  With aldehyde 246 and thioester 247 in hand, in was hoped that stereocontrol 
through an anti-aldol reaction would lead to the desired configuration at C14 and C15 
in carboxylic 242. In 1995, Paterson and Hulme
9 reported the use of thioester 271 as a 
substrate for aldol coupling with aldehyde 273 through (Z)-dicyclohexylboron enolate 
272. The reaction gave anti-aldol adducts 274, 275 and a syn adduct in a ratio of 
44:52:4 and in 71% total yield (Scheme 3.9).  
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S
O
S
O
B
OHC
OTBS O
OTBS O
t-BuS
OH O
Cy2BCl, Et3N,
pentane, 0 ºC
OTBS O
t-BuS
OH O
274 275 274 : 275 : syn = 44 : 52 : 4
-78 ºC        -20 ºC;
H2O2, MeOH/pH 7 buffer, rt
71%
+
271 272
(273)
 
Scheme 3.9 Paterson anti-aldol reaction of propionate thioester 271 with aldehyde 273 
  In  fact,  diastereoselectivity  of  aldol  reactions  of  α-methyl  chiral  aldehydes 
with enol borinates of ethyl ketones has been studied in detail.
20, 21 The  dominant 
element of stereocontrol that determines aldehyde facial selectivity is the minimization 
of gauche pentane interactions in competing chair-like transition states. In the case of 
271, the low level of intrinsic π-facial selectivity for Z-enol borinate 272 addition to 
aldehyde 273 suggested that both TS-1 and TS-2 (where R
2 is methyl) were almost 
equally favorable (Figure 3.2).  
O
B O
O
B O
R1
H
R2
H
L
L
H RL
Me
H
RL
H
Me
H
R2
R1 L
L
R1 = t-BuS
R2 = Me, Et
Felkin-Anh leads to C3-C4 syn anti-Felkin leads to C3-C4 anti
TS-1 TS-2
 
Figure 3.2 Transition states for Paterson anti-aldol reaction  
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However, when butyrate thioester 276 was used to generate Z-enol borinate 
277,  the  proportion  of  Felkin  addition  to  273  was  increased  over  its  propionate 
counterpart 271, as shown in Scheme 3.10. Anti-aldol products 278 and 279 were now 
obtained in a ratio of 37:61 (with 2% of a syn isomer). The formation of β-hydroxy 
thioester 279 (the Felkin adduct) was favored here due to increased gauche pentane 
interactions destabilizing TS-2 relative to TS-1 (where R
2 is ethyl in Figure 3.2). 
S
O
S
O
B
OHC
OTBS O
OTBS O
t-BuS
OH O
Cy2BCl, Et3N
pentane, 0 ºC
OTBS O
t-BuS
OH O
278 279 278 : 279 : syn = 37 : 61 : 2
-78 ºC        -20 ºC;
H2O2, MeOH/pH 7 buffer, rt
75%
+
276 277
273
 
Scheme 3.10 Paterson anti-aldol reaction of butyrate thioester 276 with 273 
We  hoped  that  the  enol  borinate  of  our  thioester  247,  which  has  a  longer 
carbon  chain  than  276,  would  exhibit  enhanced  Felkin  selectivity  in  an  anti-aldol 
reaction with aldehyde 246, but after many coupling experiments we observed only 
decomposition of the thioester and no product. We concluded that the ketal in 247 was 
the culprit and perhaps was unstable in the presence of dicyclohexylboron chloride. In 
light of this result, as well as a less than optimal prediction of Felkin steroselectivity in  
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anti-aldol additions of thioester 247, we decided to change our coupling strategy in 
favor of one developed by Masamune.
22 
  3.2.2  Second  Generation  Approach:  Construction  of  C13-C19  via 
Masamune Anti-Aldol Condensation 
  In this plan, we envisioned our carboxylic acid subunit 242 would be prepared 
by  a  Masamune  anti-aldol  reaction  of  aldehyde  246  with  ester  280,  as  shown  in 
Scheme 3.11.  
I
O
O
HO2C
19
13
242
Masamune anti-aldol
PMBO O
H
246 280
O
O Ph
N
Bn MesO2S
+
O O
15 19 14
 
Scheme 3.11 Retrosynthetic analysis of carboxylic acid 242 using a Masamune 
anti-aldol approach 
 
  Our second route to carboxylic acid 242 began with the synthesis of ester 281 
from carboxylic acid 270 (Scheme 3.12). Ketal acid 270 was esterified with alcohol 
281
22 using N,N-dicyclohexylcarbodiimide-assisted esterification in the presence of 4-
dimethylaminopyridine to afford 280 which was immediately reacted with aldehyde  
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270 in the presence of freshly prepared dicyclohexylboron triflate. This furnished in 
low yield the anti-aldol adduct 282 in which the cyclic ketal had been hydrolyzed. 
Since neither the low yield of this reaction nor loss of ketone protection from the 
product was compatible with advancement of 282, a modification was made to 280 
which we hoped would circumvent these problems.  
HO
O O O
N
OH
Bn MesO2S
Ph
DCC, DMAP, DCM
0 ºC       rt, 81%
O
O O O
N
Bn MesO2S
Ph
OPMB
O
Cy2BOTf, Et3N, DCM, -78 ºC;
then 246, -78 ºC        rt;
pH 7 buffer, MeOH, 30% H2O2,
rt, 23%
O
O Ph
N
Bn MesO2S
OH OPMB
O
270
(281)
280
(246) 282
14
14
19
15
19 15 13
 
Scheme 3.12 Synthesis of anti-aldol adduct 282 (19% yield, 2 steps) 
  To avoid loss of the ketal from 282, we decided to reduce the keto group of 
283 and employ in its place a protected alcohol, as shown in Scheme 3.13. Hydrolysis 
of cyclic ketal 280 under acidic conditions was achieved in excellent yield and the 
resultant  ketone  283  was  reduced  with  sodium  borohydride  to  afford  secondary 
alcohol 284 in quantitative yield as a mixture of diastereomers (d.r. 2:1 from 
1H and 
13C  NMR).  Finally,  the  free  hydroxyl  group  in  284  was  masked  as  its  tert-
butyldimethylsilyl ether 285.  
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Ph
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Scheme 3.13 Synthesis of ester 285 from cyclic ketal 280 (74% yield, 3 steps) 
  Prior to attempting an aldol coupling of 285 with aldehyde 246, a model study 
with benzaldehyde was performed, as shown in Scheme 3.14. Treatment of ester 285 
with dicyclohexylboron triflate followed by addition of benzaldehyde (286) afforded 
anti-aldol adduct 287 in good yield. As expected, the tert-butyldimethylsilyl ether was 
retained in this reaction. 
O
O
N
Bn MesO2S
Ph OTBS
Cy2BOTf, Et3N, DCM, -78 ºC;
then 286, -78 ºC        rt;
pH 7 buffer, MeOH, 30% H2O2
rt, 72%, d.r. > 20:1
O
H
O
O Ph
N
Bn MesO2S
OH
OTBS
287
285
(286)
14
14
 
Scheme 3.14 Masamune anti-aldol reaction of 285 with benzaldehyde 
  The  synthesis  of  287  gave  confidence  that  ester  285  would  be  a  viable 
candidate for an aldol reaction and we therefore scaled up preparation of 285. This led 
to a modified route, as illustrated in Scheme 3.15. For this pathway, commercially 
available keto acid 165 was treated with methanol in the presence of catalytic sulfuric  
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acid and the resulting keto ester 268 was reduced with sodium borohydride to give 
hydroxy  ester  288.  Protection  of  the  hydroxyl  group  in  288  with  tert-
butyldimethylsilyl chloride in the presence of imidazole gave silyl ether 289, from 
which the methyl ester was removed under basic conditions to furnish carboxylic acid 
290.  Esterification  of  290  with  alcohol  281  in  the  presence  of  N,N-dicyclo- 
hexylcarbodiimide and 4-dimethylaminopyridine afforded ester 285 in good yield as a 
mixture of 1:1 diastereomers.  
RO
O O
NaBH4, MeOH
67%
R1O
O OR2
DCC, DMAP, DCM
0 ºC         rt, 82%
N
OH
Bn MesO2S
Ph
O
O
N
Bn MesO2S
Ph OTBS
(281)
165: R = H
268: R = Me
MeOH, H2SO4 (cat.)
rt, 87%
TBSCl, imid., DMF, 72%
LiOH, THF-H2O, rt, 80%
288: R1 = Me, R2 = H
289: R1 = Me, R2 = TBS
290: R1 = H, R2 = TBS
285
14 14
14
 
Scheme 3.15 A modified route to ester 285 (28%, 5 steps) 
  The route from 165 to ester 285 in Scheme 3.15 gave an acceptable overall 
yield  but  required  two  extra  steps  due  to  protection  and  then  deprotection  of  the 
carboxyl group. If carboxylic acid 165 could be esterified with alcohol 281, this would 
reduce the number of steps to 285, and following this plan we first reacted 165 with 
alcohol  281  in  the  presence  of  N,N-dicyclohexylcarbodiimide  and  4-
dimethylaminopyridine to give ketone 283, as shown in Scheme 3.16. The ketone was 
reduced  with  sodium  borohydride  to  secondary  alcohol  284  as  a  mixture  of  
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stereoisomers  in  quantitative  yield  (d.r.  2:1).  Finally,  284  was  reacted  with  tert-
butyldimethylsilyl chloride in the presence of imidazole to yield silyl ether 285. 
O
O O Ph
N
Bn MesO2S
OH
Ph
NBn MesO2S
HO
O O
283 165
(281)
DCC, DMAP, DCM
0 ºC        rt, 95%
NaBH4, MeOH
quant.
O
O
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Bn MesO2S
Ph OR
TBSCl, imid.
DMF, 77%
284: R = H
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14
14
14
 
Scheme 3.16 Scaled up route to ester 285 from keto acid 165 (73% yield, 3 steps) 
  Having successfully scaled up synthesis of ester 285, we attempted an aldol 
reaction with aldehyde 246 under conditions used previously with benzaldehyde (287). 
Unfortunately, this gave an unacceptably low yield of anti-aldol product 291 (Scheme 
3.17). This disappointing result caused us to consider whether alkynal 246 was an 
appropriate  substrate  for  an  aldol  reaction  with  285,  since  in  practical  terms  an 
aldehyde similar to 37 would afford more direct access to our target 242. A new aldol 
coupling was therefore designed along this line. 
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Scheme 3.17 Anti-aldol reaction of aldehyde 246 with ester 285 
  The new aldehyde coupling partner for reaction with ester 285 was iodo alkene 
294  which  was  prepared  from  263  in  three  steps,  as  shown  in  Scheme  3.18. 
Hydrozirconation-iodination  of  alkyne  263  with  bis(cyclopentadienyl)zirconium 
chloride hydride
23 led to vinyl iodide 292, which underwent desilylation to primary 
alcohol  293.  Dess-Martin  oxidation  of  293  in  the  presence  of  sodium  hydrogen 
carbonate delivered aldehyde 294.  
294
OPMB
O I
OPMB
OTBDPS
263
19
15
15 19
Cp2ZrHCl, DCM, rt;
NIS, DCM, rt, 72%
OPMB
OR I
15 19
292: R = TBDPS
293: R = H
TBAF, THF, rt, 94%
DMP, NaHCO3
rt, 89%
 
Scheme 3.18 Synthesis of aldehyde 294 from alkyne 263 (60% yield, 3 steps) 
  To our delight, subjection of aldehyde 294 to an aldol reaction with 285 under 
conditions used with benzaldehyde furnished alcohol 295 in excellent yield (Scheme 
3.19). In contrast, ester 280 gave no product with 294 and was largely decomposed  
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under the same conditions, confirming our previous assumption that the cyclic ketal of 
280 was incompatible with this reaction. 
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Scheme 3.19 Synthesis of anti-aldol product 295 from 294 
  The sulfonamido ester of 295 was retained as a temporary protecting group for 
the  carboxylic  acid  so  that  the  p-methoxybenzyl  ether  could  be  reacted  with  2,3-
dichloro-5,6-dicyano-1,4-benzoquinone to provide cyclic acetal 296.
24 However, when 
296 was exposed to tetra-n-butylammonium fluoride we not only observed cleavage of 
the tert-butyldimethylsilyl ether but scission of the ester as well. This led to carboxylic 
acid 297 (32% yield) along with alcohol 281 (Scheme 3.20).   
 
72 
 
O
O Ph
N
Bn MesO2S
OH OPMB
I
OTBS
O
O Ph
N
Bn MesO2S
O O
I
PMP
295 296
DDQ, DCM, 4 A MS 
0 ºC, 74%
OTBS
TBAF, THF
rt, 32%
HO
O O O
I
OH
PMP
OH
Ph
N
Bn MesO2S
+
297 281
15
19
13 15
19
13
15
19
13
 
Scheme 3.20 Conversion of 295 to acetal 296 and cleavage to hydroxyl acid 297 
  In order to prevent cleavage of the ester while unmasking the silyl ether, 296 
was  treated  with  the  milder  fluoride  source  tris(dimethylamino)sulfonium 
difluorotrimethylsilicate  (TAS-F).  This  gave  secondary  alcohol  298  which  was 
oxidized with Dess-Martin periodinane to ketone 299 (Scheme 3.21). When 299 was 
subjected to p-toluenesulfonic acid in tetrahydrofuran-water, the major product was 
dihydroxy  ketone  300  resulting  solely  from  hydrolysis  of  the  benzylidene  acetal; 
however, internal ketalization of 299 was readily accomplished with the same acid 
under anhydrous conditions to give cyclic ketal 301 in excellent yield (Scheme 3.22). 
Having  served  its  dual purpose  as  a  stereocontrolling  and  a protecting  device,  the 
chiral auxiliary was removed from 301 under basic conditions to give carboxylic acid 
242.  
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Scheme 3.21 Synthesis of cyclic ketal 301 (11% yield, 4 steps) 
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Scheme 3.22 Synthesis of carboxylic acid 242 (78% yield, 2 steps) 
  Although  this  second  generation  route  to  242  was  successful  in  providing 
useful amounts of material in a linear sequence of 17 steps that gave a 6% overall 
yield from (R)-methyl 3-hydroxy-2-methylpropanoate (254), a more efficient pathway  
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to 242 with fewer steps was deemed desirable. This led to a search for an improved 
synthesis of 242 which resulted in a third generation route. 
  3.2.3 Third Generation Approach: Improved Route to 242 
  A  third  route  to  carboxylic  acid  242  was  investigated  that  began  with  full 
protection of cis-butene-1,4-diol 302 with p-methoxybenzyl bromide in the presence 
of tetra-n-butylammonium iodide to give 303 (Scheme 3.23).
25 Oxidative cleavage of 
olefin 303 was conducted under various conditions as shown in Table 3.2. Although 
each experiment gave a comparable yield of 304, we chose ozonolysis for our purpose 
(entry 1) due to its inexpensive nature and ease of product work up. After oxidative 
cleavage of 303, aldehyde 304
26 was subjected to asymmetric crotylation
11 with E-
crotyldiisopinocampheylborane  to  yield  homoallylic  alcohol  305  with  excellent 
stereoselectivity (d.r. > 20:1, Scheme 3.24). Protection of the hydroxyl group of 305 as 
its tert-butyldimethylsilyl ether 306
27 was followed by dihydroxylation of the alkene 
to produce 307. Oxidative-cleavage of the latter gave aldehyde 308, after which aldol 
reaction
22 with ester 285 furnished alcohol 309 in good yield.  
HO
OH
PMBO
OPMB
O
OPMB NaH, DMF;
TBAI, PMBCl
79%
302 303 304
conditions
17
 
Scheme 3.23 Synthesis of aldehyde 304 from diol 302 
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Table 3.2 Oxidative cleavage of olefin 303 to aldehyde 304 
 
Entry 
 
Conditions  Yield of 304 (%) 
 
1 
 
2 
 
3 
 
 
O3, DCM, -78 °C; Me2S, -78 °C to rt 
 
OsO4, NaIO4, Et2O-H2O (1:1) 
 
OsO4, NaIO4, 2,6-lutidine, dioxane-H2O (3:1) 
 
86 
 
88 
 
85 
 
OR
PMBO
O
OTBS
PMBO
Ph
O
N
MesO2S
O OTBS
Ph
OH
OPMB
OTBS
(+)-Ipc2BOMe, 
trans-2-butene,
n-BuLi, KOtBu, 
BF3·OEt2, -78 ºC
71% (d.r. > 20:1) TBSCl, imid.
DMF, 97%
NaIO4
MeOH/H2O
    95%
285, Cy2BOTf, Et3N
DCM, -78 ºC;
then 308, -78 ºC         rt;
pH 7 buffer, MeOH
30% H2O2
rt, 70%, 88% brsm, d.r. > 20:1 308 309
O
OPMB
304 305: R = H
306: R = TBS
OsO4, NMO
THF/t-BuOH/H2O
95%
17
17
TBSO
PMBO
17
15
15
OH
OH
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15
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13
 
Scheme 3.24 Synthesis of alcohol 309 from 304 (44% yield, 5 steps) 
  Our next goal with 309 was deprotection of both tert-butyldimethylsilyl ethers 
without removal of the chiral auxiliary for which the conditions listed in Table 3.4 
were  explored.  After  several  unsuccessful  experiments  that  led  either  to  α,β-
unsaturated lactone 310 (entries 1-3) or to mono-desilylated product 311 (entry 4), we 
found that exposure of 309 to hydrogen fluoride-pyridine complex
28 (entry 5) gave 
triol 312 in excellent yield. 
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Table 3.3 Deprotection of bis-tert-butyldimethylsilyl in 309 
Ph
O
N
MesO2S
O OTBS
Ph
OH
OPMB
OTBS
309
O O
OH
OPMB
Ph
O
N
MesO2S
O OH
Ph
OH
OPMB
OTBS
Ph
O
N
MesO2S
O OH
Ph
OH
OPMB
OH
312
310
311
conditions
15
18
13 15
18
13
15
18
13
13
15
18
 
 
Entry 
 
Conditions  Products  Yield (%) 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
TBAF, THF, rt 
 
HF-H2O, MeCN, rt 
 
TAS-F, DMF, 0 °C to rt 
 
TAS-F, H2O, DMF, rt 
 
HF⋅py, THF, 0 °C to rt 
 
310 
 
310 
 
310 
 
311 
 
312 
 
66 
 
66 
 
80 
 
84 
 
94 
 
With the 1,3-diol moiety of triol 312 now exposed, the latter was reacted with 
2,2-dimethoxypropane  in  the  presence  of  pyridinium  p-toluenesulfonate  to  provide 
acetonide 313.
29 In a parallel sequence, diol 311 was also converted to its acetonide 
314, which was subjected to desilylation with hydrogen-fluoride pyridine complex to  
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give  313  (Scheme  3.25).  In  this  way,  material  obtained  from  309  by  two  routes 
(entries 4 and 5, Table 3.4) were converged at acetonide 313. 
Ph
O
N
MesO2S
O OH
Ph
OH
OPMB
OTBS
Ph
O
N
MesO2S
O O
Ph
O
OPMB
OTBS
CSA, acetone,
4 A MS, reflux
82%
OMe MeO
Ph
O
N
MesO2S
O O
Ph
O
OPMB
OH
HF·Py, THF
0 ºC        rt, 96%
Ph
O
N
MesO2S
O O
Ph
O
OPMB
OH
PPTS, DCM
reflux, quant.
OMe MeO
Ph
O
N
MesO2S
O OH
Ph
OH
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OH
15
18
13 15
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13
312 313
311 314
313
15
18
13 15
18
13
15
18
13
 
Scheme 3.25 Synthesis of alcohol 313 from triol 312 and diol 311  
(quantitative yield, 1 step from 314, 79% yield, 2 steps from 313) 
 
  The remaining hydroxyl group in 313 was oxidized with Dess-Martin reagent
30 
to  ketone  315  which  upon  exposure  to  p-toluenesulfonic  acid  underwent  internal 
transketalization to furnish cyclic ketal 316.
31 The primary hydroxyl group of 316 was 
unmasked with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone
32, 33 and alcohol 317 was 
oxidized either with Dess-Martin periodinane or under Swern conditions
34 to deliver 
aldehyde 318. Takai olefination
35 of 318 in the presence of chromous chloride and  
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iodoform gave vinyl iodide 301 in good yield (E:Z  5:1), and final removal of the 
chiral auxiliary from 301 with lithium hydroxide produced carboxylic acid 242. 
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O O
Ph
O
OPMB
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89%
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Scheme 3.26 Improved route to 242 (59% yield, 6 steps) 
Whereas our second generation route to vinyl iodide 242 required 17 steps and 
resulted  in  6%  overall  yield  from  (R)-methyl  3-hydroxy-2-methylpropanoate  (254), 
the third generation synthesis gave a better overall yield (13%) and required fewer 
steps  (15).  Also,  protected  primary  alcohol  in  316  in  the  third  generation  route 
(Scheme 3.26) provides a more flexible locus for connection to its partner than the 
terminal alkyne  in 263  (Scheme  3.18)  since alkynes  are  generally  less  useful than 
alcohols in terms of synthetic modification. Lastly, the fact that starting material 302 is  
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much  less  expensive  than  254  made  our  third  generation  route  the  overwhelming 
choice for synthesis of 242. 
In summary, synthesis of carboxylic acid 242 demonstrated that a Masamune 
anti-aldol condensation strategy can be used to set in place the stereochemistry of a 
complex α-alkyl-β-hydroxy propanoyl function which is not accessible via Paterson’s 
anti-aldol methodology. Considerable effort was devoted to optimizing our route to 
242 which was prepared in 15 steps from 302 and with an overall yield of 13%. 
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3.4 Experimental Section 
 
General techniques: All reactions requiring anhydrous conditions were conducted in 
flame dried glass apparatus under an atmosphere of argon. THF, Et2O, CH2Cl2, DMF, 
benzene and acetonitrile were dried by passage through an activated alumina column 
under argon. DMSO was distilled from CaH2 at 15 mm Hg and stored over activated 
4Å molecular sieves. Anhydrous MeOH was freshly distilled from calcium hydride. 
Preparative chromatographic  separations were performed on  silica gel  (35-75 µm); 
reactions were followed by TLC analysis using silica plates with fluorescent indicator 
(254 nm) and visualized with a UV lamp or phosphomolybdic acid. All commercially 
available reagents were purchased from TCI or Aldrich and used as received unless 
stated otherwise. Melting points were measured on a Büchi melting point apparatus. 
Optical  rotations  were  measured  with  a  Perkin-Elmer  243  polarimeter  at  ambient 
temperature using a 1 mL capacity cell with 1 dm path length. Infrared (IR) spectra 
were recorded on a Nicolet NEXUS 470 FT-IR using a thin film supported on KBr 
discs or dispersed in a KBr pellet. 
1H and 
13C NMR spectra were recorded in Fourier 
transform mode at the field strength specified on either a 300 or 400 or 700 MHz 
spectrometer. Spectra were obtained on CDCl3 solutions on 5 mm diameter tubes, and 
chemical shifts in ppm (part per million) are quoted relative to the residual signals of 
chloroform (δH 7.26 ppm, or δC 77.0 ppm). Multiplicities in the 
1H NMR spectra are 
described as: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad;  
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coupling constants (J) are reported in Hz. Low (MS) and high (HRMS) resolution 
mass spectra are reported with ion mass/charge (m/z) ratios as values in atomic mass 
units. 
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MeO2C
OTBDPS
255  
(R)-Methyl 3-(tert-Butyldiphenylsilyloxy)-2-methylpropanoate (255) 
To a stirred solution of (2R)-methyl 3-hydroxy-2-methylpropionate (254) (2.0 
g, 16.9 mmol), imidazole (1.73 g, 25.4 mmol) and DMAP (0.104 g, 0.851 mmol) in 
dichloromethane (60 mL)  at room temperature was added TBDPSCl (5.58 g, 20.3 
mmol)  and  the  resulting  mixture  was  stirred  for  16  h.  The  reaction  mixture  was 
quenched with water (50 mL) and the organic layer was separated and washed with 
water and brine, then dried over anhydrous Na2SO4. The resulting solution was filtered 
and concentrated under reduced pressure to give a residue which was purified by flash 
chromatography (hexanes:EtOAc 60:1) to provide ester 255 as a colorless oil (5.42 g, 
90%): [α]D
23 -15.5 (c 1.00, CHCl3); IR (neat) 3070, 3050, 2932, 2858, 1741, 1472, 
1428, 1199, 1176, 1111, 824, 810, 739, 702, 614, 505 cm
-1; 
1H NMR (300 MHz, 
CDCl3) δ (ppm) 1.06 (s, 9H), 1.18 (d, J = 6.9 Hz, 3H), 2.74 (m, 1H), 3.71 (s, 3H), 3.74 
(dd, J = 10.5, 5.7 Hz, 1H), 3.85 (dd, J = 10.5, 6.9 Hz, 1H), 7.38-7.45 (m, 6H), 7.66-
7.69 (m, 4H); 
13C NMR (75 MHz, CDCl3) δ (ppm) 13.5, 19.2, 26.7, 42.4, 51.5, 65.9, 
127.7, 129.7, 133.7, 135.6, 175.0. 
256
OTBDPS H
O
 
(R)-3-(tert-Butyldiphenylsilyloxy)-2-methylpropanal (256)  
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To  a  stirred  solution  of  ester  255  (788.1  mg,  2.21  mmol)  in  anhydrous 
dichloromethane (8.0 mL) at -78 °C was added DIBAL-H (1.0 M solution in hexanes, 
2.36 mL, 2.36 mmol) dropwise over 8 min. After stirring for an additional 6 h at -78 
°C, the reaction mixture was quenched by adding MeOH (0.8 mL) via syringe pump 
dropwise to maintain the temperature below -70 °C. The resulting mixture was slowly 
warmed to room temperature and poured into saturated aqueous potassium-sodium 
tartrate solution (8.0 mL). The mixture was vigorously stirred at room temperature 
until phase separation occurred (usually 6 h), and the aqueous layer was extracted 
thoroughly with DCM (3 x 8.0 mL). The combined organic phases were washed with 
saturated aqueous NaCl (2 x 6.0 mL), dried over anhydrous Na2SO4, and concentrated 
under reduced pressure. Purification of the crude residue via flash chromatography 
(5% EtOAc in hexanes) afforded aldehyde 256 (619.5 mg, 86%) as a colorless oil: 
[α]D
23    -20.8 (c 0.88, CHCl3); IR (neat) 3071, 3050, 2932, 2858, 2807, 2713, 1738, 
1589, 1472, 1428, 1391, 1112, 1035, 824, 741, 702, 614, 505 cm
-1; 
1H NMR (300 
MHz, CDCl3) δ (ppm) 1.06 (s, 9H), 1.12 (d, J = 7.2, 3H), 2.59 (m, 1H), 3.87-3.92 (m, 
2H), 7.39-7.47 (m, 6H), 7.65-7.68 (m, 4H), 9.79 (d, J = 1.5 Hz, 1H); 
13C NMR (75 
MHz, CDCl3) δ (ppm) 10.3, 19.2, 26.8, 48.8, 64.1, 127.8, 129.8, 133.2, 135.6, 204.4.  
OTBDPS
EtO2C
258  
(S,E)-Ethyl 5-(tert-Butyldiphenylsilyloxy)-4-methylpent-2-enoate (258)  
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  To a stirred solution of aldehyde 256 (3.37g, 10.3 mmol) in THF (100 mL) 
was added carbethoxymethylenetriphenyl phosphorane (257) (5.39 g, 15.5 mmol) and 
the resulting mixture was heated at reflux for 16 h. The reaction mixture was cooled to 
room temperature and quenched with saturated aqueous NH4Cl (50 mL). The layers 
were  separated  and  the  aqueous  phase  was  extracted  with  Et2O  (100  mL).  The 
combined organic extracts were dried over anhydrous MgSO4 and filtered, and the 
solvent was removed by rotary evaporation under reduced pressure. The crude product 
was purified by flash chromatography (10% EtOAc in hexanes) to afford ester 258 
(3.61 g, 88%) as a colorless oil: [α]D
25 -7.8 (c 1.00, CHCl3); IR (neat) 3071, 3050, 
2931, 2858, 1722, 1653, 1589, 1472, 1428, 1367, 1390, 1149, 1182, 1087, 1034, 740, 
705, 614, 507 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 1.08 (s, 9H), 1.10 (d, J = 6.8 
Hz, 3H), 1.32 (t, J = 7.2 Hz, 3H), 2.58 (m, 1H), 3.60 (m, 2H), 4.22 (q, J = 7.2 Hz, 2H), 
5.86 (d, J = 16.0 Hz, 1H), 6.98 (dd, J = 16.0, 7.2 Hz, 1H), 7.39-7.47 (m, 6H), 7.66-
7.68 (m, 4H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 14.3, 15.6, 19.3, 26.8, 39.1, 60.2, 
67.5, 121.1, 127.7, 129.7, 133.5, 133.6, 135.6, 151.3, 166.7.  
OTBDPS HO
259  
(S,E)-5-(tert-Butyldiphenylsilyloxy)-4-methylpent-2-en-1-ol (259) 
To a stirred solution of ester 258 (3.50 g, 8.825 mmol) in DCM (90 mL) at -78 
°C was added dropwise a solution of DIBAL-H (1M solution in hexanes, 35.4 mL, 
35.4 mmol). Upon completion of the reaction (about 2 h), as judged by TLC analysis,  
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the reaction was quenched by pouring the mixture into a vigorously stirred saturated 
solution of Rochelle’s salt (50 mL) and the solution was diluted with Et2O (50 mL). 
The phases were separated and the aqueous phase was further extracted with Et2O (2 x 
70 mL). The combined organic phases were dried over anhydrous MgSO4 and filtered, 
and the solvent was removed under reduced pressure. The crude product was purified 
by flash chromatography (10% EtOAc in hexanes) to provide allylic alcohol 259 (3.08 
g, 98%) as a colorless oil: [α]D
23 -3.6 (c 1.00, CHCl3); IR (neat) 3340 (br), 3063, 3050, 
2958, 2930, 2857, 1587, 1472, 1467, 1428, 1389, 1112, 1008, 972, 824, 740, 702, 614, 
505 cm
-1; 
1H NMR (300 MHz, CDCl3) δ (ppm) 1.06 (d, J = 7.2 Hz, 3H), 1.08 (s, 9H), 
2.44 (m, 1H), 3.56 (m, 2H), 4.09 (m, 2H), 5.64-5.66 (m, 2H), 7.38-7.45 (m, 6H), 7.67-
7.69 (m, 4H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 16.4, 19.3, 26.9, 38.9, 63.9, 68.5, 
127.6, 128.8, 129.6, 133.9, 135.5, 135.6.  
OTBDPS HO
O
260  
((2R,3R)-3-((R)-1-(tert-Butyldiphenylsilyloxy)propan-2-yl)oxiran-2-yl)methanol 
(260) 
Ti(Oi-Pr)4 (30.2 mg, 0.03 mL, 0.106 mmol) was added to a stirred suspension 
containing 4 Å MS (100 mg) and diethyl (−)-tartrate (26.3 mg, 0.02 mL, 0.128 mmol) 
in  DCM  (0.4  mL)  at -20 °C  under  an  argon  atmosphere.  After  15  min, tert-butyl 
hydroperoxide (5.5 M in decane, 0.04 mL, 0.213 mmol) was added and the resulting  
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mixture was stirred for 20 min. A solution of allylic alcohol 259 (37.7 mg, 0.106 
mmol) in DCM (0.3 mL) was then added dropwise over 2 min. The mixture was 
stirred at -20 °C for 36 h and poured into a cold solution of tartaric acid (10% w/w 
solution in water) saturated with FeSO4 (0.8 mL). Stirring  was  continued at room 
temperature for 30 min, and DCM (2.0 mL) was added followed by 30% NaOH (0.1 
mL). The mixture was stirred for 30 min and extracted with DCM. The extracts were 
washed  with  brine,  dried  over  anhydrous  Na2SO4,  and  concentrated.  Flash 
chromatography (40% EtOAc in hexanes) of the residue furnished epoxy alcohol 260 
(35.4 mg, 90%) as a colorless oil: [α]D
25 +8.3 (c 1.00, CHCl3); IR (neat) 3419 (br), 
3071, 3050, 2959, 2930, 2857, 1716, 1653, 1589, 1472, 1428, 1390, 1362, 1113, 1025, 
1008, 899 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 1.03 (d, J = 6.8 Hz, 3H), 1.74 
(m, 1H), 1.10 (s, 9H), 3.64-3.77 (m, 3H), 3.03 (m, 2H), 3.94 (d, J = 12 Hz, 1H), 7.41-
7.46 (m, 6H), 7.69-7.70 (m, 4H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 12.8, 19.3, 
26.9, 37.8, 57.0, 57.5, 61.9, 65.9, 127.7, 129.7, 133.6, 135.6. 
OTBDPS Cl
O
261  
tert-Butyl((R)-2-((2R,3S)-3-(chloromethyl)oxiran-2-yl)propoxy)diphenylsilane 
(261) 
To  a  solution  of  epoxy  alcohol  260  (29.2  mg,  0.0788  mmol)  and 
triphenylphosphine  (24.8  mg,  0.0946  mmol)  in  DCM  (5.0  mL)  was  added  N- 
 
89 
 
chlorosuccinimide (12.6 mg, 0.0946 mmol), and the resulting mixture was heated at 
reflux for 1 h. After cooling to room temperature, the reaction mixture was partitioned 
between  DCM  (4.0  mL)  and  H2O  (5.0  mL).  The  organic  layer  was  dried  over 
anhydrous MgSO4, filtered, and concentrated in vacuo. Purification of the residue via 
flash chromatography (1% EtOAC in hexanes) afforded chloride 261 (27.4 mg, 89%) 
as a colorless oil: [α]D
25 +2.5 (c 1.00, CHCl3); IR (neat) 3070, 3050, 2960, 2930, 
2857, 1472, 1428, 1391, 1263, 1113, 1021, 824, 799, 740, 702, 615, 504 cm
-1; 
1H 
NMR (300 MHz, CDCl3) δ (ppm) 1.03 (d, J = 6.9 Hz, 3H), 1.09 (s, 9H), 1.68-1.75 (m, 
1H), 2.96 (dd, J = 6.9, 1.8 Hz, 1H), 3.10 (dt, J = 6.0, 1.8 Hz, 1H), 3.57 (m, 2H), 3.70 
(m, 2H), 7.39-7.46 (m, 6H), 7.67-7.70 (m, 4H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 
12.8, 19.3, 26.9, 37.8, 44.9, 55.9, 60.7, 65.8, 127.7, 129.7, 133.5, 135.6. 
OH
OTBDPS
262  
(3R,4R)-5-(tert-Butyldiphenylsilyloxy)-4-methylpent-1-yn-3-ol (262) 
To neat diisopropylamine (3.30 mL, 23.7 mmol) at 0 °C was added n-BuLi 
(14.2 mL of a 1.52 M solution in hexanes, 21.5 mmol) dropwise. After stirring for 20 
min at 0 °C, THF (4.6 mL) was added to provide a 1 M solution of LDA. The LDA 
(21.5 mL of a 1M solution, 21.5 mmol) was added via cannula to a solution of chloride 
261 (2.38 g, 6.13 mmol) in THF (35 mL) at -35 °C. After 30 min, the reaction mixture 
was quenched by addition of saturated aqueous NH4Cl (14 mL), diluted with Et2O (35  
 
90 
 
mL) and was washed with H2O (35 mL), saturated aqueous CuSO4 (35 mL), and brine 
(35  mL).  The  organic  layer  was  dried  over  anhydrous  MgSO4,  filtered  and 
concentrated in vacuo. Purification of the resultant oil via flash chromatography (20% 
EtOAc in hexanes) provided alkyne 262 (1.91 g, 88 %) as a colorless oil: [α]D
23 -9.3
 (c 
1.00, CHCl3); IR (neat) 3417 (br), 3308, 3071, 3050, 2959, 2929, 2857, 1712, 1659, 
1589, 1471, 1428, 1391, 1362, 1189, 1112, 1028, 999, 823, 802, 740, 702, 614, 505 
cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 1.05 (d, J = 7.2 Hz, 3H), 1.08 (s, 9H), 2.04 
(m, 1H), 2.51 (d, J = 2.8 Hz, 1H), 3.35 (d, J = 5.6 Hz, 1H), 3.64 (dd, J = 10.4, 6.8 Hz, 
1H), 3.95 (dd, J= 10.4, 4.0 Hz, 1H), 4.55 (br s, 1H), 7.40-7.49 (m, 6H), 7.69-7.72 (m, 
4H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 12.8, 19.2, 26.8, 40.7, 66.4, 67.2, 73.6, 
83.8, 127.8, 129.9, 132.9, 135.7. 
OPMB
OTBDPS
263  
((2R,3R)-3-(4-Methoxybenzyloxy)-2-methylpent-4-ynyloxy)(tert-
butyl)diphenylsilane (263) 
To a stirred solution of alcohol 262 (1.00 g, 2.831 mmol) and freshly prepared 
4-methoxybenzyl  trichloroacetimidate  (3.20  g,  11.322  mmol)  in  DCM  (20  mL)  at 
room temperature was added camphorsulfonic acid (65.8 mg, 0.283 mmol) and the 
resulting mixture was stirred for 48 h. The reaction mixture was filtered through a pad 
of Celite, and the pad was washed with 1:2 DCM/hexane (40 mL). The combined  
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organic  layers  were  washed  with  saturated  aqueous  NaHCO3  (25  mL),  dried  over 
anhydrous  MgSO4,  concentrated  under  reduced  pressure  and  purified  by  flash 
chromatography (10% EtOAc/hexanes) to give ether 263 (1.23 g, 92%) as a colorless 
oil: [α]D
25 +28.8 (c 1.00, CHCl3); IR (neat) 3287, 3070, 2958, 2930, 2857, 1612, 1513, 
1428, 1248, 1112, 1036, 824, 703 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 1.03 (s, 
9H), 1.06 (d, J = 6.8 Hz, 3H), 2.11 (m, 1H), 2.46 (d, J = 2.0 Hz, 1H), 3.64-3.71 (m, 
2H), 3.82 (s, 3H), 4.38 (dd, J = 6.4 and 2.0 Hz, 1H), 4.48 (A of ABq, J = 11.6 Hz, 
1H), 4.78 (B of ABq, J = 11.6 Hz, 1H), 6.88 (d, J = 8.8 Hz, 2H), 7.29 (d, J = 8.8 Hz, 
2H), 7.36-7.46 (m, 6H), 7.64-7.66 (m, 4H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 
12.3, 19.3, 26.8, 40.4, 55.3, 65.0, 69.7, 70.4, 74.9, 81.4, 113.9, 127.6, 129.6, 130.0, 
133.6,  133.7,  135.6,  135.7,  159.2;  HRMS  calcd  for  C30H36O3NaSi  [M+Na]
+  m/z 
495.2331, found m/z 495.2294. 
OPMB
OH
264  
(2R,3R)-3-(4-Methoxybenzyloxy)-2-methylpent-4-yn-1-ol (264) 
To a stirred solution of ether 263 (974 mg, 2.06 mmol) in THF (20 mL) at 
room temperature was added TBAF (2.47 mL of a 1M solution in THF, 2.47 mmol). 
After 14 h, the solution was diluted with Et2O (80 mL) and was washed with water (60 
mL) and brine (60 mL). The organic layer was dried over anhydrous MgSO4, filtered, 
and concentrated in vacuo. Purification of the resultant oil via flash chromatography  
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(10% EtOAc/hexanes) afforded alcohol 264 (433 mg, 90%) as a colorless oil: [α]D
21 
+123.3 (c 1.00, CHCl3); IR (neat) 3427 (br), 3292, 2931, 2867, 1613, 1586, 1514, 
1464, 1303, 1247, 1174, 1033, 821 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 1.03 (d, 
J = 7.2 Hz, 3H), 2.09 (m, 1H), 2.55 (d, J = 2.4 Hz, 1H), 3.60 (dd, J = 11.2, 7.2 Hz, 
1H), 3.72 (dd, J = 11.2, 3.6 Hz, 1H), 3.83 (s, 3H), 4.07 (dd,  J = 7.2, 2.4 Hz, 1H), 4.48 
(A of ABq, J = 11.2 Hz, 1H), 4.81 (B of ABq, J = 11.2 Hz, 1H), 6.91 (d, J = 8.8 Hz, 
2H), 7.30 (d, J = 8.8 Hz, 2H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 13.3, 40.5, 55.3, 
66.1, 70.6, 72.5, 75.1, 81.4, 113.9, 129.3, 129.8, 159.4; HRMS calcd for C14H18O3 
[M]
+ m/z 234.1256, found m/z 234.1258. 
OPMB
O
246  
(2S,3R)-3-(4-Methoxybenzyloxy)-2-methylpent-4-ynal (246) 
To a stirred mixture of alcohol 264 (25.5 mg, 0.109 mmol) and NaHCO3 (27.4 
mg,  0.327  mmol)  in  DCM  (5.0  mL)  at  room  temperature  was  added  Dess-Martin 
periodinane (69.2 mg, 0.163 mmol) and the mixture was stirred at room temperature 
for 1.5 h. The reaction mixture was quenched with saturated aqueous NaHCO3 and 
extracted with DCM (3 x 5.0 mL). The combined extract was washed with water (5.0 
mL) and brine (5.0 mL), dried over anhydrous MgSO4, and concentrated in vacuo. 
Purification  of  the  crude  product  via  flash  chromatography  (10%  EtOAc/hexanes) 
provided aldehyde 246 (23.2 mg, 92%) as a yellow oil: [α]D
22 +133.8 (c 1.00, CHCl3);  
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IR(neat) 3280, 2921, 2850, 2720, 2113, 1733, 1613, 1515, 1457, 1248, 1174, 1033, 
818, 708, 517 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 1.21 (d, J = 7.2 Hz, 3H), 
2.61 (d, J = 1.6 Hz, 1H), 2.76 (m, 1H), 3.83 (s, 3H), 4.32 (dd, J = 6.4, 1.6 Hz, 1H), 
4.49 (A of ABq, J =11.2 Hz, 1H), 4.79 (B of ABq, J = 11.2 Hz, 1H), 6.90 (d, J = 8.4 
Hz, 2H), 7.28 (d, J = 8.4 Hz, 2H), 9.75 (s, 1H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 
10.5, 50.7, 55.3, 68.3, 70.5, 76.2, 80.2, 113.9, 129.1, 129.8, 159.5, 202.3; HRMS calcd 
for C14H16O3Na [M+Na]
+ m/z 255.0997, found m/z 255.0979. 
MeO
O O
268  
Methyl 5-Oxohexanoate (268) 
5-Oxohexanoic acid (165) (3.01 g, 23.2 mmol) was esterified with MeOH (34 
mL) and H2SO4 (0.1 mL) at room temperature. After 13 h, most of the methanol was 
evaporated and the residue was dissolved in ether (50 mL). The solution was rinsed 
with dilute aqueous NaHCO3 (30 mL), the aqueous layer was extracted with Et2O (4 x 
25  mL)  and  the  combined  organic phases  were  dried  over  anhydrous  MgSO4  and 
concentrated in vacuo to give ester 268 (2.89 g, 87 %) as a pale yellow oil: IR (neat) 
2954, 1734, 1716, 1438, 1368, 1157, 1073, 1005, 889, 851 cm
-1; 
1H NMR (400 MHz, 
CDCl3) δ (ppm) 1.91 (m, 2H), 2.15 (s, 3H), 2.36 (t, J = 7.2 Hz, 2H), 2.52 (t, J = 7.2 
Hz, 2H), 3.68 (s, 3H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 18.8, 29.9, 33.0, 42.4, 
51.6, 173.6, 208.0.  
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MeO
O O O
269  
Methyl 4-(2-Methyl-1,3-dioxolan-2-yl)butanoate (269) 
Methyl ester 268 (2.77 g, 19.2 mmol), ethylene glycol (1.79 g, 28.8 mmol) and 
p-toluenesulfonic acid (25.6 mg, 0.135 mmol) was refluxed for 4 h in benzene (30 
mL)  beneath  a  Dean-Stark  trap.  The  solution  was  rinsed  with  saturated  aqueous 
NaHCO3 (25 mL) and the aqueous layer was extracted with ether (3 x 25 mL). The 
combined organic phases were washed with water (25 mL) and saturated aqueous 
NaCl, dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford 
ketal 269 (3.35 g, 93 %) as a yellow oil: IR (neat) 2982, 2954, 2883, 1743, 1437, 
1378, 1259, 1199, 1174, 1135, 1065, 948, 870, 846 cm
-1; 
1H NMR (400 MHz, CDCl3) 
δ (ppm) 1.34 (s, 3H), 1.67-1.80 (m, 4H), 2.26 (t, J = 7.2 Hz, 2H), 3.69 (s, 3H), 3.93-
3.97 (m, 4H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 19.6, 23.8, 34.0, 38.3, 51.5, 64.7, 
109.7, 174.0. 
HO
O O O
270  
4-(2-Methyl-1,3-dioxolan-2-yl)butanoic Acid (270) 
To a stirred solution of ester 269 (2.15 g, 9.86 mmol) in THF (30 mL) and 
water (30 mL) at room temperature was added LiOH⋅H2O (620 mg, 14.8 mmol) and  
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the resulting mixture was stirred for 2.5 h. The reaction mixture was acidified to pH 5 
with dilute aqueous HCl and extracted with EtOAc (3 x 30 mL). The extract was 
washed  with  water  (30  mL),  brine  (30  mL),  dried  over  anhydrous  MgSO4  and 
concentrated under reduced pressure to provide crude carboxylic acid 270 (1.83 g, 
quant.) as a colorless oil: IR (neat) 3300-2900 (br), 2982, 1709, 1379, 1220, 1064, 
948, 839 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 1.32 (s, 3H), 1.77-1.82 (m, 4H), 
2.41 (t, J = 6.8 Hz, 2H), 3.93-4.00 (m, 4H), 11.15-11.50 (br s, 1H); 
13C NMR (100 
MHz, CDCl3) δ (ppm) 19.2, 23.8, 33.9, 38.2, 64.7, 109.7, 179.6; HRMS calcd for 
C8H15O4 [M+1]
+ m/z 175.0970, found m/z 175.0974. 
S
O O O
247  
S-tert-Butyl 4-(2-Methyl-1,3-dioxolan-2-yl)butanethioate (247) 
DCC (1M solution in DCM, 1.57 mL, 1.57 mmol) and DMAP 9.6 mg, 0.079 
mmol) were added to a solution of carboxylic acid 270 (137 mg. 0.786 mmol) in DCM 
(4.5 mL) and the resulting mixture was cooled to -5 °C. After stirring for 5 min, t-
BuSH (89 µL, 0.786 mmol) was added in one portion and stirring was continued at -5 
°C for 45 min. The reaction mixture was allowed to warm to room temperature and 
was kept at that temperature for 14 h, at which point all of carboxylic acid 270 had 
been  consumed.  The  mixture  was  filtered  and  the  filtrate  was  concentrated  under 
reduced  pressure.  The  residue  was  purified  by  silica  gel  chromatography  (10  %  
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EtOAc/hexanes) to provide thioester 247 (164 mg, 85%) as a yellow oil: IR (neat) 
2962, 2880, 1684, 1477, 1457, 1377, 1364, 1251, 1220, 1142, 1065, 968, 947, 872, 
616 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 1.32 (s, 3H), 1.46 (s, 9H), 1.69-1.78 
(m, 4H), 2.51 (t, J = 1.6 Hz, 2H), 3.91-3.99 (m, 4H); 
13C (100 MHz, CDCl3) δ (ppm) 
20.2, 23.8, 29.8, 38.1,  44.5, 48.9, 64.7, 109.7, 200.3; HRMS calcd for C12H23O3S 
[M+1]
+ m/z 247.1368, found m/z 247.1375. 
O
O
O O
N
Bn MesO2S
Ph
280  
(1R,2S)-2-(N-Benzyl-2,4,6-trimethylphenylsulfonamido)-1-phenylpropyl              
4-(2-Methyl-1,3-dioxolan-2-yl)butanoate (280) 
DCC (1M solution in DCM, 3.3 mL, 3.30 mmol) and DMAP (20.1 mg, 0.164 
mmol) were added to a stirred solution of carboxylic acid 270 (287 mg. 1.65 mmol) in 
DCM (5.0 mL) and the resulting mixture was cooled to 0 °C. After stirring for 5 min, 
alcohol 281 (698 mg, 1.65 mmol) was added in one portion and stirring was continued 
at 0 °C for 45 min. The reaction mixture was allowed to warm to room temperature 
and was kept at that temperature for 19.5 h, at which point all of carboxylic acid 270 
had  been  consumed.  The  reaction  mixture  was  filtered  and  the  filtrate  was 
concentrated under reduced pressure. The crude product was purified by silica gel 
chromatography  (10  %  EtOAc/hexanes)  to provide  ester 280  (772  mg,  81%)  as  a 
white solid: mp 90-92 °C; [α]D
21 +14.5 (c 1.00, CHCl3); IR(neat) 3063, 3031, 2981,  
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2940, 2880, 1744, 1604, 1496, 1454, 1379, 1328, 1205, 1149, 1055, 1061, 932, 859, 
764, 731, 700, 659, 568, 537 cm-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 1.15 (d, J = 
6.8 Hz, 3H), 1.29 (s, 3H), 1.68-1.57 (m, 4H), 2.27-2.09 (m, 2H), 2.30 (s, 3H), 2.53 (s, 
6H), 3.96-3.87 (m, 4H), 4.07 (dq, J = 6.8 and 4.0 Hz, 1H), 4.62 (A of ABq, JAB = 16.8 
Hz, 1H), 4.76 (B of ABq, JAB = 16.8 Hz, 1H), 5.85 (d, J = 4.0 Hz, 1H), 6.90 (s, 2H), 
6.94-6.92 (m, 2H), 7.37-7.18 (m, 8H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 12.9, 
19.2, 20.9, 23.0, 23.8, 34.0, 38.2, 48.2, 56.7, 64.6, 78.0, 109.7, 126.0, 127.1, 127.4, 
127.8, 128.3, 128.4, 132.2, 133.4, 138.6, 138.7, 140.2, 142.5, 171.7; HRMS calcd for 
C33H42NO6S [M+1]
+ m/z 580.2733, found m/z 580.2720. 
O
O
N
Bn MesO2S
Ph O
283  
(1R,2S)-2-(N-Benzyl-2,4,6-trimethylphenylsulfonamido)-1-phenylpropyl              
5-Oxohexanoate (283) 
Method A. A solution of ketal 280 (270.8 mg, 0.467 mmol) in THF (8.0 mL) 
was treated with 1 M HCl (1.3 mL) at 0 °C and the resulting mixture was allowed to 
warm to room temperature. After 38 h, a solution of NaOH (96.0 mg) in water (5.0 
mL) was added slowly. The aqueous phase was extracted with Et2O (10.0 mL) and the 
combined organic phase was washed with water (2 x 5.0 mL), dried over anhydrous 
Na2SO4 and concentrated under reduced pressure. The crude product was purified by  
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flash chromatography (30 % EtOAc/hexanes) to provide ketone 283 (240.1 mg, 96%) 
as a white solid.  
  Method B. DCC (1M solution in DCM, 10.0 mL, 10 mmol) was added to a 
stirred solution of DMAP (94.0 mg, 0.768 mmol) and alcohol 281 (3.26 g, 7.68 mmol) 
in DCM (50 mL) and the resulting mixture was cooled to -5 °C. After stirring for 5 
min, carboxylic acid 165 (1.00 g, 7.68 mmol) was added in one portion and stirring 
was continued at -5 °C for 45 min. The reaction mixture was allowed to warm to room 
temperature and after 34 h all of carboxylic acid 165 had been consumed. The reaction 
mixture was filtered and the filtrate was concentrated in vacuo. The crude product was 
purified by flash chromatography (30 % EtOAc/hexanes) to provide ester 283 (3.91 g, 
95%) as a white solid: mp. 105-107 °C; [α]D
25 +6.7 (c 2.22, CHCl3); IR (neat) 3088, 
3064, 3029, 2982, 2940, 1743, 1715, 1604, 1565, 1496, 1454, 1418, 1381, 1322, 1205, 
1151, 1073, 1056, 1016, 931, 860, 763, 731, 700, 660 cm
-1; 
1H NMR (400 MHz, 
CDCl3) δ (ppm) 1.14 (d, J = 6.8 Hz, 3H), 1.72-1.80 (m, 2H), 2.06-2.14 (m, 1H), 2.09 
(s, 3H), 2.19-2.27 (m, 1H), 2.30 (s, 3H), 2.38 (t, J =7.2 Hz, 2H), 2.54 (s, 6H), 4.04-
4.10 (m, 1H), 4.67 (ABq, J = 16.4 Hz, 2H), 5.88 (d, J = 4 Hz, 1H), 6.89 (s, 2H), 6.94-
6.96 (m, 2H), 7.20-7.35 (m, 8H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 12.7, 18.5, 
20.9, 23.0, 29.9, 32.9, 42.2, 48.1, 56.7, 78.2, 126.0, 127.1, 127.3, 127.9, 128.4, 132.2, 
133.3, 138.5, 138.6, 140.2, 142.5, 171.5, 207.9; HRMS (ES) calcd for C31H37NO5SNa 
[M+Na]
+ m/z 558.2290, found m/z 558.2288.  
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O
O
N
Bn MesO2S
Ph OH
284  
(1R,2S)-2-(N-Benzyl-2,4,6-trimethylphenylsulfonamido)-1-phenylpropyl              
5-Hydroxyhexanoate (284) 
To a solution of keto ester 283 (300 mg, 0.560 mmol) in MeOH (22 mL) was 
added  NaBH4  (21.2  mg,  0.560  mmol)  and  the  suspension  was  stirred  at  room 
temperature for 10 min. The reaction mixture was quenched with saturated aqueous 
NH4Cl (11 mL) and the aqueous layer was extracted with Et2O (3 x 25 mL). The 
combined  organic  extracts  were  dried  over  anhydrous  NaSO4,  filtered,  and 
concentrated in vacuo.  The crude product was purified by flash chromatography (30% 
EtOAc/Hexanes) to provide alcohol 284 (301 mg, quant.) as a colorless oil: IR (neat) 
3560, 3412, 3064, 3032, 2935, 2857, 1743, 1604, 1496, 1454, 1324, 1152, 1016, 859, 
765, 732, 701, 659, 567; 
1H NMR (400 MHz, CDCl3) δ (ppm) 1.12 (s, 3H), 1.13 (s, 
3H), 1.33-1.40 (m, 2H), 1.50-1.69 (m, 3H), 2.09-2.26 (m, 2H), 2.30 (s, 3H), 2.53 (s, 
6H), 3.73 (br s, 1H), 4.06-4.14 (m, 1H), 4.59-4.75 (AB q, 2H), 5.88 (d, J = 4.0 Hz, 
1H), 6.89 (s, 2H), 6.94-6.96 (m, 2H), 7.21-7.38 (m, 8H); 
13C NMR (100 MHz, CDCl3) 
δ (ppm) 12.9, 20.7, 20.9, 23.0, 23.5, 33.9, 38.4, 48.1, 56.7, 67.5, 78.1, 126.0, 127.4, 
127.9, 128.4, 132.2, 133.3, 138.5, 138.6, 140.2, 142.5, 172.0; HRMS (ES) calcd for 
C31H40NO5S [M+H]
+ m/z 538.2627, found m/z 538.2623.  
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O
O
N
Bn MesO2S
Ph OTBS
285  
(1R,2S)-2-(N-Benzyl-2,4,6-trimethylphenylsulfonamido)-1-phenylpropyl              
5-(tert-Butyldimethylsilyloxy)hexanoate (285) 
  Method A. DCC (1M solution in DCM, 0.68 mL, 0.68 mmol) was added to a 
stirred solution of DMAP (4.2 mg, 0.034 mmol) and alcohol 281 (173.2 mg, 0.409 
mmol) in DCM (1.7 mL) and the resulting mixture was cooled to -5 °C. After 5 min, 
carboxylic acid 290 (84.0 mg, 0.341 mmol) was added in one portion and stirring was 
continued at -5 °C for 45 min. The reaction mixture was allowed to warm to room 
temperature and after 21 h all of carboxylic acid 290 had been consumed. The reaction 
mixture was filtered and the filtrate was concentrated in vacuo. The crude product was 
purified by flash chromatography (10 % EtOAc/hexanes) to provide ester 285 (181.6 
mg, 82%) as a colorless oil. 
  Method B. To a solution of alcohol 284 (275 mg, 0.511 mmol) and imidazole 
(139 mg, 2.046 mmol) in DMF (5.0 mL) was added TBSCl (154 mg, 1.023 mmol) and 
the  resulting  mixture  was  stirred  at  room  temperature  for  24  h.  The  solution  was 
diluted with Et2O  (10 mL)  and was washed  with 5%  HCl (10 mL),  H2O (5 mL), 
saturated aqueous NaHCO3 (5 mL) and brine (5 mL), then was dried over anhydrous 
MgSO4 and concentrated. The crude product was purified by flash chromatography 
(10% EtOAc/Hexanes) to afford TBS ether 285 (256 mg, 77%) as a colorless oil: IR  
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(neat)  3069,  3032,  2949,  2928,  2856,  1745,  1604,  1496,  1471,  1455,  1379,  1327, 
1207, 1155, 1096, 1017, 932, 858, 836, 808, 774, 729, 699, 659 cm
-1; 
1H NMR (400 
MHz, CDCl3) δ (ppm) 0.04, 0.05, and 0.06 (s, 6H), 0.90 and 0.90 (s, 9H), 1.11 (m, 
3H), 1.14 and 1.16 (s, 3H), 1.30-1.39 (m, 2H), 1.48-1.53 (m, 1H), 1.57-1.68 (m, 1H), 
2.05-2.24 (m, 2H), 2.31 (s, 3H), 2.54 (s, 6H), 3.74-3.78 (m, 1H), 4.05-4.09 (m, 1H), 
4.06-4.78 (AB q, 2H), 5.86 (d, J = 3.6 Hz, 1H), 6.90 (s, 2H), 6.93-6.94 (m, 2H), 7.20-
7.37 (m, 8H); 
13C NMR (100 MHz, CDCl3) δ (ppm) -4.7, -4.4, 12.8, 12.9, 18.1, 20.9, 
21.2, 23.0, 23.8, 25.9, 34.3, 34.3, 38.9, 39.0, 48.2, 56.7, 68.2, 68.2, 78.0 126.0, 127.1, 
127.4, 127.4, 127.8, 128.4, 128.4, 132.2, 133.4, 138.6, 138.7, 138.7, 140.2, 142.5, 
171.9;  HRMS  (ES)  calcd  for  C37H54NO5SSi  [M+1]
+  m/z  652.3492,  found  m/z 
652.3511. 
MeO
O OH
288  
Methyl 5-Hydroxyhexanoate (288) 
  To a stirred solution of ketone 268 (178.9 mg, 1.24 mmol) in MeOH (6.2 mL) 
was  added  NaBH4  (51.6  mg,  1.37  mmol)  at  room  temperature  and  the  resulting 
mixture was stirred for 30 min. The reaction mixture was quenched with water (3.0 
mL) and MeOH was removed under reduced pressure. The residue was partitioned 
between Et2O (6.0 mL) and water (6.0 mL) and the aqueous phase was extracted with 
Et2O (4 x 10 mL). The combined organic phase was washed with brine (10.0 mL), 
dried over  anhydrous Na2SO4  and concentrated  under reduced pressure. The crude  
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product was purified by flash chromatography (30% EtOAc in hexanes) to furnish 
alcohol 288 (121.0 mg, 67%) as a colorless oil: IR (neat) 3422 (br), 2963, 2926, 1739, 
1437,  1373,  1250,  1201,  1168,  1129,  1018,  986,  943  cm
-1; 
1H  NMR  (400  MHz, 
CDCl3) δ (ppm) 1.21 (d, J = 8.4 Hz, 3H), 1.45-1.52 (m, 2H), 1.65-1.80 (m, 3H), 2.36 
(t, J = 9.6 Hz, 2H), 3.69 (s, 3H), 3.78-3.85 (m, 1H); 
13C NMR (100 MHz, CDCl3) δ 
(ppm) 21.1, 23.5, 33.8, 38.6, 51.6, 67.5, 174.2. 
MeO
O OTBS
289  
Methyl 5-(tert-Butyldimethylsilyloxy)hexanoate (289) 
  To a stirred solution of alcohol 288 (106.4 mg, 0.73 mmol) and  imidazole 
(198.2 mg, 2.91 mmol)  in DMF (7.3  mL) at room  temperature was added TBSCl 
(219.5 mg, 1.46 mmol) and the resulting mixture was stirred for 26 h. The mixture was 
diluted with Et2O (8.0 mL) and washed with 5% HCl (8 mL). The aqueous phase was 
extracted with Et2O (3 x 8.0 mL) and the combined organic phases were washed with 
water (15 mL), saturated aqueous NaHCO3 (15 mL) and brine (15 mL). The solution 
was dried over anhydrous MgSO4 and concentrated under reduced pressure. The crude 
product was purified by flash chromatography (15% EtOAc in hexanes) to give TBS 
ether 289 (135.8 mg, 72%) as a colorless oil: 
1H NMR (400 MHz, CDCl3) δ (ppm) 
0.07 (s, 6H), 0.90 (s, 9H), 1.14 (d, J = 6.0 Hz, 3H) 1.41-1.48 (m, 2H), 1.60-1.75 (m, 
2H), 2.33 (t, J = 7.6 Hz, 2H), 3.69 (s, 3H), 3.80-3.84 (m, 1H); 
13C NMR (100 MHz, 
CDCl3) δ (ppm) -4.8, -4.4, 21.2, 23.7, 25.7, 25.9, 34.1, 39.0, 51.5, 68.2, 174.2.  
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HO
O OTBS
290  
5-(tert-Butyldimethylsilyloxy)hexanoic Acid (290) 
  To a stirred solution of methyl ester 289 (111.0 mg, 0.426 mmol) in THF (1.4 
mL) and water (1.4 mL) at room temperature was added LiOH⋅H2O (26.8 mg, 0.639 
mmol). The mixture was stirred for 6 h and was acidified with 1M HCl. The aqueous 
phase was extracted with Et2O (2 x 2.0 mL) and the organic phase was concentrated 
under reduced pressure to give carboxylic acid 290 (84.2 mg, 80%) as a colorless oil: 
IR (neat) 3200-2600, 2957, 2930, 2858, 1712, 1473, 1463, 1414, 1374, 1361, 1255, 
1137, 1096, 1042, 1005, 920, 836, 808, 774 cm
-1; 
1H NMR (400 MHz, CDCl3) δ 
(ppm) 0.13 (s, 6H), 0.91 (s, 9H), 1.15 (d, J = 6.0 Hz, 3H), 1.45-1.53 (m, 2H), 1.62-
1.79 (m, 2H), 2.39 (t, J = 7.2 Hz, 2H), 3.81-3.86 (m, 1H); 
13C NMR (100 MHz, 
CDCl3) δ (ppm) -4.8, -4.4, 21.0, 23.7, 25.7, 25.9, 33.9, 38.8, 68.2. 
OPMB
OTBDPS I
292  
((2R,3R,E)-3-(4-Methoxybenzyloxy)-5-iodo-2-methylpent-4-enyloxy)(tert-
butyl)diphenylsilane (292) 
To a solution of alkyne 263 (25.0 mg, 0.0635 mmol) in THF (0.80 mL) was 
added bis(cyclopentadienyl)zirconium(IV)  chloride  hydride  (65.5  mg,  0.254 mmol)  
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and  the  suspension  was stirred  at  room  temperature  for  30  min.  A  solution of N-
iodosuccinimide (57.1 mg, 0.254 mmol) in THF was added dropwise and the dark 
brown suspension was stirred for 1 h. The resulting mixture was concentrated in vacuo 
to  provide  a  brown  solid  which  was  purified  by  flash  chromatography  (5% 
Et2O/Hexanes) to obtain vinyl iodide 292 (22.9 mg, 72%) as a yellow oil: [α]D
26 +16.8 
(c 1.00, CHCl3); IR (neat) 3070, 2958, 2930, 2857, 1612, 1587, 1513, 1471, 1427, 
1389, 1360, 1302, 1248, 1174, 1152, 1112, 1036, 952, 823, 740, 702 cm
-1; 
1H NMR 
(400 MHz, CDCl3) δ (ppm) 0.92 (d, 3H, 6.8 Hz), 1.06 (s, 9H), 1.96 (m, aH), 3.60 (dd, 
J = 6.0, 9.6 Hz, 1H), 3.72 (dd, J = 4.8, 9.6 Hz, 1H), 3.82 (s, 3H), 3.90 (t, J = 7.6 Hz, 
1H), 4.26 (d, J = 11.2 Hz, 1H), 4.52 (d, J = 11.2, 1H), 6.27 (d, J = 14.4 Hz, 1H), 6.49 ( 
dd, J = 8.0, 14.4 Hz, 1H), 6.86 (d, J = 8.4 Hz, 2H), 7.19 (d, J = 8.4 Hz, 1H), 7.33-7.46 
(m ,6H), 7.66 (d, J = 7.2 Hz, 4H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 12.6, 19.3, 
26.9, 39.9, 55.3, 65.1, 70.4, 78.6, 82.2, 113.8, 114.3, 127.7, 129.2, 129.6, 130.0, 130.3, 
133.7, 133.8, 135.6, 145.2, 159.1; HRMS (ES) calcd for C30H37IO3NaSi [M+Na]
+ m/z 
623.1454, found m/z 623.1465. 
OPMB
OH I
293  
(2R,3R,E)-3-(4-Methoxybenzyloxy)-5-iodo-2-methylpent-4-en-1-ol (293) 
To a stirred solution of vinyl iodide 292 (13.9 mg, 0.0371 mmol) in THF (0.40 
mL)  at  room  temperature  was  added  TBAF  (1M  solution  in  THF,  50  µL,  0.0446  
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mmol) and the resulting mixture was stirred for 6 h, then diluted with Et2O (1.6 mL). 
The organic phase was washed with H2O (1.2 mL), dried over anhydrous MgSO4, 
filtered and concentrated in vacuo. Purification of the residue by flash chromatography 
(10% - 30% EtOAc/Hexanes) provided alcohol 293 (7.9 mg, 94%) as a yellow oil: 
[α]D
25 +89.2 (c 1.00, CHCl3); IR (neat) 3421, 3039, 2953, 2924, 2844, 1717, 1611, 
1586, 1559, 1514, 1464, 1387, 1302, 1248, 1173, 1108, 1062, 1035, 952, 820, 758, 
668; 
1H NMR (400 MHz, CDCl3) δ (ppm) 0.86 (d, J = 6.8 Hz, 3H), 1.84-1.92 (m, 1H), 
2.63 (br s, 1H), 3.54-3.69 (m, 3H), 3.83 (s, 3H), 4.29 (d, J = 11.6 Hz, 1H), 4.59 (d, J 
11.6 Hz, 1H), 6.36 (d, J = 14.8 Hz, 1H), 6.50 (dd, J = 8.0, 14.8 Hz, 1H), 6.91 (d, J = 
8.8 Hz, 2H), 7.25 (d, J = 8.8 Hz, 2H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 13.5, 
29.7, 39.5, 55.3, 66.6, 70.5, 79.5, 86.1, 114.0, 129.5, 145.4, 159.4; HRMS (CI) calcd 
for C14H19IO3 [M]
+ m/z 362.0379, found m/z 362.0371. 
294
OPMB
O I
 
(2S,3R,E)-3-(4-Methoxybenzyloxy)-5-iodo-2-methylpent-4-enal (294) 
To a stirred suspension of alcohol 293 (128 mg, 0.353 mmol) and NaHCO3 (97 
mg, 1.153 mmol) in DCM (8.8 mL) was added DMP (245 mg, 0.577 mmol) and the 
resulting  mixture  was  stirred  for  75  min  at  room  temperature.  The  reaction  was 
quenched  with  saturated  aqueous  NaHCO3  (8.0  mL)  and  the  aqueous  phase  was 
extracted with DCM (3 x 15 mL). The organic phase was washed with H2O (20 mL),  
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brine (20 mL), and dried over anhydrous MgSO4. Removal of the solvent provided a 
crude product which was purified by flash chromatography (10 % EtOAc/hexanes) to 
obtain aldehyde 294 (113 mg, 89%) as a colorless oil: [α]D
20 +90.0 (c 1.00, CHCl3); 
IR (neat) 3036, 2954, 2934, 2862, 2836, 2718, 1727, 1611, 1586, 1514, 1456, 1389, 
1340, 1302, 1248, 1175, 1113, 1061, 1035, 953, 820, 758 cm
-1; 
1H NMR (400 MHz, 
CDCl3) δ (ppm) 1.03 (d, J = 6.8 Hz, 3H), 2.56-2.64 (m, 1H), 3.83 (s, 3H), 3.96 (t, J = 
7.6 Hz, 1H), 4.31 (d, J = 11.6 Hz, 1H), 4.57 (d, J = 11.6 Hz, 1H), 6.43-6.53 (m, 2H), 
6.90 (d, J = 8.4 Hz, 2H), 7.22 (d, J = 8.4 Hz, 2H), 9.68 (d, J = 2.0 Hz, 1H); 
13C NMR 
(100 MHz, CDCl3) δ (ppm) 10.5, 50.0, 55.3, 70.5, 80.4, 81.7, 114.0, 129.5, 143.9, 
159.4,  202.8;  HRMS  (EI)  calcd  for  C14H17IO3  [M]
+  m/z  360.0223,  found  m/z 
360.0208. 
O
O Ph
N
Bn MesO2S
OH OPMB
I
OTBS
295  
(2R,3R,4R,5R,E)-((1R,2S)-2-(N-Benzyl-2,4,6-trimethylphenylsulfonamido)-1-
phenylpropyl)     5-(4-Methoxybenzyloxy)-2-(3-(tert-butyldimethylsilyloxy)butyl)-
3-hydroxy-7-iodo-4-methylhept-6-enoate (295) 
  To a solution of ester 285 (199 mg, 0.305 mmol) in DCM (1.4 mL) at room 
temperature was added triethylamine (0.1 mL, 0.666 mmol) and the resulting mixture 
was cooled to – 78 °C. A solution of freshly prepared dicyclohexylboron triflate (1M  
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solution  in  hexane,  0.67  mL,  0.67  mmol)  was  added  dropwise  over  2  min.  The 
resulting cloudy mixture was stirred at – 78 °C for 2.5 h, at which point a solution of 
aldehyde 294 (100 mg, 0.278 mmol) in DCM (1.4 mL) was added dropwise. The 
reaction mixture was stirred for another 8.5 h at – 78 °C, then was allowed to warm to 
room temperature over 1 h and was quenched by the addition of pH 7 buffer solution 
(1.1 mL). The mixture was diluted with MeOH (5.6 mL), and 30% aqueous hydrogen 
peroxide (0.6 mL) was added carefully. The mixture was stirred vigorously overnight 
and was concentrated under reduced pressure. The residue was partitioned between 
water (3.0 mL) and DCM (6.0 mL) and the aqueous layer was extracted with DCM (3 
x 6.0 mL). The combined organic extracts were washed with water (6.0 mL), dried 
over anhydrous Na2SO4 and filtered. The filtrate was concentrated and the residue was 
purified by flash chromatography (5% EtOAc/hexane) to provide alcohol 295 (242 
mg, 86%) as a colorless oil: IR (neat) 3461 (br), 3063, 3025, 2960, 2926, 2853, 1740, 
1653, 1607, 1558, 1514, 1497, 1456, 1379, 1323, 1250, 1207, 1153, 1048, 1034, 953, 
909, 836, 775, 730, 699, 661; 
1H NMR (400 MHz, CDCl3) δ (ppm) -0.02 and -0.00 (s, 
6H), 0.85 and 0.86 (s, 9H), 0.89-0.94 (m, 6H), 1.10-1.13 (m, 2H), 1.16-1.20 (m, 3H), 
1.21-1.23 (m, 2H), 1.70-1.72 (m, 1H), 2.05 (br s, 1H), 2.33 (s, 3H), 2.40-2.43 (m, 1H), 
2.49 (s, 3H), 2.51 (s, 3H), 3.48-3.55 and 3.56-3.62 (m, 1H), 3.69-3.75 (m, 1H), 3.79 
and 3.79 (s, 3H), 4.02-4.11 (m, 1H), 4.18-4.23 (m, 1H), 4.26 (A of AB q, J = 11.2 Hz, 
1H), 4.57 (B of AB q, J = 11.2 Hz, 1H), 4.59-4.66 (m, 1H), 4.81-4.88 (m ,1H), 5.74-
5.78 (m, 1H), 6.37 (dd, J = 3.2, 14.4 Hz, 1H), 6.53 (dd, J = 8.0, 14.4 Hz, 1H), 6.75-
6.79 (m, 2H), 6.87 (d, J = 8.4 Hz, 2H), 6.93 (d, J = 6.0 Hz, 2H), 7.12-7.26 (m, 8H),  
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7.36 (br s, 2H); 
13C NMR (100 MHz, CDCl3) δ (ppm) -4.4, -4.3, 9.6, 13.8, 14.1, 18.0, 
20.9, 22.9, 25.8, 36.0 and 36.7, 38.5 and 38.7, 48.2, 49.3 and 49.6, 55.3, 56.7, 68.0 and 
68.3, 70.6, 70.9, 77.9 and 78.2, 79.1, 83.7, 114.0, 126.5, 127.0, 127.9, 128.0, 128.1, 
128.2, 129.4, 129.5, 132.1, 133.7, 138.4, 139.0 and 139.2, 140.4, 142.4, 145.5, 159.4, 
174.5; HRMS (ES) calcd for C51H70INO8NaSSi [M+Na]
+ m/z 1034.3534, found m/z 
1034.3481. 
O
O Ph
N
Bn MesO2S
O O
I
PMP
296
OTBS
 
(R)-((1R,2S)-2-(N-Benzyl-2,4,6-trimethylphenylsulfonamido)-1-phenylpropyl)     
5-(tert-Butyldimethylsilyloxy)-2-((4R,5R,6R)-6-((E)-2-iodovinyl)-2-(4-
methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)hexanoate (296) 
  To a mixture of alcohol 295 (17.0 mg, 16.8 µmol) and 4 Å MS in DCM (0.4 
mL) at 0 °C was added DDQ (6.2 mg, 20.2 µmol) and the resulting mixture was 
stirred at 0 °C for 2 h. The reaction mixture was warmed to room temperature for 30 
min and quenched with saturated aqueous NaHCO3 (0.4 mL). The aqueous layer was 
extracted with DCM (3 x 0.5 mL) and the organic phase was washed with brine (2.0 
mL), dried over anhydrous Na2SO4, filtered, and concentrated. Flash chromatography 
of the crude product (10% EtOAc in hexanes) gave acetal 296 (12.6 mg, 74%) as a  
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colorless oil: IR (neat) 3063, 3031, 2956, 2929, 2855, 1741, 1614, 1516, 1496, 1456, 
1382, 1322, 1250, 1205, 1153, 1033, 1010, 910, 834, 775, 731, 698, 660, 566 cm
-1; 
1H 
NMR (400 MHz, CDCl3) δ (ppm) -0.03 and 0.00 (s, 6H), 0.84 and 0.85 (s, 9H), 0.88-
0.93 (m, 6H), 1.07-1.28 (m, 5H), 1.98-2.09 (m, 1H), 2.31 (s, 9H), 2.31-2.40 (m, 1H), 
2.68-2.79 (m, 1H), 3.45-3.51 and 3.58-3.67 (m, 2H), 3.72-3.80 (m, 1H), 3.83 (s, 3H), 
3.90-3.94 (m, 2H), 4.33-4.37 (m, 2H), 4.55-4.59 (m, 1H), 5.63 (d, J = 4.8 Hz, 1H), 
5.74 (d, J = 2.4 Hz, 1H), 6.46-6.51 (m, 1H), 6.60-6.65 (m, 3H), 6.88-6.89 (m, 2H), 
7.03-7.07  (m,  2H),  7.13-7.14  (m,  1H),  7.24-7.30  (m,  6H),  7.36-7.38  (m, 2H); 
13C 
NMR (100 MHz, CDCl3) δ (ppm) -4.8 and -4.7, -4.4 and -4.3, 12.7 and 12.7, 14.1 and 
14.3, 15.3, 18.0 and 18.1, 20.9, 22.8, 22.9 and 23.1, 23.9, 24.1 and 25.6, 25.8 and 25.9, 
36.3, 36.5 and 37.2, 47.0, 47.4, 47.7, 55.3, 56.6, 65.9, 67.7, 68.1, 71.6, 76.7, 77.0, 
77.4, 78.2, 78.4, 78.9, 82.2, 98.2, 113.7, 126.5 and 126.6, 127.2, 127.7, 127.8, 128.0, 
128.3, 128.4, 131.2, 132.1, 133.2, 138.3, 139.3, 140.5, 142.4, 143.9, 160.0, 173.2 and 
173.5; HRMS (ES) calcd for C51H68INNaO8SSi [M+Na]
+ m/z 1032.3377, found m/z 
1032.3325. 
O
O Ph
N
Bn MesO2S
O O
I
PMP
298
OH
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(R)-((1R,2S)-2-(N-Benzyl-2,4,6-trimethylphenylsulfonamido)-1-phenylpropyl)     
5-Hydroxy-2-((4R,5R,6R)-6-((E)-2-iodovinyl)-2-(4-methoxyphenyl)-5-methyl-1,3-
dioxan-4-yl)hexanoate (298) 
  To a solution of TBS ether 296 (9.4 mg, 9.9 µmol) in DMF (0.4 mL) at 0 °C 
was added TAS-F (6.8 mg, 24.7 µmol) and the resulting mixture was stirred at 0 °C 
for 1.5 h and then warmed to room temperature. The reaction was monitored by TLC 
and further quantities (6.8 mg, 24.7 µmol) of TAS-F were added at 8 h and 24 h 
intervals. After 47 h, the mixture was diluted with EtOAc (1.0 mL) and washed with 
pH 7 buffer (1.0 mL). The aqueous phase was extracted with EtOAc (3 x 2.0 mL) and 
the organic extract was dried over anhydrous MgSO4, filtered, and concentrated. The 
crude  product  was  purified  by  flash  chromatography  (40%  EtOAc  in  hexanes)  to 
provide alcohol 298 (4.3 mg, 52%) as a colorless oil: IR (neat) 3522 (br), 3063, 3025, 
2960, 2923, 2851, 1738, 1615, 1602, 1518, 1496, 1455, 1402, 1379, 1317, 1250, 1172, 
1152, 1118, 1055, 1032, 1010, 991, 910, 861, 831, 774, 731, 699, 660, 597, 566 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 0.91-1.02 (m, 6H), 1.12-1.61 (m, 6H), 1.75-1.83 
(m, 1H), 2.34 (s, 9H), 2.35-2.40 (m, 1H), 2.65-2.78 (m, 1H), 3.45-3.65 (m, 1H), 3.76 
(s, 3H), 3.80-3.91 (m, 2H), 4.05-4.35 (m, 4H), 4.45-4.46 (m, 1H), 5.57-5.58 (m, 1H), 
5.69 (s, 1H), 6.48-6.52 (m, 1H), 6.58-6.63 (m, 2H), 6.70-6.72 (m, 2H), 6.85-6.95 (m, 
4H), 7.00-7.05 (m, 2H), 7.10-7.15 (m, 1H), 7.25-7.35 (m, 5H); 
13C NMR (100 MHz, 
CDCl3) δ (ppm) 12.2 and 12.3, 14.3 and 14.3, 20.9, 22.9, 23.4 and 24.1, 23.7 and 23.7, 
31.9, 35.6 and 36.2, 47.6 and 48.1, 47.9, 55.4, 56.2 and 56.3, 60.4, 67.0 and 67.6, 78.0,  
 
111 
 
80.4,  81.4,  96.6  and  96.6,  113.6,  126.8,  126.9,  127.2,  127.7,  128.1,  128.2,  128.6, 
128.6, 130.3, 132.1, 133.3, 138.0, 139.1 and 139.3, 140.5, 142.4, 144.3, 160.2, 173.5 
and 173.8; HRMS (ES) calcd for C45H54INO8SNa [M+Na]
+ m/z 918.2513, found m/z 
918.2494. 
O
O Ph
N
Bn MesO2S
O O
I
PMP
299
O
 
(R)-((1R,2S)-2-(N-Benzyl-2,4,6-trimethylphenylsulfonamido)-1-phenylpropyl)     
2-((4R,5R,6R)-6-((E)-2-Iodovinyl)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-
yl)-5-oxohexanoate (299) 
To a stirred mixture of alcohol 298 (17.7 mg, 26.5 µmol) and NaHCO3 (6.7 
mg, 79.4 µmol) in DCM (1.3 mL) at room temperature was added DMP (16.8 mg, 
39.7 µmol) and the resulting mixture was stirred for 2 h. The mixture was quenched 
with H2O (1.0 mL) and the aqueous layer was extracted with DCM (3 x 1.0 mL). The 
organic phase was washed with brine (2.0 mL), dried over anhydrous MgSO4, filtered, 
and concentrated. Purification of the crude product by flash chromatography (30% 
EtOAc in hexanes) provided ketone 299 (16.6 mg, 94%) as a colorless oil: [α]D
20 +5.8 
(c 1.00, CHCl3); IR (neat) 3058, 3028, 2824, 2853, 1742, 1718, 1615, 1518, 1496, 
1456, 1379, 1320, 1250, 1152, 1120, 1032, 1010, 860, 830, 760, 731, 700, 659 cm
-1;  
 
112 
 
1H NMR (400 MHz, CDCl3) δ (ppm) 0.89 (d, J = 4 Hz, 3H), 1.21-1.32 (m, 3H), 1.69-
1.85 (m, 4H), 1.83 (s, 3H), 1.96-2.01 (m, 1H), 2.33 (s, 9H), 2.67-2.71 (m ,1H), 3.76 (s, 
3H), 3.91-3.95 (m, 1H), 4.20-4.34 (m, 4H), 4.47 (d, J = 4 Hz, 1H), 5.61 (d, J = 6.4 Hz, 
1H), 5.68 (s, 1H), 6.48-6.52 (m, 1H), 6.64-6.66 (m, 2H), 6.72-6.74 (m, 2H), 6.85-6.89 
(m, 4H), 7.04-7.08 (m, 2H), 7.17-7.18 (m, 1H), 7.20-7.28 (m, 5H); 
13C NMR (100 
MHz, CDCl3) δ (ppm) 12.2, 14.4, 20.9, 22.9, 29.7, 31.9, 39.6, 47.1, 47.7, 55.4, 56.0, 
77.9, 80.3, 81.3, 96.5, 113.6, 127.0, 127.3, 127.7, 128.2, 128.3, 128.7, 130.2, 130.9, 
132.1, 133.1, 138.0, 140.5, 142.5, 144.3, 160.2, 173.5, 207.0; HRMS (ES) calcd for 
C45H52INO8Na [M+Na]
+ m/z 916.2356, found m/z 916.2391. 
I
O
O
O
O
301
Ph
N
MesO2S
Bn
 
(4R,5R,6R,7R)-((1R,2S)-2-(N-Benzyl-2,4,6-trimethylphenylsulfonamido)-1-
phenylpropyl)     7-((E)-2-Iodovinyl)-1,6-dimethyl-8,9-dioxa-bicyclo[3.3.1]nonane-
4-carboxylate (301) 
  Method A. To a stirred solution of ketone 299 (5.0 mg, 5.6 µmol) in PhH (0.6 
mL)  at  room  temperature  was  added  p-TsOH⋅H2O  (0.1  mg,  0.6  µmol)  and  the 
resulting solution was stirred for 8 h. The reaction mixture was diluted with PhH (1.0 
mL) and quenched with saturated aqueous NaHCO3 (1.0 mL). The organic phase was 
dried  over  anhydrous  MgSO4,  filtered,  and  concentrated.  Purification  of  the  crude  
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product by flash chromatography (30% EtOAc in hexanes) afforded cyclic ketal 301 
(4.6 mg, quant.) as a yellow solid.  
Method B. To a stirred suspension of CrCl2 (163 mg, 1.326 mmol) in THF 
(2.7 mL) at 0 °C was added dropwise a solution of aldehyde 318 (16.8 mg, 0.027 
mmol) and CHI3 (209 mg, 0.530 mmol) in THF (2.7 mL). The ice-bath was removed 
and the resulting mixture was stirred vigorously at room temperature for 1.5 h. The 
mixture  was  diluted  with  Et2O  (3  mL)  and  quenched  with  half-saturated  aqueous 
Na2S2O3 (6.0 mL). The aqueous phase was extracted with Et2O (6.0  mL) and the 
combined  organic  phases  were  washed  with  H2O  (10  mL),  dried  over  anhydrous 
Na2SO4,  filtered  and  concentrated.  Purification  of  the  crude  product  by  flash 
chromatography (10% EtOAc/hexanes) provided vinyl iodide 301 (18 mg, 89%, E:Z 
5:1) as a yellow oil: [α]D
20 +11.2 (c 0.50, CHCl3); IR (neat) 3058, 3025, 2924, 2854, 
1732, 1604, 1496, 1456, 1381, 1322, 1261, 1204, 1154, 1120, 1075, 1052, 1014, 932, 
910, 880, 854, 763, 731, 699, 659 cm
-1; 
1H NMR (700 MHz, CDCl3) δ (ppm) 0.43 (d, 
J = 7.7 Hz, 3H), 1.28 (d, J = 7.0 Hz, 3H), 1.34 (s, 3H), 1.77-1.83 (m, 1H), 1.93-1.97 
(m, 1H), 2.03-2.09 (m, 2H), 2.13-2.20 (m, 1H), 2.30 (s, 3H), 2.42 (s, 6H), 2.82 (dt, J = 
13.3, 4.2 Hz, 1H), 4.21-4.23 (m, 1H), 4.38 (dd, J = 11.2, 6.3 Hz, 1H), 4.41-4.42 (m, 
1H), 4.45 (A of AB quartet, J = 16.1 Hz, 1H), 4.67 (B of AB quartet, J = 16.1 Hz, 
1H), 5.79 (d, J = 6.3 Hz, 1H), 6.34 (dd, J = 14.0, 6.3 Hz, 1H), 6.38 (d, 14.0 Hz, 1H), 
6.85 (s, 2H), 6.93 (d, J = 7.7 Hz, 2H), 7.17 (t, J = 7.7 Hz, 2H), 7.25 (t, J = 7.0 Hz, 1H), 
7.27-7.29 (m, 5H); 
13C NMR (175 MHz, CDCl3) δ (ppm) 12.1, 14.9, 20.9, 22.2, 22.9, 
29.2, 33.8, 36.5, 43.7, 48.1, 56.4, 71.9, 78.2, 79.6, 80.0, 95.4, 127.0, 127.5, 127.9,  
 
114 
 
128.2, 128.3, 128.5, 132.1, 132.9, 137.4, 138.0, 140.3, 142.6, 145.7, 170.5; HRMS 
(ES) calcd for C37H44INO6SNa [M+Na]
+ m/z 780.1832, found m/z 780.1871. 
I
O
O
HO2C
242  
(4R,5R,6R,7R,E)-7-(2-Iodovinyl)-1,6-dimethyl-8,9-dioxa-bicyclo[3.3.1]nonane-4-
carboxylic Acid (242) 
  To a stirred mixture of ester 301 (17.0 mg, 0.022 mmol) in THF (1.5 mL) and 
H2O (0.75 mL) at room temperature was added LiOH⋅H2O (4.7 mg, 0.112 mmol) and 
the resulting mixture was stirred for 4 days. The reaction mixture was quenched with 
H2O (1.0 mL) and acidified with 1M HCl until the pH reached 5. The aqueous phase 
was  extracted  with  EtOAc  (2.0  mL),  dried  over  anhydrous  MgSO4,  filtered  and 
concentrated.  The  crude  product  was  purified  by  flash  chromatography  (30% 
EtOAc/hexanes) to give carboxylic acid 242 (6.2 mg, 78%, 83% brsm) as a white 
solid: [α]D
22 +14.1 (c 1.00, CHCl3); IR (neat) 3500-2500 (br), 2954, 2923, 2845, 1722, 
1604, 1423, 1381, 1114, 956, 792, 734 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 
0.91 (d, J = 6.8 Hz, 3H), 1.37 (s, 3H), 1.86-1.89 (m, 1H), 2.06-2.21 (m, 4H), 2.71 (br 
s, 1H), 4.40 (dd, J = 4.0, 10.8 Hz, 1H), 4.48 (d, J = 5.6 Hz, 1H), 6.48 (s, 2H); 
13C 
NMR (100 MHz, CDCl3) δ (ppm) 12.6, 20.6, 29.5, 30.9, 35.9, 37.7, 72.3, 78.1, 79.9,  
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95.9, 145.2, 179.3; HRMS (CI) calcd for C12H17IO4 [M]
+ m/z 352.0172, found m/z 
352.0162. 
PMBO
OPMB
303  
(Z)-1-((4-(4-Methoxybenzyloxy)but-2-enyloxy)methyl)-4-methoxybenzene (303) 
  A solution of 2-butene-1,4-diol 302 (3.55 g, 40.28 mmol) in DMF (23 mL) 
was added to a stirred suspension of NaH (3.71 g, 92.64 mmol from 60% suspension 
in mineral oil after washing with hexane) in DMF (60 mL). The reaction mixture was 
then heated to 60 °C and stirred for 2 h. The resulting mixture was treated with TBAI 
(0.74 g, 2.01 mmol) and PMBCl (12.6 mL, 92.64 mmol) and was stirred at 60 °C for 
another 2.5 h. After the solution had cooled to room temperature, Et2O (100 mL) and 
water (100 mL) were added. The aqueous phase was extracted with Et2O (3 x 70 mL) 
and the organic phase was washed with water (2 x 35 mL) and brine (35 mL), dried 
over anhydrous MgSO4, filtered and concentrated. The crude product was purified by 
column chromatography (hexane/EtOAc 6:1) to afford ether 303 (10.39 g, 79%) as a 
colorless oil: IR (neat) 2905, 2836, 1612, 1586, 1513, 1464, 1375, 1302, 1248, 1174, 
1083, 1034, 819 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 3.83 (s, 6H), 4.04 (d, J = 
10.4 Hz, 4H), 4.45 (s, 4H), 5.80 (t, J = 4.0 Hz, 2H), 6.90 (d, J = 8.4 Hz, 4H), 7.28 (d, J 
= 8.4 Hz, 4H); 
13C NMR (100 MHz, CDCl3) ) δ (ppm) 55.3, 65.5, 71.9, 113.8, 129.4, 
129.6, 130.3, 159.2.  
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O
OPMB
304  
2-(4-Methoxybenzyloxy)acetaldehyde (304) 
Method A.  To a stirred solution of olefin 303  (100 mg, 0.305 mmol) and 
NaIO4  (144  mg,  0.673  mmol)  in  Et2O  (0.9  mL)  and  water  (0.9  mL)  at  room 
temperature was added a solution of OsO4 (0.1 M solution in t-BuOH, 0.06 mL, 6.0 
µmol) and the resulting mixture was stirred for 6 h. The solution was diluted with 
water (5.0 mL) and the aqueous phase was extracted with Et2O (3 x 5.0 mL). The 
combined organic extracts were washed with brine (5.0 mL), dried over anhydrous 
Na2SO4 and concentrated under reduced pressure. The crude product was purified by 
flash chromatography (100% DCM) to provide aldehyde 304 (96.2 mg, 88%) as a 
brown oil. 
  Method B. To a stirred solution of olefin 303 (100 mg, 0.305 mmol), NaIO4 
(144 mg, 0.673 mmol) and 2,6-lutidine (0.071 mL, 0.609 mmol)) in dioxane (2.25 
mL) and water (0.75 mL) at room temperature was added a solution of OsO4 (0.1M 
solution in t-BuOH, 0.06 mL, 6.0 µmol) and the resulting mixture was stirred for 6 h. 
The mixture was partitioned between water (3.75 mL) and DCM (7.5 mL), and the 
aqueous phase was extracted with DCM (3 x 5.0 mL). The combined organic extracts 
were washed with brine (5.0 mL), dried over anhydrous Na2SO4 and concentrated 
under  reduced  pressure.  The  crude  product  was  purified  by  flash  chromatography 
(10% EtOAc in hexanes) to provide aldehyde 304 (93.4 mg, 85%) as a brown oil.  
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  Method C.  Ozone  was bubbled through  a  solution  of olefin 303 (12.28 g, 
37.38 mmol) in DCM (415 mL) and MeOH (13.8 mL) at -78 °C until the solution 
turned blue. The reaction mixture was stirred until all starting material was consumed 
as judged by TLC. The ozone source was removed and Ar was bubbled through the 
solution until it became clear. Me2S (13.8 mL, 186.89 mmol) was  added at -78 °C and 
the resulting solution was stirred at this temperature for 10 min, before being warmed 
to room temperature. The solution was stirred for 17 h, water (70 mL) was added, and 
most of the solvent was removed under reduced pressure. The residue was extracted 
with Et2O (4 x 70 mL), dried over anhydrous MgSO4, filtered and concentrated. The 
crude product was purified by flash chromatography (40% EtOAc/hexanes) to afford 
aldehyde 304 (11.54 g, 86%) as a yellow oil: IR (neat) 2998, 2933, 2911, 2867, 2837, 
2715, 1735, 1612, 1586, 1514, 1465, 1375, 1303, 1249, 1175, 1109, 1033, 820, 739 
cm 
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 3.82 (s, 3H), 4.08 (s, 2H), 4.58 (s, 2H), 
6.91 (s, J = 8.4 Hz, 2H), 7.30 (d, J = 8.4 Hz, 2H), 9.71 (s, 1H); 
13C NMR (100 MHz, 
CDCl3) δ (ppm) 55.3, 73.3, 75.0, 114.0, 128.9, 129.8, 159.7, 200.6. 
OH
PMBO
305  
(2R,3R)-1-(4-Methoxybenzyloxy)-3-methylpent-4-en-2-ol (305) 
  To a stirred suspension of potassium tert-butoxide (8.50 g, 69.55 mmol) in dry 
THF (90 mL) at -78 °C was added trans-2-butene (12.0 mL, 133.74 mmol) followed  
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by  n-butyllithium  (1.6M  in  hexanes,  46.8  mL,  74.90  mmol).  The  resulting  yellow 
solution was stirred at -45 °C for 0.5 h, then was cooled to -78 °C and a solution of 
(+)-B-methoxydiisopinocampheylborane (22.0 g, 69.55 mmol) in THF (90 mL) was 
added.  The  mixture  was  stirred  for  1  h,  BF3·OEt2  (9.24  mL,  74.90  mmol)  was 
introduced slowly, and the solution was stirred for 0.5 h. A solution of aldehyde 304 
(9.64 g, 53.50 mmol) in THF (90 mL) was added, the mixture was stirred for 4 h and 
then was quenched at -78 °C with NaOH (3N, 90 mL) followed by a 30% aqueous 
solution of H2O2 (90 mL). The mixture was warmed slowly to room temperature and 
stirred for 3 h. The aqueous layer was separated and extracted with Et2O (3 x 250 mL), 
and  the  combined  organic  extracts  were  washed  with  brine  (250  mL),  dried  over 
anhydrous MgSO4 and filtered. The filtrate was concentrated in vacuo and the residue 
was purified by flash chromatography (4:1 DCM:Et2O) to afford alcohol 305 (9.00 g, 
71%) as a colorless oil: [α]D
20 +5.6 (c 3.33, CHCl3); IR (neat) 3465 (br), 3073, 2954, 
2906, 2856, 2829, 1612, 1586, 1514, 1464, 1302, 1248, 1174, 1098, 1035, 999, 917, 
821 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 1.06 (d, J = 6.8 Hz, 3H), 2.35-2.40 (m, 
1H), 2.46 (br s, 1H), 3.41 (dd, J = 7.6, 9.6 Hz, 1H), 3.53 (dd, J = 3.2, 9.6 Hz, 1H), 3.68 
(br s, 1H), 3.83 (s, 3H), 4.50 (s, 2H), 5.08 (s, 1H), 5.12 (d, J = 4.0 Hz, 1H), 5.81-5.90 
(m, 1H), 6.91 (d, J = 8.8 Hz, 2H), 7.29 (d, J = 8.8 Hz, 2H); 
13C NMR (100 MHz, 
CDCl3) δ (ppm) 16.2, 40.8, 55.3, 72.3, 73.1, 73.5, 113.9, 115.4, 129.4, 130.2, 140.2, 
159.3; HRMS (EI) calcd for C14H20O3 [M]
+ m/z 236.1413, found m/z 236.1403. 
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OTBS
PMBO
306  
((2R,3R)-1-(4-Methoxybenzyloxy)-3-methylpent-4-en-2-yloxy)(tert-
butyl)dimethylsilane (306) 
  To a stirred solution of alcohol 305 (1.60 g, 6.771 mmol) and imidazole (922 
mg, 13.542 mmol) in DMF (13.5 mL) at room temperature was added TBSCl (1.33 g, 
8.802 mmol) and the resulting mixture was stirred at room temperature for 18 h. The 
reaction mixture was quenched with H2O (15 mL) and extracted with Et2O (3 x 15 
mL). The combined organic phases were washed with water (2 x 20 mL), dried over 
anhydrous MgSO4, filtered and concentrated. Flash chromatography (10% EtOAc in 
hexanes) of the crude product gave TBS ether 306 (2.29 g, 97%) as a colorless oil: 
[α]D
20 +3.5 (c 1.00, CHCl3); IR (neat) 3073, 2956, 2929, 2897, 2857, 1613, 1587, 
1514, 1471, 1463, 1361, 1302, 1249, 1173, 1120, 1038, 1005, 914, 836, 776 cm
-1; 
1H 
NMR (CDCl3, 400 MHz) δ (ppm) 0.07 (s, 3H), 0.08 (s, 3H), 0.92 (s, 9H), 1.05 (d, J = 
7.2 Hz, 3H), 2.42-2.45 (m, 1H), 3.33-3.42 (m, 2H), 3.74-3.78 (m, 1H), 3.84 (s, 3H), 
4.41-4.48 (AB quartet, 2H), 5.00 (s, 1H), 5.04 (d, J = 3.2 Hz, 1H), 5.80-5.88 (m, 1H), 
6.90 (d, J = 8.4 Hz, 2H), 7.28 (d, J = 8.4 Hz, 2H); 
13C NMR (100 MHz, CDCl3) δ 
(ppm) -4.9, -4.2, 17.0, 18.2, 25.9, 41.6, 55.3, 72.9, 73.0, 74.8, 113.7, 114.7, 129.2, 
130.6,  140.2,  159.1;  HRMS  (EI)  calcd  for  C20H34O3NaSi  [M+Na]
+  m/z  373.2175, 
found m/z 373.2163.  
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TBSO
PMBO
OH
OH
307  
(3R,4R)-5-(4-Methoxybenzyloxy)-4-(tert-butyldimethylsilyloxy)-3-methylpentane-
1,2-diol (307) 
  To a stirred solution of olefin 306 (7.00 g, 19.97 mmol) in THF (91 mL), t-
BuOH (91 mL) and water (18 mL) at 0 °C was added NMO (3.51 g, 29.96 mmol) and 
the resulting mixture was stirred for 3 min at which point a solution of OsO4 (0.05 M 
in t-BuOH, 20.0 mL, 1.00 mmol) was added. The reaction mixture was stirred for 47 h 
and quenched with saturated aqueous Na2SO3 (55 mL). EtOAc (100 mL) and water 
(100 mL) were added to the mixture and the aqueous phase was extracted with EtOAc 
(2  x  200  mL).  The  organic  phase  was  dried  over  anhydrous  MgSO4,  filtered  and 
concentrated. Purification of the crude product by flash chromatography (50% EtOAc 
in hexanes) gave diol 307 (7.31 g, 95%) as a colorless oil: IR (neat) 3406 (br), 2954, 
2929, 2856, 1613, 1587, 1514, 1463, 1361, 1303, 1249, 1173, 1101, 1037, 1005, 953, 
836, 777 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 0.10 (s, 6H), 0.90 (s, 9H), 0.91 
(d, J = 12.6 Hz, 3H), 1.86-1.93 (m, 1H), 2.40 (br s, 1H), 3.40-3.57 (m, 3H), 3.65-3.72 
(m, 3H), 3.83 (s, 3H), 3.96-4.02 (m, 1H), 4.47 (s, 2H), 6.90 (d, J = 8.8 Hz, 2H), 7.25 
(d, J = 8.8 Hz, 2H); 
13C NMR (100 MHz, CDCl3) δ (ppm) -5.0, -4.5, 10.9 and 12.6, 
18.0 and 18.1, 25.8, 30.3, 37.1 and 39.9, 55.3, 65.0 and 65.4, 71.6 and 72.5, 73.1 and 
73.2, 73.8 and 74.0, 113.9, 129.4, 129.7, 159.4; HRMS (CI) calcd for C20H37O5Si 
[M+H]
+ m/z 385.2410, found m/z 385.2418.  
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O
OTBS
PMBO
308  
(2S,3R)-4-(4-Methoxybenzyloxy)-3-(tert-butyldimethylsilyloxy)-2-methylbutanal 
(308) 
  Method A. A solution of olefin 306 (477.9 mg, 1.363 mmol) in DCM (7.0 
mL) and MeOH (7.0 mL) was cooled to -78 °C and a stream of O3 was bubbled gently 
through  the  solution  until  a  light  purple  color  persisted  (or  TLC  showed  that  all 
starting material was consumed). The stream of O3 was terminated and the flask was 
flushed with Ar until the solution was colorless. NaBH4 (206.3 mg, 5.45 mmol) was 
added slowly at -78 °C and the mixture was allowed to warm to room temperature. 
The mixture was concentrated and EtOAc was added (7.0 mL). The organic phase was 
washed with H2O (7.0 mL) and the aqueous phase was extracted with EtOAc (3 x 7.0 
mL).  The  organic  phase  was  dried  over  anhydrous  Na2SO4  and  concentrated  to 
provide the crude product which was purified by flash chromatography (20% EtOAc 
in  hexanes)  to  give  (2R,3R)-4-(4-Methoxybenzyloxy)-3-(tert-butyldimethylsilyloxy)-
2-methylbutan-1-ol (210.7 mg, 44%) as a colorless oil: [α]D
24 +9.8 (c 2.35, CHCl3); IR 
(neat)  3450,  2949,  2922,  2857,  1613,  1587,  1515,  1471,  1361,  1302,  1247,  1173, 
1085, 1035, 957, 835, 777, 671 cm
-1; 
1H NMR (400 MHz, CDCl3) δ 008 (s, 3H), 0.10 
(s, 3H), 0.90 (s, 9H), 1.03 (d, J = 7.2 Hz, 3H), 1.91 (m, 1H), 2.87 (br s, 1H), 3.45-3.61 
(m 3H), 3.72-3.75 (m, 1H), 3.83 (s, 3H), 3.85-3.89 (m, 1H), 4.47 (AB quartet, 2H),  
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6.90 (d, J = 8.8 Hz, 2H), 7.27 (d, J = 8.8 Hz, 2H); 
13C NMR (100 MHz, CDCl3) δ 
(ppm) -5.0, -4.3, 14.3, 18.1, 25.9, 37.8, 55.3, 64.8, 72.6, 73.1, 75.8, 113.8, 129.4, 
130.0, 159.3; HRMS (ES) calcd for C19H35O4Si [M+H]
+ m/z 355.2305, found m/z 
355.2292. The alcohol was used immediately in the next step. 
  To a stirred solution of oxalyl chloride (22 µL, 0.257 mmol) in DCM (0.85 
mL) at -78 °C was added dropwise a solution of DMSO (31 µL, 0.434 mmol) in DCM 
(0.85 mL) and the resulting mixture was stirred for 15 min, at which point a solution 
of the alcohol prepared above (70.0 mg, 0.197 mmol) in DCM (0.50 mL) was added 
slowly.  The cloudy mixture was stirred for 10 min and Et3N (0.14 mL, 0.987 mmol) 
was added dropwise. The reaction mixture was stirred for 30 min and warmed to 0 °C. 
H2O (1.5 mL) was added and the aqueous phase was extracted with DCM (2 x 2.5 
mL).  The  organic  phase  was  washed  with  brine  (2.5  mL),  dried  over  anhydrous 
Na2SO4, filtered, and concentrated under reduced pressure. Purification of the crude 
product by flash chromatography (10% EtOAc in hexanes) furnished aldehyde 308 
(61.3 mg, 88%) as a yellow oil. 
  Method B. To a stirred solution of alkene 306 (1.5 g, 4.279 mmol) in dioxane-
water (3:1, 44 mL) was added 2,6-lutidine (0.99 mL, 8.558 mmol), OsO4 (0.05 M in 2-
methyl-2-propanol, 1.71 mL, 0.0856 mmol), and NaIO4 (3.661 g, 17.115 mmol). The 
mixture was stirred at room temperature and monitored by TLC. After the reaction 
was complete (1.5 h), water (55 mL) and DCM (110 mL) were added. The organic 
layer was separated, and the aqueous layer was extracted with DCM (3 x 55 mL). The  
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combined organic layer was washed with brine and dried over anhydrous Na2SO4. The 
solvent was removed and the crude product was purified by flash chromatography 
(20% Et2O/Hexanes) to afford aldehyde 308 (1.140 g, 76%) as a pale yellow oil. 
Method C. To a stirred mixture of diol 307 (426.1 mg, 1.11 mmol) in MeOH 
(7.4 mL) and water (3.7 mL) at 0 °C was added NaIO4 (1.42 g, 6.65 mmol) and the 
resulting mixture was allowed to warm to room temperature with stirring over 1.5 h. 
The reaction mixture was partitioned between DCM (13 mL) and water (13 mL) and 
the aqueous phase was extracted with DCM (20 mL). The organic phase was washed 
with brine (20 mL), dried over anhydrous MgSO4, filtered and concentrated under 
reduced pressure. The residue was purified by flash chromatography (10% EtOAc in 
hexanes) to deliver aldehyde 308 (372.7 mg, 95%) as a colorless oil: [α]D
20 +39.5 (c 
1.00, CHCl3); IR (neat) 2955, 2931, 2857, 2709, 1725, 1613, 1586, 1514, 1464, 1361, 
1302, 1250, 1174, 1103, 1038, 1006, 837, 777 cm
-1; 
1H NMR (400 MHz, CDCl3) δ 
(ppm) 0.08 (s, 3H), 0.09 (s, 3H), 0.90 (s, 9H), 1.12 (d, J = 7.0 Hz, 3H), 2.58-2.65 (m, 
1H), 3.47-3.49 (m, 2H), 3.83 (s, 3H), 4.11-4.15 (m, 1H), 4.45 (s, 2H), 6.90 (d, J = 8.6 
Hz, 2H), 7.25 (d, J = 8.6 Hz, 2H), 9.76 (d, J = 1.8 Hz, 1H); 
13C NMR (100 MHz, 
CDCl3) δ (ppm)     -5.1, -4.4, 10.0, 18.0, 25.7, 50.0, 55.3, 71.7, 72.7, 73.1, 113.8, 
129.3, 130.0, 159.3, 203.8; HRMS (ES) calcd for C19H32O4NaSi m/z 375.1968, found 
m/z 375.1976. 
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OTBS
309  
(2R,3R,4R,5R)-((1R,2S)-2-(N-Benzyl-2,4,6-trimethylphenylsulfonamido)-1-
phenylpropyl)     6-(4-Methoxybenzyloxy)-5-(tert-butyldimethylsilyloxy)-2-(3-
(tert-butyldimethylsilyloxy)butyl)-3-hydroxy-4-methylhexanoate (309) 
To a solution of ester 285 (1.06 g, 1.63 mmol) in DCM (8.0 mL) at room 
temperature was added triethylamine (0.54 mL, 3.90 mmol) and the resulting mixture 
was  cooled  to  –  78  °C.  A  solution  of  dicyclohexylboron  triflate  (1M  solution  in 
hexane, 3.58 mL, 3.58 mmol) was added dropwise over 5 min. The resulting cloudy 
mixture was stirred at – 78 °C for 2 h, at which point a solution of aldehyde 308 (0.57 
g,  1.63  mmol)  in  DCM  (4.0  mL)  was  added  dropwise.  The  reaction  mixture  was 
stirred for another 15.5 h at – 78 °C and was allowed to warm to room temperature 
over 1 h, then quenched by addition of pH 7 buffer solution (8.0 mL). The mixture 
was diluted with MeOH (40 mL), and 30% hydrogen peroxide (4.0 mL) was added 
carefully.  The  reaction  mixture  was  stirred  vigorously  overnight  and  concentrated 
under reduced pressure. The residue was partitioned between water (20 mL) and DCM 
(40 mL). The aqueous layer was extracted with DCM (3 x 30 mL) and the combined 
organic extracts were washed with water (3 x 20 mL), dried over anhydrous NaSO4 
and  filtered.  The  filtrate  was  concentrated  and  the  residue  was  purified  by  flash  
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chromatography (5% - 10% EtOAc/hexanes) to provide alcohol 309 (1.14 g, 70%, 
88% brsm) as a white foam: IR (neat) 3474 (br),3065, 3033, 2954, 2930, 2857, 1741, 
1607, 1587, 1514, 1497, 1471, 1463, 1372, 1325, 1251, 1206, 1155, 1094, 1005, 910, 
838, 776, 731, 699, 660, 597, 567 cm
-1; 
1H NMR (700 MHz, CDCl3) δ (ppm) -0.06 
and -0.03 (s, 3H), -0.02 and -0.02 (s, 3H), 0.07 (s, 3H), 0.09 (s, 3H), 0.84 and 0.85 (s, 
9H), 0.85 and 0.86 (s, 9H), 0.92 (m, 3H), 0.93-0.98 (m, 2H), 1.08 (m, 3H), 1.09-1.18 
(m, 2H), 1.12 (m, 3H), 1.91-1.95 (m, 1H), 2.35 (s, 3H), 2.54 and 2.56 (s, 6H), 2.57-
2.65 (m, 1H), 3.45-3.51 (m, 1H), 3.45-3.56, 3.56-3.59 and 3.60-3.62 (m, 2H), 3.81 (s, 
3H), 3.88-3.95 (m, 1H), 3.88-4.00 (m, 1H), 4.15-4.20 (m, 1H), 4.44-4.46 (m, 2H), 
4.80-4.85 (m, 1H), 5.02-5.08 (m, 1H), 5.61 (m, 1H), 6.66-6.68 (m, 2H), 6.86-6.89 (m, 
2H), 6.95-7.00 (m, 2H), 7.01-7.03 (m, 2H), 7.03-7.05 (m, 1H), 7.20-7.27 (m, 5H), 
7.48-7.49 (m, 2H); 
13C NMR (100 MHz, CDCl3) δ (ppm) -4.8, -4.7, -4.4, -4.3, 9.8, 9.9, 
13.4, 13.6, 14.1, 18.0, 20.9, 22.7, 22.9, 23.4, 24.0, 24.5, 25.8, 25.9, 31.6, 34.7, 35.6, 
36.4, 37.2, 48.3, 49.6, 50.1, 55.2, 56.8, 67.9, 68.4, 71.7, 72.8, 73.0, 73.2, 74.9, 76.7, 
77.1, 77.4, 78.1, 78.4, 126.2, 126.3, 126.7, 127.7, 127.9, 128.0, 128.1, 128.2, 129.4, 
129.7, 132.2, 134.0, 134.1, 138.8, 140.0, 140.1, 140.5, 142.4, 159.3, 174.6, 175.1; 
HRMS (ES) calcd for C56H86NO9SSi2 [M+H]
+ m/z 1004.5562, found m/z 1004.5648. 
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311  
(2R,3R,4R,5R)-((1R,2S)-2-(N-Benzyl-2,4,6-trimethylphenylsulfonamido)-1-
phenylpropyl)      6-(4-Methoxybenzyloxy)-2-(3-(tert-butyldimethylsilyloxy)butyl)-
3,5-dihydroxy-4-methylhexanoate (311) 
  To a stirred mixture of bisTBS ether 309 (100.0 mg, 0.0996 mmol) in DMF 
(1.24 mL) and water (9.0 µL) at room temperature was added TAS-F (68.6 mg, 0.249 
mmol) and the resulting mixture was stirred for 45 min. The reaction mixture was 
diluted with EtOAc (2.0 mL) and washed with pH 7 buffer (2.0 mL). The aqueous 
layer was extracted with EtOAc (3 x 2.0 mL) and the combined organic phases were 
dried  over  anhydrous  MgSO4,  filtered  and  concentrated  under  reduced  pressure. 
Purification  of  the  residue  by  flash  chromatography  (20-40%  EtOAc  in  hexanes) 
furnished diol 311 (74.6 mg, 84%) as a white solid: IR (neat) 3492 (br), 3063, 3031, 
2954, 2929, 2856, 1740, 1611, 1514, 1497, 1456, 1375, 1324, 1250, 1207, 1153, 1099, 
1034, 1010, 910, 836, 775, 730, 699, 660 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) -
2.03 and -0.02 (s, 3H), -0.01 and 0.00 (s, 3H), 0.85 and 0.86 (s, 9H), 0.89-0.93 (m, 
3H), 1.00-1.05 (m, 3H), 1.05-1.75 (m, 5H), 1.19-1.21 (m, 3H), 2.32 (s, 3H), 2.50 and 
2.52 (s, 6H), 2.55-2.62 (m, 1H), 2.79-2.81 (m, 1H), 3.04 (s, 1H), 3.50-3.56 (m, 2H), 
3.57-3.62 (m, 1H), 3.79-3.85 (m, 1H), 3.82 (s, 3H), 4.02-4.10 (m, 1H), 4.15-4.21 (m,  
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1H), 4.50 (s, 2H), 4.61-4.71 (m, 1H), 4.80-4.90 (m, 1H), 5.77 (d, J = 4.4 Hz, 1H), 
6.75-6.80  (m,  2H),  6.88-6.93  (m,  4H),  7.15-7.28  (m,  8H),  7.37-7.39  (m, 2H); 
13C 
NMR (100 MHz, CDCl3) δ (ppm) -4.8 and -4.7, -4.3, 9.8 and 9.9, 13.7 and 14.0, 18.0, 
20.9, 22.9, 23.4, 23.9, 24.7, 25.8, 29.7, 35.8, 36.2, 36.7, 48.2, 49.2 and 49.5, 55.3, 
56.7, 68.0 and 68.3, 71.9, 72.1, 72.3, 73.1, 73.9, 78.1 and 78.4, 113.9, 126.5, 127.0, 
127.9, 128.0, 128.2, 128.3, 129.3, 129.4, 129.5, 129.9, 132.1, 133.6, 133.7, 138.3, 
138.4,  139.1,  139.2,  140.4,  142.4,  159.4,  174.5  and  174.8;  HRMS  (ES)  calcd  for 
C50H72NO9SSi [M+H]
+ m/z 890.4662, found m/z 890.4697. 
Ph
O
N
MesO2S
O OH
Ph
OH
OPMB
OH
312  
(2R,3R,4R,5R)-((1R,2S)-2-(N-Benzyl-2,4,6-trimethylphenylsulfonamido)-1-
phenylpropyl)      6-(4-Methoxybenzyloxy)-3,5-dihydroxy-2-(3-hydroxybutyl)-4-
methylhexanoate (312) 
To a stirred solution of bisTBS ether 309 (126 mg, 0.125 mmol) in THF (2.5 
mL) at 0°C was added dropwise HF⋅py complex (1.40 mL) and the resulting mixture 
was stirred at 0°C for 30 min, then was allowed to warm to room temperature over 30 
min. The reaction mixture was cooled to 0°C and diluted with Et2O (2.5 mL). The 
combined organic phases were washed with NaHCO3 (4.0 mL) and the aqueous phase 
was extracted with Et2O (4.0 mL). The combined organic layers were washed with  
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brine  (5.0  mL),  dried  over  anhydrous  MgSO4,  filtered  and  concentrated  in  vacuo. 
Flash chromatography (50% EtOAc/hexanes) of the residue provided triol 312 (91 mg, 
94%) as a white foam: IR (neat) 3453 (br), 3063, 3025, 2954, 2924, 2854, 1738, 1610, 
1514, 1455, 1378, 1318, 1249, 1152, 1034, 1011, 910, 853, 731, 699, 661 cm
-1; 
1H 
NMR (400 MHz, CDCl3) δ (ppm) 0.95-0.96 (m, 3H), 1.00-1.02 (m, 3H), 1.21-1.23 (m, 
3H), 1.35-1.50 (m, 2H), 1.50-1.63 (m, 2H), 1.72-1.79 (m, 1H), 2.33 (s, 3H), 2.49 (s, 
6H), 2.61-2.69 (m, 1H), 3.50-3.56 (m, 3H), 3.79-3.85 (m, 1H), 3.83 (s, 3H), 4.09-4.20 
(m, 2H), 4.50 (s, 2H), 4.60-4.69 (m, 1H), 4.80-4.87 (m, 1H), 5.80-5.82 (m, 1H), 6.80-
6.83 (m, 2H), 6.89-6.91 (m, 4H), 7.14-7.17 (m, 2H), 7.20-7.29 (m, 6H), 7.36-7.38 (m, 
2H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 9.7, 14.0, 20.9, 22.9, 23.4, 24.9, 25.4, 35.7 
and 36.2, 35.8, 48.1, 48.9, 49.4, 55.3, 56.6, 67.3 and 67.6, 71.9 and 72.1, 72.2, 73.1, 
73.7, 78.2, 113.9, 126.6, 126.7, 127.1, 128.0, 128.2, 128.3, 129.5, 129.8, 132.1, 133.0, 
138.3,  139.0,  140.4,  142.5,  159.4,  174.6  and  174.8;  HRMS  (ES)  calcd  for 
C44H57NO9SNa [M+Na]
+ m/z 798.3690, found m/z 798.3652. 
Ph
O
N
MesO2S
O O
Ph
O
OPMB
OH
313  
(R)-((1R,2S)-2-(N-Benzyl-2,4,6-trimethylphenylsulfonamido)-1-phenylpropyl)    
2-((4R,5R,6R)-6-((4-Methoxybenzyloxy)methyl)-2,2,5-trimethyl-1,3-dioxan-4-yl)-
5-hydroxyhexanoate (313)  
 
129 
 
Method A. To a stirred solution of TBS ether 314 (56.0 mg, 0.0602 mmol) in 
THF (1.2 mL) at 0 °C was added HF⋅py (0.25 mL) and the resulting mixture was 
allowed to warm to room temperature over 2.5 h. The reaction mixture was diluted 
with Et2O (2.0 mL), cooled to 0 °C and neutralized with saturated aqueous NaHCO3. 
The aqueous phase was extracted with Et2O (3 x 5.0 mL) and the combined organic 
phases were  washed with saturated  aqueous NaCl (5.0 mL), dried over anhydrous 
MgSO4, filtered and concentrated under reduced pressure. The residue was purified by 
flash  chromatography  (30-40%  EtOAc  in  hexanes)  to  give  alcohol  313  (47.4  mg, 
96%) as a colorless oil. 
Method  B.  To  a  stirred  mixture  of  triol  312  (407  mg,  0.525  mmol),  2,2-
dimethoxypropane (0.10 mL, 0.788 mmol) and 4 Å MS in acetone (10.5 mL) at room 
temperature  was  added  CSA  (24  mg,  0.105  mmol)  and  the  resulting  mixture  was 
heated to reflux for 1 h. The solution was cooled to room temperature and filtered. The 
filtrate  was  evaporated  to  give  a  residue  which  was  diluted  with  DCM  (10  mL), 
washed with NaHCO3 (5 mL), dried over anhydrous MgSO4, filtered and concentrated 
under  reduced  pressure.  The  crude  product  was  purified  by  flash  chromatography 
(30% EtOAc/hexanes) to deliver cyclic ketal 313 (310 mg, 72%) as a white foam.  
Method C. To a stirred mixture of triol 312 (218 mg, 0.281 mmol) and 2,2-
dimethoxypropane (0.10 mL, 0.844 mmol) in DCM (7.0 mL) at room temperature was 
added PPTS (9.9 mg, 0.0394 mmol), and the resulting mixture was heated at reflux for 
3 h. The solution was cooled and the reaction mixture was quenched with saturated  
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aqueous NaHCO3 (7.0 mL). The aqueous phase was extracted with DCM (2 x 10.0 
mL) and the organic phase was dried over anhydrous MgSO4, and concentrated under 
reduced  pressure.  The  crude  product  was  purified  by  flash  chromatography  (30% 
EtOAc/hexanes)  to  deliver  cyclic  ketal 313  (245  mg,  quant.)  as  a  white foam:  IR 
(neat) 3470 (br), 3063, 3031, 2965, 2924, 2853, 1741, 1610, 1513, 1458, 1379, 1320, 
1247, 1224, 1153, 1034, 1011, 930, 910, 854, 821, 732, 699, 660, 598, 567 cm
-1; 
1H 
NMR (400 MHz, CDCl3) δ (ppm) 0.94-0.97 (m, 6H), 1.10-1.13 (m, 3H), 1.28-1.32 (m, 
6H), 1.30-1.52 (m, 4H), 1.60-1.70 (br s, 1H) 1.75-1.85 (m, 1H), 2.36 (s, 3H), 2.49 and 
2.50 (s, 6H), 2.57-2.70 (m, 1H), 3.40-3.52 (m, 4H), 3.82 (s, 3H), 3.90-4.02 (m, 2H), 
4.01-4.55 (m, 2H), 4.56-4.61 and 4.91-4.97 (m, 2H), 5.74-5.75 (m, 1H), 6.67-6.71 (m, 
2H), 6.89-6.91 (m, 2H), 6.95-6.96 (m, 2H), 7.09-7.12 (m, 2H), 7.18-7.19 (m, 1H), 
7.26-7.32 (m, 5H), 7.46-7.48 (m, 2H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 11.9 and 
12.0, 14.1 and 14.2, 21.0, 22.9, 23.5 and 23.6, 23.7, 24.3 and 25.1, 24.7, 34.1, 36.1 and 
36.7, 46.3 and 46.9, 48.1, 55.3, 46.5, 66.8 and 67.5, 70.7 and 70.8, 71.4, 73.1, 74.5, 
78.1 and 78.2, 101.3, 113.8, 126.6 and 126.7, 127.3, 128.0, 128.1, 128.3, 128.4, 129.3, 
130.3, 132.2, 133.4, 138.4, 139.2 and 139.3, 140.4, 142.5, 159.2, 173.9 and 174.2; 
HRMS (ES) calcd for C47H62NO9S [M+H]
+ m/z 816.4145, found m/z 816.4174. 
Ph
O
N
MesO2S
O O
Ph
O
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(R)-((1R,2S)-2-(N-Benzyl-2,4,6-trimethylphenylsulfonamido)-1-phenylpropyl)    
2-((4R,5R,6R)-6-((4-Methoxybenzyloxy)methyl)-2,2,5-trimethyl-1,3-dioxan-4-yl)-
5-(tert-butyldimethylsilyloxy)hexanoate (314) 
  To  a  stirred  solution  of  diol  311  (13.0  mg,  0.0146  mmol),  2,2-
dimethoxypropane (2.7 µL, 0.0219 mmol) and 4 Å MS in acetone (0.30 mL) at room 
temperature was added CSA (0.5 mg, 0.00146 mmol) and the resulting mixture was 
stirred for 3.0 h. The reaction mixture was filtered and the filtrate was evaporated to 
give a residue which was diluted with DCM (2.0 mL), washed with NaHCO3 (2.0 
mL),  dried  over  anhydrous  MgSO4,  and  concentrated  under  reduced pressure. The 
crude product was purified by flash chromatography (20% EtOAc/hexanes) to deliver 
cyclic ketal 314 (11.2 mg, 82%) as a colorless oil: IR (neat) 3063, 3025, 2954, 2929, 
2856, 1743, 1607, 1514, 1456, 1380, 1326, 1248, 1224, 1153, 1036, 1011, 909, 836, 
775, 730, 699, 672, 660 cm
-1; 
1H NMR (400MHz, CDCl3) δ (ppm) -0.04 and -0.03 (s, 
6H), 0.84 and 0.86 (s, 9H), 0.92-0.94 (m, 3H), 0.96-0.98 (m, 3H), 1.06-1.10 (m, 3H), 
1.20-1.39 (m, 4H), 1.29-1.35 (m, 6H), 1.82-1.84 (m, 1H), 2.36 (s, 3H), 2.51 and 2.54 
(s, 6H), 2.59-2.63 (m, 1H), 3.48-3.51 (m, 1H), 3.49-3.51 and 3.61-3.65 (m, 1H), 3.56-
3.57 (m, 2H), 3.83 (s, 3H), 3.88-3.92 (m, 1H), 4.04 (dd, J = 11.2, 4.8 Hz, 1H), 4.51-
4.56 (m, 2H), 4.57-4.62 and 4.99-5.03 (m, 2H), 5.70-5.72 (m, 1H), 6.65-6.68 (m, 2H), 
6.89-6.91 (m, 2H), 6.97-6.99 (m, 2H), 7.09-7.13 (m, 2H), 7.16-7.20 (m, 1H), 7.24-
7.31 (m, 5H), 7.49-7.51 (m, 2H); 
13C NMR (100 MHz, CDCl3) δ (ppm) -4.8 and -4.7, 
-4.4 and -4.3, 11.9 and 12.0, 13.8 and 14.1, 17.9 and 18.0, 20.9, 22.9, 23.2, 23.8, 23.9, 
24.7, 25.3, 25.8, 29.7, 34.1 and 34.2, 36.6 and 37.4, 46.9 and 47.2, 48.1 and 48.2, 55.3,  
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56.7, 67.8 and 68.2, 70.6 and 70.9, 71.5, 73.0, 74.5 and 74.6, 78.1 and 78.4, 101.3, 
113.8, 126.4 and 126.5, 127.1 and 127.2, 127.8, 128.0, 128.1, 128.3, 128.4, 129.2, 
130.4, 132.2, 133.6 and 133.7, 138.4 and 138.5, 139.4 and 139.5, 140.4, 142.4, 159.2, 
173.8  and  174.1;  HRMS  (ES)  calcd  for  C53H75NO9SSiNa  [M+Na]
+  m/z  952.4988, 
found m/z 952.4830. 
Ph
O
N
MesO2S
O O
Ph
O
OPMB
O
315  
(R)-((1R,2S)-2-(N-Benzyl-2,4,6-trimethylphenylsulfonamido)-1-phenylpropyl)    
2-((4R,5R,6R)-6-((4-Methoxybenzyloxy)methyl)-2,2,5-trimethyl-1,3-dioxan-4-yl)-
5-oxohexanoate (315) 
  To a stirred mixture of alcohol 313 (300 mg, 0.368 mmol) and NaHCO3 (93 
mg, 1.103 mmol) in DCM (18 mL) at room temperature was added DMP (234 mg, 
0.551 mmol) and the resulting mixture was stirred for 30 min. The reaction mixture 
was quenched with H2O (18 mL) and the aqueous phase was extracted with DCM (2 x 
25 mL). The organic phase was washed with brine, dried over anhydrous MgSO4, 
filtered and concentrated in vacuo. Flash chromatography (30% EtOAc/hexanes) of 
the crude product provided ketone 315 (302 mg, quant.) as a white solid: mp. 153-155 
°C; [α]D
20 +35.2 (c 1.00, CHCl3); IR (neat) 3058, 3025, 2924, 2854, 1740, 1718, 1610, 
1513, 1456, 1380, 1322, 1247, 1153, 1035, 1011, 909, 854, 731, 699, 660 cm
-1; 
1H  
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NMR (400 MHz, CDCl3) δ (ppm) 0.99 (d, J = 6.8 Hz, 3H), 1.14 (d, J = 6.8 Hz, 3H), 
1.29 (s, 3H), 1.31 (s, 3H), 1.40-1.51 (m, 1H), 1.67-1.76 (m, 1H), 1.81-1.83 (m, 1H), 
1.82 (s, 3H), 2.03 (t, J = 7.6 Hz, 2H), 2.36 (s, 3H), 2.47 (s, 6H), 2.65 (dt, J = 3.6, 11.2 
Hz, 1H), 3.46-3.55 (m, 3H), 3.83 (s, 3H), 3.97-4.01 (m, 2H), 4.51-4.56 (m, 2H), 4.58 
and 4.90 (AB quartet, 2H), 5.78 (d, J = 5.6 Hz, 1H), 6.73 (d, J = 7.2 Hz, 2H), 6.89 (d, 
J = 7.2 Hz, 2H), 6.94 (s, 2H), 7.12-7.16 (m, 2H), 7.23-7.31 (m, 6H), 7.41-7.44 (m, 
2H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 11.8, 14.4, 20.9, 22.1, 22.9, 23.7, 24.7, 
29.6, 34.1,  40.0, 45.8,  48.0,  55.3, 56.3,  70.7, 71.5,  73.0,  74.6, 77.8,  101.3, 113.8, 
126.9, 127.3, 128.1, 128.2, 128.3, 128.6, 129.3, 130.4, 132.2, 133.3, 138.4, 138.9, 
140.5, 142.6, 159.2, 173.7, 206.9; HRMS (ES) calcd for C47H59NO9SNa [M+Na]
+ m/z 
836.3808, found m/z 836.3759. 
PMBO
O
O
O
O Ph
N
MesO2S
Bn
316  
(4R,5R,6R,7R)-((1R,2S)-2-(N-Benzyl-2,4,6-trimethylphenylsulfonamido)-1-
phenylpropyl)      7-((4-Methoxybenzyloxy)methyl)-1,6-dimethyl-8,9-dioxa-
bicyclo[3.3.1]nonane-4-carboxylate (316) 
  To a stirred solution of ketone 315 (280 mg, 0.344 mmol) in benzene (17 mL) 
was added p-TsOH⋅H2O (7 mg, 0.034 mmol) and the resulting mixture was stirred for 
8 h at room temperature. The reaction mixture was quenched with saturated aqueous  
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NaHCO3 (10  mL)  and  the  aqueous phase  was  extracted  with  DCM  (20  mL).  The 
combined  organic  phases  were  washed  with  brine,  dried  over  anhydrous  MgSO4, 
filtered  and  concentrated.  Flash  chromatography  (10-20%  EtOAc/hexanes)  of  the 
crude product provided cyclic ketal 316 (234 mg, 90%) as a white foam. [α]D
20 +8.2° 
(c 1.00, CHCl3); IR (neat) 3058, 3031, 2982, 2938, 2851, 1737, 1610, 1513, 1496, 
1455, 1381, 1324, 1248, 1152, 1101, 1055, 1032, 931, 912, 859, 818, 763, 731, 699, 
672, 658 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 0.40 (d, J = 7.2 Hz, 3H), 1.26 (d, 
J = 6.8 Hz, 3H), 1.35 (s, 3H), 1.71-1.80 (m, 1H), 1.83-1.95 (m, 1H), 2.05-2.25 (m, 
3H), 2.30 (s, 3H), 2.42 (s, 6H), 2.79-2.83 (m, 1H), 3.29-3.32 (m, 1H), 3.49-3.43 (m, 
1H), 3.82 (s, 3H), 4.10-4.15 (m, 1H), 4.15-4.19 (m, 1H), 4.35-4.39 (m, 1H), 4.46 and 
4.68 (AB quartet, J = 16.4 Hz, 2H), 4.51 (s, 2H), 5.78 (d, J = 6.4 Hz, 1H), 6.85-6.91 
(m, 6H), 7.10-7.15 (m, 2H), 7.19-7.29 (m, 8H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 
12.5, 14.8, 20.9, 22.2, 22.9, 29.4, 33.3, 34.0, 44.1, 48.1, 55.3, 56.5, 72.0, 72.5, 73.1, 
76.4, 78.2, 95.1, 113.8, 127.0, 127.5, 127.9, 128.1, 128.2, 128.4, 129.3, 130.4, 132.1, 
133.0, 137.5, 138.1, 140.4, 142.5, 159.2, 170.7; HRMS (ES) calcd for C44H53NO8SNa 
[M+Na]
+ m/z 778.3390, found m/z 778.3414. 
HO
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(4R,5R,6R,7R)-((1R,2S)-2-(N-Benzyl-2,4,6-trimethylphenylsulfonamido)-1-
phenylpropyl)      7-(Hydroxymethyl)-1,6-dimethyl-8,9-dioxa-
bicyclo[3.3.1]nonane-4-carboxylate (317) 
  To a stirred solution of PMB ether 316 (14.5 mg, 19.2 µmol) and DDQ (6.6 
mg, 28.8 µmol) in DCM (0.95 mL) at room temperature was added H2O (0.05 mL) 
and the resulting brown-green solution was stirred for 1.5 h. The reaction mixture was 
quenched  with  saturated  aqueous  NaHCO3  (3.0  mL)  and  the  aqueous  layer  was 
extracted with DCM (3 x 3.0 mL). The organic layer was washed with water (6.0 mL), 
dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The 
crude product was purified by flash chromatography (30% EtOAc/hexanes) to afford 
alcohol 317 (12 mg, 98%) as a colorless oil: [α]D
26 +16.2 (c 1.00, CHCl3); IR (neat) 
3492 (br), 3063, 3025, 2939, 1737, 1604, 1496, 1454, 1382, 1324, 1207, 1152, 1125, 
992, 930, 860, 758, 699, 658 cm
-1; 
1H NMR (700 MHz, CDCl3) δ (ppm) 0.40 (d, J = 
7.0 Hz, 3H), 1.27 (d, J = 4.2 Hz, 3H), 1.33 (s, 3H), 1.77-1.82 (m, 1H), 1.91-1.95 (m, 
1H), 2.01-2.10 (m, 1H), 2.15-2.27 (m, 2H), 2.30 (s, 3H), 2.42 (s, 6H), 2.80-2.85 (m, 
1H), 3.30-3.36 (m, 1H), 3.59-3.62 (m, 1H), 4.04-4.08 (m, 1H), 4.19-4.22 (m, 1H), 
4.38-4.41 (m, 1H), 4.45 (A of AB quartet, J = 16.4 Hz, 1H), 4.67 (B of AB quartet, J = 
16.4 Hz, 1H), 5.80 (d, J = 6.0 Hz, 1H), 6.85 (s, 2H), 6.91 (d, J = 7.2 Hz, 2H), 7.14-
7.16 (m, 2H), 7.25-7.29 (m, 6H); 
13C NMR (175 MHz, CDCl3) δ (ppm) 12.3, 14.8, 
20.9, 22.0, 22.9, 29.2, 29.7, 32.0, 34.0, 43.8, 48.1, 56.4, 64.3, 71.8, 76.7, 78.2, 95.2, 
127.0, 127.5, 127.9, 128.2, 128.3, 128.5, 132.2, 132.9, 137.4, 138.1, 140.4, 142.6,  
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170.5;  HRMS  (ES)  calcd  for  C36H45NO7SNa  [M+Na]
+  m/z  658.2814,  found  m/z 
658.2801. 
O
O
O
O
O Ph
N
MesO2S
Bn
318  
(4R,5R,6R,7R)-((1R,2S)-2-(N-Benzyl-2,4,6-trimethylphenylsulfonamido)-1-
phenylpropyl)       7-Formyl-1,6-dimethyl-8,9-dioxa-bicyclo[3.3.1]nonane-4-
carboxylate (318) 
  Method A. To a stirred mixture of alcohol 317 (300 mg, 0.368 mmol) and 
NaHCO3 (93 mg, 1.103 mmol) in DCM (18 mL) at room temperature was added DMP 
(234 mg, 0.551 mmol) and the resulting cloudy mixture was stirred for 30 min, then 
quenched with H2O (18 mL). The aqueous phase was extracted with DCM (2 x 25 
mL) and the organic phase was washed with brine (30 mL), dried over anhydrous 
MgSO4 and filtered. The filtrate was concentrated under reduced pressure to leave a 
crude product which was purified by flash chromatography (30% EtOAc/hexanes) to 
give aldehyde 318 (302 mg, quant.) as a white foam. 
  Method B. To a stirred solution of oxalyl chloride (27 µL, 0.301 mmol) in 
DCM (3.0 mL) at -78 °C was added dropwise a solution of DMSO (43 µL, 0.602 
mmol) in DCM (1.2 mL) and the resulting mixture was stirred for 10 min, at which  
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point a solution of alcohol 317 (160 mg, 0.252 mmol) in DCM (2.5 mL) was added 
slowly. The solution was stirred at -78 °C for 20 min and Et3N (0.19 mL) was added 
dropwise. The mixture was stirred for 10 min then was slowly allowed to warm to 
room temperature. The reaction mixture was quenched with water (6.0 mL) and the 
aqueous layer was extracted with DCM (6.0 mL). The organic layer was washed with 
brine (6.0 mL), dried over anhydrous MgSO4, filtered and concentrated. The crude 
product  was  purified  by  flash  chromatography  (25%  EtOAc/Hexanes)  to  provide 
aldehyde 318 (156 mg, 93%) as a colorless viscous oil: [α]D
26 +29.8 (c 1.00, CHCl3); 
IR (neat) 3069, 3031, 2940, 2851, 2813, 1738, 1604, 1496, 1454, 1382, 1324, 1206, 
1153,  1124,  1012,  930,  910,  860,  763,  731,  699,  658  cm
-1; 
1H  NMR  (700  MHz, 
CDCl3) δ (ppm) 0.44 (d, J = 7.7 Hz, 3H), 1.27 (d, J = 4.2 Hz, 3H), 1.39 (s, 3H), 1.76-
1.82 (m, 1H), 1.95-2.01 (m, 1H), 2.06-2.12 (m, 2H), 2.22-2.27 (m, 1H), 2.30 (s, 3H), 
2.45 (s, 6H), 2.75-2.78 (m, 1H), 4.18-4.22 (m, 2H), 4.44-4.45 (m, 1H), 4.47 (A of AB 
quartet, J = 16.1 Hz, 1H), 4.65 (B of AB quartet, J = 16.1, 1H), 5.82 (d, J = 5.6 Hz, 
1H), 6.85 (s, 2H), 6.94 (d, J = 7.7 Hz, 2H), 7.17 (t, J = 7.7 Hz, 2H), 7.23-7.29 (m, 6H), 
9.33 (d, J = 2.1 Hz, 1H); 
13C
 NMR (175 MHz, CDCl3) δ (ppm) 11.6, 14.7, 20.9, 21.6, 
22.9, 28.9, 30.4, 34.0, 43.6, 48.1, 56.3, 71.2, 78.3, 80.6, 95.1, 127.0, 127.5, 127.8, 
128.3,  128.5,  132.2,  132.9,  137.2,  138.1,  140.3,  142.6,  170.1,  200.0;  HRMS  (ES) 
calcd for C36H43NO7SNa [M+Na]
+ m/z 656.2658, found m/z 656.2634.     
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CHAPTER 4: SYNTHESIS OF THE C1-N12 TRIPEPTIDE 
OF SANGLIFEHRIN A 
 
  Our route to the C1-N12 tripeptide 241 of SFA first required preparation of 
piperazic  acid  derivative  113  and  (S)-m-hydroxyphenylalanine  derivative  244.  The 
latter would be linked with L-valine via racemization-free peptide synthesis to form 
tripeptide  241  which  would  be  used  for  fabrication  of  a  C1-C19  substructure  by 
coupling  with  carboxylic  acid  242.  Synthesis  of  the  components  of  241  and  their 
assembly into the complete tripeptide are described in the sections that follow. 
4.1 Synthesis of Piperazic Acid Methyl Ester 113 
  Following Hale’s protocol,
1 the synthesis of piperazic acid methyl ester 113 
commenced with treatment of δ-valerolactone (319) with hydrobromic acid in acetic 
acid to give 5-bromopentanoic acid 320 (Scheme 4.1). The carboxyl group of 320 was 
activated with thionyl chloride in refluxing chloroform and the resultant acyl chloride 
321 was condensed with (S)-oxazolidinone 131 to afford N-acylated oxazolidinone 
322.    Enolization  of  322  was  accomplished  using  Evans’  procedure,
2  wherein  a 
precooled  solution  of  the  oxzolidinone  in  tetrahydrofuran  was  added  to  lithium 
diisopropylamide in tetrahydrofuran at −78 °C. The resulting mixture was treated with 
di-tert-butyl azodicarboxylate in dichloromethane at −78 °C, then with 1,3-dimethyl-
3,4,5,6-tetrahydro-2(1H)-pyrimidinone,  and  the  frozen  reactants  were  allowed  to  
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warm to room temperature. This one-pot procedure provided 96 in 76% yield and 90% 
diastereomeric ratio.  
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Scheme 4.1 Synthesis of piperazic acid methyl ester 113 (22% yield, 7 steps) 
The mechanism for the transformation of bromide 322 into 96 is illustrated in 
Scheme 4.2 and rationalizes how the (S)-oxazolidinone in enolate 323 directs attack by 
di-tert-butyl azodicarboxylate to the re face of the enolate and leads to intermediate 
324. Intramolecular displacement of bromide from 324 occurs after addition of 1,3-
dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone  at  -78  ºC  to  produce  96.  The 
oxazolidinone auxiliary was removed from 96 by treatment with lithium hydroxide in 
wet  tetrahydrofuran  and  the  resultant  carboxylic  acid  40  was  esterified  with 
trimethylsilyldiazomethane to deliver methyl ester 112 (Scheme 4.1). The pair of tert- 
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butoxycarbonyl  protecting  groups  was  removed  from  112  by  treatment  with 
trifluoroacetic acid to yield piperazic acid methyl ester 113 as its bis-trifluoroacetate. 
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Scheme 4.2 Mechanism for enantioselective formation of 96 
4.2 Synthesis of (S)-m-Hydroxyphenylalanine Derivative 244 
  While  synthesis  of  piperazic  acid  methyl  ester  113  was  in  progress,  the 
synthesis  of  (S)-m-hydroxyphenylalanine  derivative  244  was  explored  using  an 
asymmetric  catalytic  phase-transfer  method  for  introducing  the  α-amino  function
3 
(Scheme 4.3). First, the phenolic hydroxyl group of 3-hydroxybenzaldehyde (325) was 
masked with triisopropylsilyl trifluoromethanesulfonate to give silyl ether 326
4 which 
was reduced with sodium borohydride in methanol to primary alcohol 327.
5 Treatment 
of 327 with a mixture of iodine and triphenylphosphine in the presence of imidazole 
gave iodide 328,
6 and this was reacted with imino ester 329 in the presence of phase-
transfer catalyst 330 in a mixture of dichloromethane and toluene at −10 °C and then  
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with 50% aqueous potassium hydroxide. This afforded tert-butyl ester 331 in good 
yield. The enantioselectivity of this reaction results from the transition state shown in 
Figure 4.1 where an ion pair is formed between the enolate of imino ester 329 and 
catalyst 330. This configuration is the lowest energy transition state due to direction-
specific  ion  pairing  which  brings  the  enolate  oxygen  into  proximity  with  the  less 
sterically  hindered  face  of  the  bridgehead  quaternary  nitrogen  atom.  A  π-stacking 
interaction  between  the  isoquinoline  moiety  and  the  enolate  double  bond  helps 
stabilize this orientation. The alkyl halide 328 approaches the enolate in this complex 
from the more accessible si face leading to the (S)-product 331.
3 The enantiomeric 
excess  of  331  could  not  be  determined  by  chiral  high-performance  liquid 
chromatography and therefore 331 was converted to 332 in which the enantiomeric 
excess was determined to be 88% by chiral high-performance liquid chromatography.   
Attempts to conduct the phase-transfer reaction of 329 with the bromide and chloride 
analogs of iodide 328 in the presence of 330 were unsuccessful.  
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Scheme 4.3 Synthesis of imine 331 using asymmetric phase-transfer catalysis       
(78% yield, 4 steps) 
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Figure 4.1 Stereoview of the ion pair formed between the enolate of imino ester 329             
and catalyst 330 
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  With  331  in  hand,  hydrolysis  of  the  imine  was  attempted  with  12M 
hydrochloric  acid  in  warm  acetonitile  (40  °C)  but  these  conditions  led  only  to 
decomposition of 331. Treatment of 331 with dilute hydrochloric acid (1M) resulted in 
a low yield (12%) of amino ester 244 but when 331 was exposed to a mixture of 1:1:1 
acetic  acid-tetrahydrofuran-water  amino  ester  244  was  produced  in  excellent  yield 
(Scheme 4.4). 
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Scheme 4.4 Hydrolysis of imine 331 to (S)-m-hydroxyphenylalanine derivative 244 
4.3 Synthesis of the C7-C19 Segment of SFA 
  In  our  initial  approach  to  the  C1-N12  tripeptide  241,  we  planned  to  link 
piperazic acid methyl ester 113 with carboxylic acid 335, and to this end coupling of 
(S)-m-hydroxyphenylalanine  derivative  244  with  commercially  available  tert-
butoxycarbonyl-L-valine  (333)  in  the  presence  of  1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide and 1-hydroxybenzotriazole gave dipeptide 334 in 
good  yield  and  high  diastereomeric  ratio  (Scheme  4.5).  Unfortunately,  attempts  to 
effect selective hydrolysis of the tert-butyl ester from dipeptide 334 under conditions 
published  by  Yadav
7  resulted  in  recovered  starting  material  with  no  evidence  for 
formation of 335 (Scheme 4.5). This failure led to a new pathway which avoided the  
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need  for  selective  cleavage  of  a  tert-butyl  ester  in  the  presence  of  a  tert-
butoxycarbonyl group by replacing 333 with N-carbobenzyloxzy-L-valine (336). 
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Scheme 4.5 Synthesis of dipeptide 334 
  In this modified route, 336 was merged with 244 in the presence of N,N,N′,N′-
tetramethyl-O-(7-azabenzotriazol-1-yl)uronium  hexafluorophosphate  to  afford 
dipeptide  337  in  excellent  yield  and  good  diastereomeric  ratio  (Scheme  4.6). 
Subjection of 337 to palladium-catalyzed hydrogenolysis under atmospheric pressure 
gave  amine  338  and  subsequent  coupling  of  338  with  carboxylic  acid  242  in  the 
presence  of  N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium  hexafluoro-
phosphate at ambient temperature provided tert-butyl ester 339. At this point, cleavage 
of the tert-butyl ester of 339 was required for linkage of the C7-C19 carboxylic acid 
341 with piperazic acid methyl ester 113. It was obvious that acidic hydrolysis of the 
tert-butyl  ester  of  339  in  the  presence  of  an  acid  labile  cyclic  ketal  moiety  was 
impractical and an alternative method for this transformation was therefore sought. 
Bromocatecholborane  (340)
8  has  been  used  to  cleave  protecting  groups  such  as 
methoxyethoxymethyl  ethers,  N-carbobenzyloxy  groups  and  tert-butyl  esters  in 
peptide  synthesis,
9  and  this  reagent  was  tested  with  339.  However,  after  several  
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experiments, we could find no evidence for the formation of 341; decomposition of 
the starting material was the sole outcome from this reaction, probably a consequence 
of the sensitivity of the cyclic ketal towards 340. 
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Scheme 4.6 Synthesis of the C7-C19 subunit 339 (63% yield, 3 steps) 
  Our failure to cleave the tert-butyl ester in 334 and 339 caused us to terminate 
this route to the C7-C19 subunit of SFA in favor of one that avoided complications 
associated  with  the  internal  ketal  moiety.  To  that  end,  a  new  goal  was  set  that 
accomplished ester hydrolysis at dipeptide 337. 
4.4 Synthesis of the C1-N12 Tripeptide of SFA 
  Our new route focused on the C1-N12 tripeptide 241 and began with cleavage 
of tert-butyl ester 337 using trifluoroacetic acid and thioanisole to give carboxylic acid  
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342
10 (Scheme 4.7). The presence of excess thioanisole, a carbocation scavenger, is 
important for this reaction since acid-catalyzed cleavage of tert-butyl esters of amino 
acids containing an electron-rich aromatic moiety can lead to products with a tert-
butyl group  substituted  on  the  aromatic  ring  in  the  absence  of  a  carbocation  trap. 
Carboxylic acid 342 was reacted with piperazic acid methyl ester 113 in the presence 
of  N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium  hexafluorophosphate  at 
ambient  temperature  to  provide  tripeptide  343;  subsequent  palladium-catalyzed 
hydrogenolysis  of  343  in  ethanol  under  atmospheric  pressure  funished  241.  This 
sequence completed the synthesis of tripeptide 241 in 18% overall yield from 319 with 
a longest linear sequence of nine steps. Importantly, it left a free amino group at the 
terminus of 241 for linkage with carboxylic acid 242. 
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Scheme 4.7 Synthesis of tripeptide 241 from dipeptide 337 (63% yield, 3 steps)  
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  Synthesis of the C1-N12 tripeptide subunit of sanglifehrin A in this chapter 
was optimized in terms of peptide coupling efficiency and deprotection methodology. 
The synthesis of imino ester 331 employed a phase-transfer reaction in the presence of 
cinchodinium bromide catalyst 330 that afforded useful for the introduction of the 
amino function  and a  good  yield of the product in high enantiomeric  excess. The 
method offers a valuable and potentially general method for the synthesis of α-amino 
acids from alkyl halides. 
4.5 References 
1.   Hale, K. J.; Cai, J. Q.; Delisser, V.; Manaviazar, S.; Peak, S. A.; Bhatia, G. S.; 
Collins, T. C.; Jogiya, N., Tetrahedron 1996, 52 (3), 1047-1068. 
 
2.  Evans, D. A.; Britton, T. C.; Dorow, R. L.; Dellaria, J. F., J. Am. Chem. Soc. 
1986, 108 (20), 6395-6397. 
 
3.  O'Donnell, M. J., Acc. Chem. Res. 2004, 37 (8), 506-517. 
 
4.  Ji, N.; Rosen, B. M.; Myers, A. G., Org. Lett. 2004, 6 (24), 4551-4553. 
 
5.  Wu, Y. C.; Liron, M.; Zhu, J. P., J. Am. Chem. Soc. 2008, 130 (22), 7148-
7152. 
 
6.  Nicolaus, N.; Strauss, S.; Neudorfl, J. M.; Prokop, A.; Schmalz, H. G., Org. 
Lett. 2009, 11 (2), 341-344. 
 
7.  Yadav,  J.  S.;  Balanarsaiah,  E.;  Raghavendra,  S.;  Satyanarayana,  M., 
Tetrahedron Lett. 2006, 47 (28), 4921-4924. 
 
8.  Boeckman, R. K.; Potenza, J. C., Tetrahedron Lett. 1985, 26 (11), 1411-1414. 
 
9.  Ma, B.; Litvinov, D. N.; He, L.; Banerjee, B.; Castle, S. L., Angew. Chem. Int. 
Ed. 2009, 48 (33), 6104-6107. 
 
10. Evans, D. A.; Ellman, J. A., J. Am. Chem. Soc. 1989, 111 (3), 1063-1072.  
 
148 
 
4.6 Experimental Section 
 
Br HO
O
320  
5-Bromopentanoic Acid (320) 
To a solution of 33% HBr in AcOH (0.50 mL) at room temperature was added 
δ-valerolactone 319 (100 mg, 0.999 mmol) and the resulting mixture was stirred for 
26.5 h. The yellow solution was quenched with water (1 mL), extracted with EtOAc (2 
x 2 mL), washed with water (2 mL) and brine (2 mL), dried over anhydrous MgSO4, 
and filtered. The filtrate was concentrated in vacuo to provide crude carboxylic acid 
320 (196 mg, quant.) as a yellow oil: 
1H NMR (300 MHz, CDCl3) δ (ppm) 1.79-1.97 
(m, 4H), 2.42 (t, J = 9.6, 2H), 3.44 (d, J = 8.8 Hz, 2H), 10.82-11.48 (br s, 1H); 
13C 
NMR (75 MHz, CDCl3) δ (ppm) 23.2, 31.8, 32.9, 33.0, 179.3. The carboxylic acid 
was used in the next step without purification. 
Br Cl
O
321  
5-Bromopentanoyl Chloride (321)  
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  To a stirred solution of 5-bromopentanoic acid (320, 3.073 g, 16.98 mmol) in 
CHCl3 (100 mL) at room temperature was slowly added SOCl2 (2.8 mL, 33.96 mmol) 
over a period of 10 min. The resulting mixture was heated at reflux for 15 h to give the 
crude acyl chloride 321 (3.172 g, ca. 94%) as a dark yellow oil: IR (neat) 2960, 2871, 
1817,  1746,  1452,  1411,  1359,  1255,  1045,  742,  681  cm
-1; 
1H  NMR  (300  MHz, 
CDCl3) δ (ppm) 1.85-1.93 (m, 4H), 2.97 (t, J = 6.9 Hz, 2H), 3.433 (t, J = 6.3 Hz, 2H); 
13C NMR (75 MHz, CDCl3) δ (ppm) 23.6, 31.1, 32.4, 46.1, 173.4. The acyl chloride 
was used in the next step without purification. 
O N Br
O O
Bn
322  
(S)-4-Benzyl-3-(5-bromopentanoyl)oxazolidin-2-one (322) 
To a stirred solution of oxazolidinone 131 (2.56 g, 14.46 mmol) in THF (54 
mL) at – 78 °C was added n-BuLi (2.6M solution in hexane, 5.84 mL, 15.18 mmol) 
and the resulting mixture was stirred at – 78 °C for 20 min, at which point acyl choride 
321 (3.17 g, 15.90 mmol) was added dropwise. After stirring for 2.5 h, the reaction 
mixture  was  allowed  to  warm  to  room  temperature  and  quenched  with  saturated 
aqueous NH4Cl (15 mL). DCM (60 mL) was added followed by 10% NaOH (30 mL) 
and the aqueous layer was extracted with DCM (3 x 30 mL). The combined organic 
extracts were washed with brine (40 mL), dried over anhydrous Na2SO4, filtered and 
concentrated  under  reduced  pressure.  The  crude  product  was  purified  by  flash  
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chromatography  (1:6  EtOAc/hexanes)  to  provide  bromide  322  (3.14  g,  64%)  as  a 
white  solid:  mp.  56-58  °C;  [α]D
26  +43.6  (c  1.00,  CHCl3),  [α]D
25  +78.5  (c  1.00, 
MeOH); IR (neat) 3062, 3028, 2923, 2869, 1780, 1699, 1604, 1497, 1480, 1454, 1389, 
1352, 1290, 1213, 1105, 1076, 1051, 1013, 762, 747, 703 cm
-1; 
1H NMR (400 MHz, 
CDCl3) δ (ppm) 1.85-2.07 (m, 4H), 2.80 (dd, J = 9.6, 13.6 Hz, 1H), 2.92-3.08 (m, 2H), 
3.32 (dd, J = 3.2, 13.6 Hz, 1H), 3.48 (t, J = 6.4 Hz, 2H), 4.19-4.26 (m, 2H), 4.67-4.73 
(m, 1H), 7.22-7.38 (m, 5H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 22.8, 32.0, 33.2, 
34.6, 38.0, 55.2, 66.3, 127.4, 129.0, 129.4, 135.2, 153.2, 153.5, 172.6; HRMS (EI) 
calcd for C15H18NBrO3 [M]
+ m/z 339.0470, found m/z 339.0468. 
O N
O
Bn
O
BocN
N
Boc
96  
(S)-di-tert-Butyl 3-((S)-4-Benzyl-2-oxooxazolidine-3-carbonyl)piperazine-1,2-
dicarboxylate (96) 
  To a stirred solution of bromide 322 (2.57 g, 7.56 mmol) in THF (9.3 mL) at   
– 78 °C was added dropwise a freshly prepared LDA solution (1M solution in THF, 
8.32 mL, 8.32 mmol) and the resulting mixture was stirred at – 78 °C for 55 min, at 
which point a precooled (– 78 °C) solution of DBAD (2.09 g, 9.07 mmol) in DCM 
(13.6 mL) was added in one portion via cannula. After stirring the solution at – 78 °C 
for 1 h, DMPU (23.7 mL, 197 mmol) was added dropwise over 1 h. By the end of the  
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addition, the reaction mixture had frozen. The reaction mixture was slowly warmed to 
room temperature and was stirred for 6 h, then added to Et2O (190 mL) layered on top 
of saturated aqueous KH2PO4 (70 mL). The two layers were briefly but vigorously 
shaken and the aqueous phase was extracted with Et2O (3 x 70 mL). The combined 
ether layers were washed with saturated aqueous NaHCO3 (70 mL) amd H2O (120 
mL), then dried over anhydrous MgSO4 and filtered. The solvent was removed in 
vacuo to afford a yellow oily residue which was purified by flash chromatography (1:1 
Et2O/hexanes) to provide 96 (2.80 g, 76%) as a white foam: [α]D
30 +29.0 (c 1.00, 
MeOH); IR (neat) 3055, 3022, 2978, 2932, 2853, 1783, 1698, 1478, 1455, 1393, 1367, 
1296, 1253, 1220, 1166, 1111, 1071, 1049, 1031, 988, 911, 881, 854, 823, 753, 737, 
704 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 1.50 (m), 1.70-2.20 (m), 2.60-2.71 
(m), 2.90 (br s), 3.95 (br s), 4.10-4.25 (m), 4.70 (br s), 5.80 (br s), 6.05 (br s), 7.20-
7.49 (m); 
13C NMR (100 MHz, CDCl3) δ (ppm) 28.1, 28.2, 37.6, 55.6, 66.5, 80.3, 
81.3, 127.4, 129.0, 129.4, 135.2, 152.6, 170.4; HRMS (CI) calcd for C25H35N3O7 [M]
+ 
m/z 489.2475, found m/z 489.2481. 
BocN
N
Boc
O
HO
40  
(S)-1,2-Bis(tert-butoxycarbonyl)piperazine-3-carboxylic Acid (40) 
  To a stirred solution of 96 (2.22 g, 4.53 mmol) in THF (17.8 mL) at – 5 °C was 
added a solution of lithium hydroxide monohydrate (438 mg, 10.43 mmol) in H2O (8.9  
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mL) and the resulting mixture was stirred vigorously for 2 h at 0 °C. The reaction 
mixture was diluted with water (22 mL) and the aqueous layer was extracted with 
Et2O (3 x 55 mL). The organic extracts were washed with saturated aqueous NaHCO3 
(55 mL) and the aqueous layers were combined, acidified to pH 2 with solid NaHSO4, 
and extracted with EtOAc (3 x 110 mL). The organic extract was dried over anhydrous 
MgSO4, filtered and concentrated in vacuo to afford carboxylic acid 40 (1.31 g, 87%) 
as white prisms: mp. 103-106 °C; [α]D
26 -18.2 (c 1.00, MeOH); IR (neat) 3200-2500 
(br), 2979, 2934, 1732, 1479, 1457, 1417, 1367, 1317, 1254, 1156, 1086, 1064, 1050, 
1033, 967, 919, 881, 852, 735, 704, 647, 614 cm
-1; 
1H NMR (400 MHz, CDCl3) δ 
(ppm) 1.45 (s), 1.48 (s), 1.36-2.30 (br m), 2.85 (br m), 3.10 (br m), 3.90 (m), 4.03 (m), 
4.60-5.08 (br m); 
13C NMR (100 MHz, CDCl3) δ (ppm) 20.2, 20.5, 23.4, 23.7, 28.0, 
28.1, 42.2, 44.2, 56.9, 82.7, 83.3, 83.6, 152.7, 170.9, 171.5; HRMS (EI) calcd for 
C15H27O6N2 [M+H]
+ m/z 331.1869, found m/z 331.1861. 
BocN
N
Boc
O
MeO
112  
(S)-1,2-di-tert-Butyl 3-Methyl Piperazine-1,2,3-tricarboxylate (112) 
  To a cooled (0 °C) solution of crude carboxylic acid 40 (1.22 g, 3.70 mmol) in 
MeOH (20 mL) was added dropwise a solution of TMSCHN2 (2M solution in Et2O, 
2.8 mL, 5.56 mmol) at 0 °C and the resulting mixture was allowed to warm to room  
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temperature with stirring. After 12.5 h, the reaction mixture was quenched with 10% 
aqueous AcOH (10 mL) and extracted with Et2O (3 x 30 mL). The organic phase was 
washed with saturated NaHCO3 (30 mL), dried over anhydrous MgSO4, filtered and 
concentrated. The residue was purified by flash chromatography (1:7 Et2O/hexanes 
10-40% EtOAc/hexanes) to afford methyl ester 112 (800 mg, 63%) as a colorless oil: 
[α]D
30 -36.4 (c 1.00, CHCl3); IR (neat) 2977, 2931, 2856, 1740, 1703, 1478, 1456, 
1393, 1367, 1326, 1297, 1252, 1168, 1127, 1086, 1051, 1033, 1007, 952, 910, 880, 
857, 755 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 1.48 (s), 1.49 (s), 1.75 (br m), 
1.90 (br m), 2.20 (m), 2.85 (br m), 3.74 (s), 3.95 (br), 4.12 (m), 4.81 (br), 5.01 (br); 
13C NMR (100 MHz, CDCl3) δ (ppm) 20.0, 24.3, 28.2, 42.7, 51.9, 54.5, 80.2, 81.7, 
154.0, 154.6, 170.4; HRMS (CI) calcd for C16H29N2O6 [M+H]
+ m/z 345.2026, found 
m/z 345.2014.  
HN
N
H
O
MeO ·2CF3COOH
113  
(S)-Methyl Piperazine-3-carboxylate (113) 
  To a stirred solution of methyl ester 112 (776 mg, 2.25 mmol) in DCM (7.5 
mL) at 0 °C was added TFA (7.5 mL) over 1 min and the resulting mixture was 
allowed  to  warm  to  room  temperature  with  stirring  for  1  h.  The  mixture  was 
concentrated in vacuo and the oily residue was azeotroped with toluene to remove  
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residual traces of acid. This gave crude TFA salt 113 (743 mg, 89%) as a yellow oil: 
[α]D
23 +2.5 (c 1.00, CHCl3); IR (neat) 3420, 3259, 2960, 2922, 2851, 2747, 1734, 
1682, 1444, 1204, 1139, 840, 801, 723 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 
1.94-2.01 (m, 3H), 2.18-2.21 (m, 1H), 3.30-3.40 (m, 2H), 3.82 (s, 3H), 3.99-4.02 (m, 
1H), 6.20 (br s, 2H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 19.7, 24.7, 45.1, 52.8, 
55.8,  171.4;  HRMS  (CI)  calcd  for  C6H11N2O2  [M-H]
+  m/z  143.0821,  found  m/z 
143.0813. The TFA salt was used in the next step without purification. 
OTIPS
H
O
326  
3-(Triisopropylsilyloxy)benzaldehyde (326) 
  To a stirred solution of 3-hydroxybenzaldehyde (325) (1.12 g, 9.89 mmol) and 
imidazole  (2.02  g,  29.66  mmol)  in  DMF  (33  mL)  at  -50  °C  was  added  dropwise 
TIPSOTf (4.54 g, 14.83 mmol) and the resulting mixture was allowed to warm to 
room  temperature  with  stirring.  After  10  h,  the  reaction  mixture  was  partitioned 
between EtOAc (60 mL) and water (24 mL) and the aqueous layer was extracted with 
EtOAc-hexanes (1:1, 3 x 48 mL). The combined organic extracts were washed with 
brine and dried over anhydrous Na2SO4. Removal of the solvent in vacuo afforded the 
crude product which was purified by flash chromatography (10% Et2O/hexanes) to 
provide ether 326 (3.05 g, quant.) as a colorless oil: IR (neat) 2945, 2889, 2868, 2723,  
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1705, 1598, 1583, 1483, 1446, 1387, 1279, 1167, 1146, 1073, 1003, 968, 920, 882, 
829, 789, 733, 683, 644 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 1.13 (d, J = 7.2 
Hz, 18H), 1.34-1.27 (m, 3H), 7.17 (d, J = 8.0 Hz, 1H), 7.39-7.42 (m, 2H), 7.46-7.48 
(d, J = 7.6 Hz, 1H), 9.97 (s, 1H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 12.6, 17.9, 
119.6, 123.2, 126.3, 130.0, 138.0, 156.8, 192.0. 
OTIPS
OH
327  
(3-(Triisopropylsilyloxy)phenyl)methanol (327) 
  To a stirred solution of aldehyde 326 (2.87 g, 10.31 mmol) in MeOH (50 mL) 
at  room  temperature  was  added  NaBH4  (585  mg,  15.46  mmol)  and  the  resulting 
suspension was stirred for 40 min. The reaction mixture was concentrated, the residue 
was quenched with H2O (30 mL) and the mixture was extracted with EtOAc (3 x 50 
mL). The organic layer was washed with brine, dried over anhydrous Na2SO4 and 
filtered. The filtrate was concentrated in vacuo to give crude alcohol 327 (2.87 g, 
99%) as a colorless oil: IR (neat) 3331 (br), 2945, 2892, 2867, 1604, 1587, 1486, 
1464, 1444, 1385, 1367, 1281, 1166, 1004, 958, 920, 883, 821, 782, 689 cm
-1; 
1H 
NMR (400 MHz, CDCl3) δ (ppm) 1.13 (d, J = 7.6 Hz, 18H), 1.26-1.33 (m, 3H), 2.00 
(br s, 1H), 4.66 (s, 2H), 6.83 (d, J = 8.0 Hz, 1H), 6.92-6.95 (m, 2H), 7.22 (t, J = 8.0 
Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 12.7, 17.9, 65.2, 118.4, 119.0, 119.4,  
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129.5, 142.5, 156.3; HRMS (CI) calcd for C16H28O2Si [M]
+ m/z 280.1859, found m/z 
280.1851. The crude alcohol was used in the next step without purification. 
OTIPS
I
328  
(3-(Iodomethyl)phenoxy)triisopropylsilane (328) 
  To a stirred solution of PPh3 (561 mg, 2.14 mmol) and imidazole (146 mg, 
2.14 mmol) in DCM (10 mL) at room temperature was added I2 (543 mg, 2.14 mmol). 
After 15 min, a solution of alcohol 327 (500 mg, 1.78 mmol) in DCM (5 mL) was 
added dropwise to the reaction mixture and stirring was continued for 30 min. The 
resulting  suspension  was  passed  through  a  short  column  of  silica  and  eluted  with 
DCM. The DCM eluate was shaken with saturated aqueous Na2S2O3 (15 mL), dried 
over anhydrous MgSO4, filtered and concentrated to provide crude iodide 328 (669 
mg, 96 %) as a pale yellow oil: IR (neat) 2944, 2891, 2866, 1602, 1584, 1484, 1464, 
1440, 1385, 1282, 1173, 1156, 1072, 1003, 978, 920, 882, 817, 782, 690 cm
-1; 
1H 
NMR (400 MHz, CDCl3) δ (ppm) 1.13 (d, J = 7.2 Hz, 18H), 1.23-1.32 (m, 3H), 4.42 
(s, 2H), 6.77 (d, J = 8.0 Hz, 1H), 6.92 (s, 1H), 6.96 (d, J = 7.6 Hz, 1H), 7.15 (t, J = 7.6 
Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 5.5, 12.7, 17.9, 119.5, 120.4, 121.3, 
129.6, 140.6, 156.2; HRMS (EI) calcd for C16H27IOSi [M]
+ m/z 390.0876, found m/z 
390.0873. The iodide was used in the next step without further purification. 
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OTIPS
N
O
Ot-Bu
Ph
Ph
331              
(S)-tert-Butyl 2-(Diphenylmethyleneamino)-3-(3-(triisopropylsilyloxy)phenyl) 
propanoate (331) 
  To a stirred solution of iodide 328 (2.50 g, 6.40 mmol), imino ester 329 (1.89 
g, 6.40 mmol), and catalyst 330 (556 mg, 1.02 mmol) in a mixture of DCM (25 mL) 
and toluene (50 mL) at -10 °C was added a 50% aqueous KOH solution (50 mL) and 
the resulting mixture was stirred vigorously at -5 °C for 33 h. Heptane (65 mL) and 
water (65 mL) were added to the mixture and the aqueous layer was extracted with 
heptane (2 x 100 mL). The combined organic phases were washed with H2O (200 
mL),  dried  over  anhydrous  MgSO4,  filtered,  and  concentrated  to  afford  the  crude 
product which was purified by flash chromatography (10% EtOAc in hexanes with 1% 
Et3N) to furnish ester 331 (2.92 g, 82%) as a viscous orange oil: [α]D
22 -110.6 (c 1.00, 
CHCl3); IR (neat) 3059, 3020, 2944, 2892, 2867, 1735, 1624, 1601, 1585, 1485, 1463, 
1445, 1391, 1368, 1272, 1152, 1073, 1030, 1004, 980, 910, 883, 850, 805, 780, 694 
cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 1.05 (d, J = 7.2 Hz, 18H), 1.13-1.19 (m, 
3H), 1.47 (s, 9H), 3.12 (dd, J = 9.2, 13.2 Hz, 1H), 3.23 (dd, J = 4.4, 13.2 Hz, 1H), 4.14 
(dd, J = 4.4, 9.2 Hz, 1H), 6.64-6.75 (m, 5H), 7.07 (t, J = 8.0 Hz, 1H), 7.29-7.41 (m, 
6H), 7.63 (d, J = 8.0 Hz, 2H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 12.6, 17.9, 28.1,  
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39.6, 67.9, 81.0, 117.6, 121.4, 122.5, 127.8, 127.9, 128.1, 128.2, 128.8, 128.9, 130.0, 
136.5, 139.6, 139.9, 155.8, 170.2, 170.8; HRMS (ES) calcd for C35H48NO3Si [M+H]
+ 
m/z 558.3403, found m/z 558.3384. 
332
OH
N
O
Ot-Bu
Ph
Ph
 
(S)-tert-Butyl 2-(Diphenylmethyleneamino)-3-(3-hydroxyphenyl)propanoate (332) 
  To a stirred solution of TIPS ether 331 (50.0 mg, 0.0896 mmol) in THF (0.45 
mL) at room temperature was added TBAF (1M solution in THF, 0.11 mL, 0.110 
mmol) and the resulting solution was stirred at room temperature for 4 h. The reaction 
mixture was quenched with H2O (0.50 mL) and the aqueous phase was extracted with 
ether (3 x 0.50 mL). The combined organic layers were dried over anhydrous MgSO4, 
filtered and concentrated under reduced pressure. Purification of the residue by flash 
chromatography (10% to 30% EtOAc in hexanes) furnished phenol 332 (34.2 mg, 
95%) as a colorless oil: [α]D
25 -137.6 (c 1.00, CHCl3); IR (neat) 3414, 3059, 2977, 
2928, 1729, 1602, 1589, 1488, 1454, 1393, 1369, 1275, 1152, 1076, 1029, 1000, 978, 
934, 911, 876, 845, 780, 698; 
1H NMR (400 MHz, CDCl3) δ (ppm) 1.46 (s, 9H), 3.12 
(dd, J = 9.2, 13.2 Hz, 1H), 3.20 (dd, J = 4.4, 13.2 Hz, 1H), 4.15 (dd, J = 4.4, 9.2 Hz, 
1H), 5.48 (br s, 1H), 6.55 (s, 1H), 6.62-6.71 (m, 4H), 7.06 (t, J = 8.0 Hz, 1H), 7.28-
7.37 (m, 6H), 7.59 (d, J = 7.6 Hz, 2H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 28.1,  
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39.4, 67.8, 81.4, 113.3, 116.8, 122.1, 127.7, 128.0, 128.1, 128.4, 128.8, 129.3, 130.2, 
136.3, 139.5, 140.0, 155.6, 170.8, 170.9; HRMS (ES) calcd for C26H28NO3 [M+H]
+ 
m/z 402.2069, found m/z 402.2055. 
OTIPS
NH2
O
Ot-Bu
244  
(S)-tert-Butyl 2-Amino-3-(3-(triisopropylsilyloxy)phenyl)propanoate (244) 
To a stirred mixture of imine 331 (302 mg, 0.542) in THF (1.1 mL) and H2O 
(1.1  mL)  at  room  temperature  was  added  acetic  acid  (1.1  mL)  and  the  resulting 
mixture was stirred at room temperature for 6 h. The mixture was diluted with H2O 
(3.0 mL) and neutralized with solid Na2CO3 at 0 °C. The aqueous phase was extracted 
with EtOAc (3 x 5.0 mL) and the combined organic phases were washed with brine 
(10 mL), dried over anhydrous MgSO4, filtered, and concentrated. The residue was 
purified by flash chromatography (30% EtOAc in hexanes) to afford amino ester 244 
(197 mg, 93%) as a yellow oil: [α]D
20 +4.5 (c 1.00, CHCl3); IR (neat) 2944, 2867, 
1732, 1603, 1584, 1486, 1464, 1445, 1391, 1367, 1277, 1156, 1005, 883, 837, 782, 
688 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 1.12 (d, J = 7.6 Hz, 18H), 1.24-1.32 
(m, 3H), 1.47 (s, 9H), 1.55 (br s, 2H), 2.80 (dd, J = 7.6, 13.6 Hz, 1H), 3.02 (dd, J = 
5.2, 13.6 Hz, 1H), 3.62 (br s, 1H), 6.77-6.82 (m, 3H), 7.14-7.18 (m, 1H); 
13C NMR 
(100 MHz, CDCl3) δ (ppm) 12.7, 17.9, 28.0, 41.2, 56.3, 81.2, 118.0, 121.1, 122.1,  
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129.3, 139.1, 156.1, 174.2; HRMS (ES) calcd for C22H40NO3Si [M+H]
+ m/z 394.2777, 
found m/z 394.2748. 
O
N
H
O
NHBoc
OTIPS
t-BuO
334  
(S)-tert-Butyl 2-((S)-2-(tert-Butoxycarbonyl)-3-methylbutanamido)-3-(3-
(triisopropylsilyloxy)phenyl)propanoate (334) 
To a stirred solution of amino ester 244 (170.9 mg, 0.434 mmol), Boc-Val-OH 
(333) (141.5 mg, 0.651 mmol) and HOBt (167.2 mg, 1.237 mmol) in DCM (3.0 mL) 
at  0  °C  was  added  EDCI  (249.7  mg,  1.303  mmol)  and  the  resulting  mixture  was 
allowed to warm to room temperature and stirred at that temperature for 3 h. The 
reaction mixture was quenched with H2O (3.0 mL) and the two layers were separated. 
The aqueous phase was extracted with EtOAc (3 x 5 mL) and the combined organic 
layers were  dried  over  anhydrous  MgSO4,  filtered  and  concentrated  under reduced 
pressure. Purification of the crude product by flash chromatography (20% EtOAc in 
hexanes) afforded dipeptide 334 (221.9 mg, 86%) as a white foam: [α]D
21 +19.5 (c 
1.00, CHCl3); IR (neat) 3316 (br), 2965, 2929, 2868, 1737, 1656, 1604, 1585, 1530, 
1487, 1447, 1392, 1367, 1278, 1160, 1005, 920, 883, 844, 784, 737, 688 cm
-1; 
1H 
NMR (400 MHz, CDCl3) δ (ppm) 0.90 (d, J = 6.8 Hz, 3H), 0.97 (d, J = 6.8 Hz, 3H), 
1.12 (d, J = 7.2 Hz, 18H), 1.24-1.31 (m, 3H), 1.41 (s, 9H), 1.47 (s, 9H), 2.11-2.19 (m,  
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1H), 2.98-3.10 (m, 2H), 3.95 (br s, 1H), 4.70-4.75 (m, 1H), 5.04 (br s, 1H), 6.29 (br s, 
1H), 6.74-6.77 (m, 3H), 7.12-7.15 (m, 1H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 
12.7, 17.9, 19.2, 27.9, 28.3, 31.0, 38.1, 53.5, 59.8, 82.3, 118.2, 121.1, 122.2, 129.2, 
137.5,  156.1,  170.3,  170.9;  HRMS  (ES)  calcd  for  C32H56N2O6NaSi  [M+Na]
+ m/z 
615.3805, found m/z 615.3809.
 
O
N
H
O
NHCbz
OTIPS
t-BuO
337  
(S)-tert-Butyl 2-((S)-2-(Benzyloxycarbonyl)-3-methylbutanamido)-3-(3-
(triisopropylsilyloxy)phenyl)propanoate (337) 
  To a stirred solution of carbobenzyloxy-L-valine (336) (597 mg, 2.375 mmol) 
and HATU (903 mg, 2.375 mmol) in DMF (14 mL) at room temperature was added 
DIPEA (1.24 mL, 7.126 mmol) and the resulting mixture was stirred for 5 min, at 
which point a solution of amino ester 244 (850 mg, 2.159 mmol) in DMF (14 mL) was 
added. The reaction was stirred for 45 min and diluted with EtOAc (30 mL). The 
mixture was washed with H2O (30 mL) and brine (30 mL), then dried over anhydrous 
MgSO4,  filtered  and  concentrated.  The  crude  product  was  purified  by  flash 
chromatography (10% EtOAc/hexanes) to provide dipeptide 337 (1.258 g, 93%) as a 
white foam: [α]D
20 +20.1 (c 1.00, CHCl3); IR (neat) 3309 (br), 2965, 2944, 2868, 
1732, 1657, 1604, 1585, 1537, 1486, 1455, 1392, 1368, 1279, 1246, 1159, 1105, 1028,  
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1005, 919, 883, 833, 784, 735, 695, 661 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 
0.91 (d, J = 6.8 Hz, 3H), 0.97 (d, J = 6.8 Hz, 3H), 1.11 (d, J = 7.2 Hz, 18H), 1.22-1.28 
(m, 3H), 1.41 (s, 9H), 2.11-2.16 (m, 1H), 3.00-3.05 (m, 2H), 4.02-4.04 (m, 1H), 4.70-
4.75 (m, 1H), 5.12 (s, 2H), 5.39 (d, J = 8.4 Hz, 1H), 6.29 (d, J = 8.0 Hz, 1H), 6.72-
6.76 (m, 3H), 7.11 (t, J = 8.4 Hz, 1H), 7.32-7.38 (m, 5H); 
13C NMR (100 MHz, 
CDCl3) δ (ppm) 12.7, 17.6, 17.9, 19.1, 27.9, 29.7, 31.2, 38.0, 53.6, 60.2, 67.0, 82.4, 
118.2, 121.1, 122.2, 128.0, 128.1, 128.5, 129.3, 136.4, 137.4, 156.1, 156.2, 170.3, 
170.5;  HRMS  (CI)  calcd  for  C35H55O6N2Si  [M+H]
+  m/z  627.3829,  found  m/z 
627.3852. 
O
N
H
O
NH2
OTIPS
t-BuO
338  
(S)-tert-Butyl 2-((S)-2-Amino-3-methylbutanamido)-3-(3-(triisopropylsilyloxy) 
phenyl)propanoate (338) 
A mixture of dipeptide 337 (28 mg, 0.045 mmol) and Pd/C (10%, 3.5 mg) in 
EtOH at room temperature was stirred under H2 gas (1 atm) for 19 h. The suspension 
was filtered and the filtrate was concentrated under reduced pressure. The residue was 
purified by flash chromatography (50% EtOAc/hexanes) to give dipeptide 338 (18.4 
mg, 84%) as a colorless oil: [α]D
21 +12.1 (c 1.00, CHCl3); IR (neat) 3369 (br), 3002 
(br), 2968, 2920, 2831, 1731, 1652, 1600, 1582, 1539, 1481, 1390, 1366, 1240, 1149,  
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1101, 1023, 918, 883, 834, 789, 730, 691, 659 cm
-1;  
1H NMR (400 MHz, CDCl3) δ 
(ppm) 0.75 (d, J = 6.8 Hz, 3H), 0.954 (d, J = 6.8 Hz, 3H), 1.10 (d, J = 7.2 Hz, 18H), 
1.20-1.30 (m, 3H), 1.39 (s, 9H), 2.24-2.25 (m, 1H), 3.03 (d, J = 6.4 Hz, 2H), 3.21-3.22 
(m, 1H), 4.72-4.77 (m, 1H), 6.73-6.77 (m, 3H), 7.10-7.14 (m, 1H), 7.66-7.68 (m, 1H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 12.7, 16.1, 17.9, 19.7, 28.0, 30.8, 38.3, 53.1, 
60.2, 82.0, 118.0, 121.1, 122.1, 129.1, 137.9, 156.0, 170.9, 174.0; HRMS (CI) calcd 
for C27H49O4N2Si [M+H]
+ m/z 493.2257, found m/z 493.2284. 
I
O
O
O
O
N
H
O
H
N
OTIPS
t-BuO
339  
(S)-tert-Butyl 2-((S)-2-((3R,4R,5R,6R)-3-((E)-2-iodovinyl)-1,4-dimethyl-2,9-dioxa-
bicyclo[3.3.1]nonane-6-carboxamido)-3-methylbutanamido)-3-(3-
(triisopropylsilyloxy)phenyl)propanoate (339) 
  To a stirred solution of iodo acid 242 (6.0 mg, 0.0170 mmol) and HATU (7.1 
mg, 0.0187 mmol) in DMF (0.68 mL) at room temperature was added DIPEA (10 µL, 
0.0562  mmol)  and  the  resulting  mixture  was  stirred  for  5  min,  at  which  point  a 
solution of dipeptide 338 (9.2 mg, 0.0187 mmol) in DMF (0.38 mL) was added. The 
solution was stirred for 1.5 h and diluted with EtOAc (1.0 mL). The mixture was 
washed with H2O (1.0 mL) and brine (1.0 mL), dried over anhydrous MgSO4, filtered  
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and concentrated under reduced pressure. The crude product was purified by flash 
chromatography  (25%  EtOAc/hexanes)  to  provide  ester  339  (11.4  mg,  81%)  as  a 
colorless oil: [α]D
20 +6.2 (c 0.85, CHCl3); IR (neat) 3284, 3069, 2961, 2942, 2929, 
2867, 2896, 1737, 1639, 1605, 1585, 1549, 1486, 1463, 1448, 1385, 1368, 1279, 1157, 
1005, 952, 883, 846, 837, 781, 734, 688 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 
0.85 (d, J = 6.8 Hz, 3H), 0.93 (d, J = 6.8 Hz, 3H), 0.97 (d, J = 6.8 Hz, 3H), 1.11 (d, J = 
7.2 Hz, 18H), 1.20-1.30 (m, 6H), 1.42 (s, 9H), 1.85-1.98 (m, 2H), 2.00-2.21 (m, 4H), 
2.62-2.63 (m, 1H), 3.01-3.07 (m, 2H), 4.24-4.31 (m, 2H), 4.41-4.44 (m, 1H), 4.68-
4.77 (m, 1H), 6.14 (d, J = 7.6 Hz, 1H), 6.47 (s, 1H), 6.48 (s, 1H), 6.73-6.79 (m, 3H), 
7.11-7.15 (m, 1H), 7.40 (d, J = 8.4 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 
12.6, 17.9, 19.3, 22.8, 27.9, 29.6, 30.9, 31.0, 36.2, 38.0, 38.8, 53.5, 58.1, 71.9, 77.2, 
78.8, 79.9, 82.4, 95.7, 118.2, 121.1, 122.1, 129.3, 137.4, 145.3, 156.2, 170.3, 170.5, 
174.4;  HRMS  (ES)  calcd  for  C39H64N2O7ISi  [M+H]
+  m/z  827.3528,  found  m/z 
827.3552. 
O
N
H
O
NHCbz
OTIPS
HO
342  
(S)-2-((S)-2-(Benzyloxycarbonyl)-3-methylbutanamido)-3-(3-
(triisopropylsilyloxy)phenyl)propanoic Acid (342)  
 
165 
 
  To a solution of tert-butyl ester 337 (10.0 mg, 0.0160 mmol) and thioanisole 
(0.04 mL, 0.340 mmol) in DCM (0.40 mL) at 0 °C was added TFA (0.04 mL, 0.522 
mmol)  and  the  resulting  mixture  was  allowed  to  warm  to  room  temperature  with 
stirring.  After  5  h,  another  portion  of  TFA  (0.30  mL)  was  added  to  the  reaction 
mixture (TLC showed that starting material remained), the mixture was stirred for a 
further  4  h,  and  was  then  concentrated  under  reduced  pressure.  The  residue  was 
purified by flash chromatography (30% EtOAc in hexanes) to furnish carboxylic acid 
342 (7.0 mg, 77%) as a white solid: mp. 120-122 °C; [α]D
20
 +73.6 (c 3.71, CHCl3); IR 
(film)  3310,  3066,  3035,  2961,  2945,  2867,  1717,  1653,  1603,  1585,  1540,  1487, 
1446, 1279, 1248, 1162, 1004, 883, 831, 694 cm
-1; 
1H NMR (400 MHz, CDCl3) δ 
(ppm) 0.86 (d, J = 6.1 Hz, 3H), 0.91 (d, J = 6.5 Hz, 3H), 1.10 (d, J = 7.2 Hz, 18H), 
1.21-1.30 (m, 3H), 2.04-2.10 (m, 1H) 3.05-3.06 (m, 1H), 3.12-3.15 (m, 1H), 4.02-4.09 
(m, 1H), 4.80-4.83 (m, 1H), 5.07-5.15 (AB quartet, 2H), 5.56 (br s, 1H), 6.54 (br s, 
1H), 6.74-6.76 (m, 3H), 7.10 (t, J = 7.9 Hz, 1H), 7.30-7.38 (m, 5H); 
13C NMR (100 
MHz, CDCl3) δ (ppm) 12.7, 17.7, 17.9, 19.0, 30.3, 31.0, 37.3, 53.2, 60.4, 60.5, 67.2, 
118.7, 120.8, 122.0, 128.0, 128.2, 128.5, 129.5, 137.2, 156.3, 156.5, 171.5, 174.5; 
HRMS (CI) calcd for C31H47N2O6Si [M+H]
+ m/z 571.3203, found m/z 571.3220.  
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N
NH
CO2Me
O
N
H
O
NHCbz
OTIPS
343  
(S)-Methyl 1-((S)-2-((S)-2-(Benzyloxycarbonyl)-3-methylbutanamido)-3-(3-
(triisopropylsilyloxy)phenyl)propanoyl)piperazine-3-carboxylate (343) 
  To a solution of carboxylic acid 342 (4.5 mg, 7.9 µmol) in DMF (0.10 mL) at 
room temperature was added HATU (3.6 mg, 9.5 µmol) and DIPEA (4.9 µL, 28.4 
µmol) and the reaction mixture was stirred for 5 min, at which point piperazic methyl 
ester 113 (2.9 mg, 7.9 µmol) in DMF (0.10 mL) was added. The resulting mixture was 
stirred for 2 h, diluted with EtOAc (2 mL), and washed with brine (2 mL). The organic 
phase  was  dried  over  anhydrous  MgSO4,  filtered,  and  concentrated  under  reduced 
pressure.  The  residue  was  purified  by  flash  chromatography  (20%-40%  EtOAc  in 
hexanes) to give tripeptide 343 (4.5 mg, 82%) as a colorless oil: [α]D
20 -25.4 (c 1.00, 
CHCl3); IR (neat) 3302, 3066, 3032, 2945, 2867, 1745, 1642, 1537, 1486, 1442, 1271, 
1236, 1164, 1004, 983, 883, 834, 757, 695; 
1H NMR (400 MHz, CDCl3) δ (ppm) 0.81 
and 0.96 (d, J = 6.8 Hz, 3H), 0.90 (d, J = 6.8 Hz, 3H), 1.11 (d, J = 7.2 Hz, 18H), 1.22-
1.28 (m, 3H), 1.42-1.51 (m, 2H), 1.61-1.86 (m, 3H), 2.02-2.18 (m, 1H), 2.50-2.61 (m, 
1H), 2.83-2.96 (m, 2H), 3.23 and 3.47 (d, J = 11.0 Hz, 1H), 3.72 and 3.76 (s, 3H),  
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4.03-4.08 (m, 1H), 4.03-4.08 and 4.48-4.52 (m, 1H), 5.10-5.17 (m, 2H), 5.38 (br s, 
1H), 5.61-5.66 and 5.73-5.78 (m, 1H), 6.51 (m, 1H), 6.67-6.79 (m, 3H), 7.09-7.14 (m, 
1H), 7.32-7.39 (m, 5H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 12.7, 17.3 and 17.5, 
17.9, 19.2, 22.4 and 22.9, 28.2 and 28.7, 31.4 and 31.7, 39.1 and 39.5, 41.9 and 42.0, 
49.7 and 50.0, 52.1, 57.7 and 58.4, 60.0 and 60.2, 67.0, 118.1, 121.0 and 121.4, 122.2 
and 122.4, 128.1, 128.5, 129.1 and 129.2, 136.4, 138.0, 156.0, 156.1, 156.3, 170.2 and 
170.4,  171.5  and  171.7,  172.3;  HRMS  (ES)  calcd  for  C37H57N4O7Si  [M+H]
+  m/z 
697.3997, found m/z 697.3976. 
N
NH
CO2Me
O
N
H
O
NH2
OTIPS
241  
(S)-Methyl 1-((S)-2-((S)-2-Amino-3-methylbutanamido)-3-(3-
(triisopropylsilyloxy)phenyl)propanoyl)piperazine-3-carboxylate (241) 
  A  suspension  of  tripeptide  343  (164  mg,  0.236  mmol)  and  10%  Pd/C  in 
ethanol (12.0 mL) was stirred under an atmosphere of H2 (1 atm) for 19 h. The catalyst 
was  removed by  filtration  and  the  filtrate  was  evaporated.  The crude product  was 
purified  by  flash  chromatography  (10%  MeOH  in  DCM  +  1%  Et3N)  to  afford 
tripeptide 241 (131 mg, 99%) as a yellow oil: [α]D
20 -21.5 (c 1.00, CHCl3); IR (neat)  
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3336, 3245, 2925, 2867, 1746, 1652, 1603, 1585, 1486, 1443, 1273, 1164, 1004, 982, 
883, 834, 688, 662 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 0.84-1.00 (m, 6H), 1.10 
(d, J = 7.2 Hz, 18H), 1.21-1.29 (m, 3H), 1.40-1.80 (m, 4H), 2.01-2.30 (m, 3H), 2.70-
2.95 (m, 3H), 3.50 (br s, 1H), 3.60-3.70 (m, 6H), 4.20-4.30 (m, 1H), 5.65-5.72 (m, 
1H), 6.69-6.90 (m, 3H), 7.05-7.12 (m, 1H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 
12.7, 14.1, 17.1, 17.5, 17.9, 19.2, 22.7, 28.2, 29.7, 29.7, 30.6, 30.8, 38.0, 39.0, 41.7, 
49.7, 52.1, 57.9, 59.9, 70.6, 118.0, 120.9, 121.4, 122.4, 129.1, 129.2, 138.3, 138.6, 
156.0, 156.1, 171.8, 172.1, 172.5; HRMS (ES) calcd for C29H51N4O5Si [M+H]
+ m/z 
563.3629, found m/z 563.3615.  
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CHAPTER 5: STUDIES TOWARDS THE SYNTHESIS OF 
THE C1-C25 MACROLATONE OF SFA: ASSEMBLY OF 
TRIPEPTIDE 241, CARBOXYLIC ACID 242 AND VINYL 
BORONATE 240 
 
  Our  approach  to  macrolactone  239  required  three  subunits,  specifically 
tripeptide 241, carboxylic acid 242 and vinyl boronate 240. In this plan, amide bond 
formation at N12-C13 was programmed to produce C1-C19 segment 357, which upon 
esterification  with  alcohol  240  would  provide  a  C1-O  connection.  Intramolecular 
palladium-catalyzed Suzuki-Miyaura cross coupling
1, 2 of 358 would create the C19-
C20 linkage leading to mactolactone 239. 
5.1 Synthesis of C20-C25 Vinyl Boronate 240 
  Synthesis of vinyl boronate 240 comprising C20-C25 of SFA commenced with 
zirconation-methylation-iodination  of  propargyl  alcohol  344  to  give  known  iodide 
345.
3 Oxidation of this alcohol with manganese dioxide
4 provided aldehyde 346 which 
was subjected to asymmetric allylboration
5 using allylmagnesium bromide (347) to
 
afford homoallylic alcohol 348 (Scheme 5.1). Subsequent protection of the secondary 
alcohol of 348 with tert-butyldimethylsilyl chloride delivered silyl ether 349 which 
was  transformed  into  diol  350  using  a  regioselective  osmium  tetroxide-mediated 
dihydroxylation  in  the  presence  of  stoichiometric  N-methylmorpholine-N-oxide. 
Oxidation of 350 with sodium periodate in methanol-water furnished aldehyde 37.
6  
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Scheme 5.1 Synthesis of aldehyde 37 (14% yield, 6 steps) 
Our next task was conversion of aldehyde 37  into a vinyl boronate using Takai 
olefination.
7 This operation required dichloromethylboronate 243 which was prepared 
from dichloromethane (351) by the method  of Wuts and  Thompson,
8 as shown in 
Scheme  5.2.  Thus,  dichloromethane  was  lithiated  with  n-butyllithium  at  low 
temperature to give carbanion 352 which was treated with trimethoxyborane and then 
with 5N hydrochloric acid to deliver dichloromethylboronic acid 353. Finally, 353 was 
reacted with pinacol (354) in refluxing benzene to afford boronate 243. 
243
Cl Cl Cl Cl
Li
Cl B(OH)2
Cl
n-BuLi
THF, -100 ºC
B(OMe)3, -100 ºC;
5 N HCl
-100 ºC       rt
OH
OH
PhH, reflux
90% (from 351)
(354)
20
20 20
20
O
O
B
Cl
Cl
351 352 353
 
Scheme 5.2 Synthesis of dichloromethylboronate 243 (90% yield, 3 steps)  
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With aldehyde 37 and boronate 243 in hand, the synthesis of vinyl boronate 
240 was carried out using Takai’s methodology.
7 As shown in Scheme 5.3, aldehyde 
37 was treated with boronate 243 in the presence of chromous chloride and lithium 
iodide to  give 355 from  which the tert-butyldimethylsilyl group was removed with 
tetra-n-butylammonium  fluoride  to  yield  alcohol  240.  The  synthesis  of  240  was 
completed in 9% overall yield from propargyl alcohol (344) in a sequence of eight steps. 
I
OR
B
O
O
CrCl2, LiI, dark,
THF, rt, 79%
(243)
37
I
OTBS
O
355: R = TBS
240: R = H
TBAF, THF
rt, 81%
20
O
O
B
Cl
Cl
25 21 25
20
 
Scheme 5.3 Synthesis of vinyl boronate 240 (64% yield, 2 steps) 
5.2 Studies Toward the Synthesis of the C1-C25 Macrolactone 239 
  The approach to macrolactone 239 began with acylation of tripeptide 241 with 
carboxylic acid 242 in the presence of N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-
yl)uronium hexafluorophosphate  and  Hunig’s base  in acetonitrile.  This led  to 356, 
from which the methyl ester was cleaved with lithium hydroxide to furnish carboxylic 
acid 357 (Scheme 5.4). This carboxylic acid was esterified with alcohol 240 in the 
presence  of  4-pyrrolidinopyridine,  1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
and diisopropylethylamine to afford macrocyclization precursor 358.   
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Scheme 5.4 Synthesis of vinyl iodide 358 (42% yield, 3 steps) 
  With  intramolecular  Suzuki-Miyaura  coupling
1  envisioned  as  the  key  to 
closing  358  to  macrocycle  239,  precedent  was  sought  as  a  guide  in  selecting 
appropriate  reaction  conditions  for  this  challenging  operation.  In  1998,  White  and 
coworkers
2,  9  utilized  an  intramolecular  Suzuki-Miyaura  coupling  to  complete 
macrocycle  360  from  vinyl  boronate  359  in  their  total  synthesis  of  rutamycin  B 
(Scheme  5.5),  and  following  that  precedent  358  was  reacted  with 
bis(acetonitrile)dichloropalladium(II)  and  triphenylarsine  in  the  presence  of  silver 
oxide and water. However, no evidence for macrocyclization was found, hydrolysis of 
the  ester  bond  at  C1-O  to  give  357  being  the  sole  outcome  (Scheme  5.6).  In  the 
presence  of  silver(I)  oxide  (four  equivalents)  and  water,  this  reaction  generates  
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hydroxide ion and we believe that, in contrast to 359, saponification of 358 to return 
357 and (presumably) 240 takes precedence over intramolecular coupling in this case. 
The  approach  to  macrolactone  239  ended  at  this  point  due  to  a  lack  of  advanced 
materials.  
OTBS
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I
OTBS
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B
O O
O O O
TBS TBS
OTBS
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O O O O
TBS TBS
PdCl2(MeCN)2
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THF, H2O
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359 360
 
Scheme 5.5 White’s synthesis of macrolactone 360 from 359 using intramolecular 
Suzuki-Miyaura coupling 
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Scheme 5.6 Formation of carboxylic acid 357 under Suzuki-Miyaura conditions 
  
 
174 
 
  The  unsuccessful  attempt  at  intramolecular  Suzuki-Miyaura  coupling  under 
conditions shown in Scheme 5.6 will require a new strategy for acquiring macrocycle 
239. Shown in Schemes 5.7 and 5.8 are approaches to 239 based on intermolecular 
Suzuki-Miyaura coupling where the order of assembly of subunits has been changed. 
In Scheme 5.7, esterification of 361 with 240 is proposed as a route to 362, after which 
intermolecular Suzuki-Miyaura coupling of 362 with vinyl iodide 363 would generate 
amino  acid  364.  Protecting  groups  would  be  removed  from  364  and 
macrolactamization should then give 239.  
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Scheme 5.7 A new approach to macrocycle 239 via intermolecular 
Suzuki-Miyaura coupling  
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  An alternative strategy for reaching 239 is shown in Scheme 5.8 where amide 
bond formation between 241 and 242 initiates the sequence. This would lead to vinyl 
iodide 365 which should undergo intermolecular Suzuki-Miyaura coupling with 355 to 
produce  macrolactone  precursor  366.  Removal  of  protecting  groups  and 
macrolactonization at the C1-O bond would be the end game strategy in this pathway 
to 239. 
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Scheme 5.8 An alternative strategy for synthesis of macrolactone 239  
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5.4 Experimental Section 
 
I OH
345  
(E)-3-Iodo-2-methylprop-2-en-1-ol (345) 
To a suspension of zirconocene dichloride (652 mg, 2.23 mmol) in DCM (19 
mL) at room temperature was added trimethylaluminum (2.57 mL) and the mixture 
was cooled to 0 °C. A solution of propargyl alcohol (344) (500 mg, 8.92 mmol) in 
DCM (18 mL) was added via cannula and the mixture was allowed to warm to room 
temperature with stirring for 10 h. The mixture was cooled to -30 °C and a solution of 
iodine (3.39 g, 13.38 mmol) in Et2O (5.2 mL) was added. The resulting mixture was 
stirred at -30 °C for 30 min and allowed to warm to 0 °C. The solution was poured 
into a mixture of saturated aqueous sodium potassium tartrate (26 mL) and pentane 
(173  mL)  and  stirred  vigorously  for  10  min.  The  layers  were  separated  and  the 
aqueous phase was extracted with Et2O (3 x 43 mL). The combined organic extracts 
were washed with brine (100 mL) and dried over anhydrous MgSO4. Removal of the 
solvent in vacuo gave alcohol 345 (615.1 mg, 35%) as a yellow oil: IR (neat) 3335, 
3074, 3047, 2915, 2864, 1732, 1683, 1621, 1446, 1377, 1276, 1253, 1147, 1069, 1013, 
942, 883, 832, 776, 704, 667, 576 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 1.81 (br,  
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1H), 1.87 (s, 3H), 4.14 (s, 2H), 6.30 (s, 1H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 
21.3, 67.2, 77.3, 147.2. 
I O
346  
(E)-3-Iodo-2-methylacrylaldehyde (346) 
  To a stirred solution of alcohol 345 (270 mg, 1.52 mmol) in Et2O (15 mL) was 
added freshly prepared MnO2 (1.32 g, 15.15 mmol) and the suspension was stirred 
vigorously  for 10 h. The suspension was filtered and the filtrate was concentrated 
under reduced pressure to give aldehyde 346 (230 mg, 86%) as a yellow oil: IR (neat)  
3527, 3345, 3047, 2954, 2920, 2821, 2722, 1690, 1593, 1375, 1294, 1147, 1013, 831, 
799, 695, 633 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 1.93 (s, 3H), 7.82 (s, 1H), 
9.54 (s, 1H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 16.5, 109.5, 150.8, 189.5. The 
aldehyde was used in the next step without purification. 
I
OH
348  
(S,E)-1-Iodo-2-methylhexa-1,5-dien-3-ol (348) 
Allylmagnesium bromide (347) (3.60 mL, 1M solution in ether, 3.60 mmol) 
was added dropwise to a solution of (−)-(Ipc)2BOMe (1.13 g, 3.58 mmol) in Et2O 
(16.0 mL) at 0 °C and the resulting pale gray slurry was allowed to warm to 25 °C 
over 1 h. The solvent was removed under reduced pressure and pentane (4.0 mL) was  
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added to the residual solid. The resulting slurry was stirred at 25 °C for 10 min and the 
solids  were  allowed  to  settle  over  30  min.  The  clear  supernatant  was  transferred 
carefully to a  flask via  cannula. This process was repeated four times (4.0 mL of 
pentane each, 16.0 mL total volume) and the resulting solution was added dropwise 
over 1 h to a solution of aldehyde 346 (540.0 mg, 2.76 mmol) in Et2O (10 mL) at -100 
°C.  After 1 h at -100 °C, MeOH (0.2 mL) was added to the solution and the mixture 
was allowed to warm to room temperature over 40 min. Saturated aqueous NaHCO3 
(2.4 mL) and H2O2 (2.0 mL of a 30% aqueous solution) were added with stirring over 
12 h. The layers were separated and the aqueous phase was extracted with EtOAc (3 x 
15 mL). The combined organic phases were washed with saturated aqueous NH4Cl (15 
mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. Flash 
chromatography (silica gel, 20% ether in hexanes) furnished alcohol 348 (497.7 mg, 
76%) as a colorless oil: [α]D
20 -18.7 (c 0.9, CHCl3); IR (neat) 3384, 3069, 2922, 1702, 
1641,  1478,  1454,  1386,  1368,  1277,  1040,  995,  914  cm
-1; 
1H  NMR  (400  MHz, 
CDCl3) δ (ppm) 1.85 (s, 3H), 1.86 (br s, 1H), 2.29-2.43 (m, 2H), 4.24 (dd, J = 5.2, 7.6 
Hz, 1H), 5.16 (s, 1H), 5.19 (d, J = 3.2 Hz, 1H), 5.71-5.82 (m, 1H), 6.33 (s, 1H); 
13C 
NMR (100 MHz, CDCl3) δ (ppm) 20.2, 39.9, 75.4, 78.4, 118.7, 133.6, 149.0; HRMS 
(CI) calcd for C7H11IO [M]
+ m/z 237.9855, found m/z 237.9867. 
I
OTBS
349  
(S,E)-tert-Butyl(1-iodo-2-methylhexa-1,5-dien-3-yloxy)dimethylsilane (349)  
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  To a stirred solution of alcohol 348 (138 mg, 0.581 mmol) in DMF (2.0 mL) at 
0 °C was added imidazole (111 mg, 1.627 mmol) followed by TBSCl (149 mg, 0.988 
mmol) and the resulting mixture was stirred at room temperature for 7 h. The reaction 
mixture was diluted with Et2O (2.5 mL) and quenched with saturated aqueous NH4Cl 
(2.5 mL). The aqueous phase was extracted with Et2O (2.5 mL) and the combined 
organic  phases  were  washed  with  water  (5.0  mL)  and  brine  (5.0  mL),  dried  over 
anhydrous MgSO4 and filtered. The filtrate was concentrated under reduced pressure 
to  give  the  crude  product  which  was  purified  by  flash  chromatography  (5% 
Et2O/hexanes) to provide silyl ether 349 (172 mg, 84%) as a colorless oil: [α]D
20 -16.5 
(c 1.00, CHCl3); IR (neat) 3078, 2955, 2929, 2900, 2857, 1641, 1615, 1472, 1278, 
1253, 1082, 1005, 939, 914, 836, 776, 676 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 
0.01 (s, 3H), 0.05 (s, 3H), 0.90 (s, 9H), 1.79 (s, 3H), 2.21-2.34 (m, 2H), 4.18 (t, J = 6.4 
Hz, 1H), 5.03 (s, 1H), 5.07 (d, J = 5.2 Hz, 1H), 5.67-5.77 (m, 1H), 6.18 (s, 1H); 
13C 
NMR (100 MHz, CDCl3) δ (ppm) -5.0, -4.9, 18.2, 19.7, 25.8, 41.0, 77.2, 77.6, 117.1, 
134.4,  149.9;  HRMS  (CI)  calcd  for  C13H25IOSi  [M]
+  m/z  352.0719,  found  m/z 
352.0745. 
I
TBSO
OH
OH
350  
(S,E)-4-(tert-Butyldimethylsilyloxy)-6-iodo-5-methylhex-5-ene-1,2-diol (350) 
To a solution of olefin 349 (28.9 mg, 85.2 µmol) in a mixture of THF (0.39 
mL),  tert-BuOH  (0.39  mL)  and  H2O  (0.08  mL)  at  0  °C  was  added  4- 
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methylmorpholine N-oxide (NMO) (12.7 mg, 93.7 µmol) followed by OsO4 (0.10 mL, 
0.05M in tBuOH, 4.26 µmol, 0.05 equiv). The mixture was stirred vigorously at room 
temperature for 15 h and quenched with saturated aqueous Na2SO3 (0.24 mL). The 
resulting mixture was stirred for 2 h and partitioned between EtOAc (0.30 mL) and 
water  (0.30  mL).  The  organic  phase  was  separated  and  the  aqueous  phase  was 
extracted with EtOAc (2 x 0.40 mL). The combined organic extracts were dried over 
anhydrous  MgSO4  and  filtered,  and  the  solvents  were  removed  under  reduced 
pressure.  Flash  chromatography  of  the  residue  (50%  Et2O/hexanes)  furnished  an 
inseparable 1:1 mixture of diols 350 (25.9 mg, 82%) as a colorless oil: IR (neat) 3329 
(br), 3063, 2956, 2928, 1638, 1611, 1469, 1274, 1250, 1087, 1001, 928, 914, 836, 776, 
676 cm
-1;  
1H NMR (400 MHz, CDCl3) δ (ppm) 0.40 and 0.52 (s, 3H), 0.11 and 0.12 
(s, 3H), 0.92 (s, 9H), 1.65-1.68 (m, 2H), 1.80 and 1.81 (s, 3H), 3.43-3.52 (m, 1H), 
3.60-3.62 (m, 1H), 3.83-3.88 (m, 1H), 4.46-4.52 (m, 1H), 6.30 and 6.32 (s, 1H); 
13C 
NMR (100 MHz, CDCl3) δ (ppm) -5.4 and -5.3, -5.0 and -4.7, 18.0 and 18.1, 19.4 and 
20.7, 25.8, 38.2 and 38.9, 66.7 and 67.0, 68.7 and 70.7, 74.9, 78.0 and 78.8, 149.2 and 
149.7; HRMS (CI) calcd for C13H27IO3Si [M]
+ m/z 386.0774, found m/z 386.0734. 
I
OTBS
O
37  
(S,E)-3-(tert-Butyldimethylsilyloxy)-5-iodo-4-methylpent-4-enal (37) 
  Diols 350 (20.0 mg, 0.052 mmol) were dissolved in a mixture of MeOH (0.35 
mL) and water (0.17 mL) and the solution was cooled to 0 °C. NaIO4 (66.4 mg, 0.311  
 
182 
 
mmol) was added portionwise over 5 min, and the resulting slurry was vigorously 
stirred for 40 min at 25 °C. The mixture was partitioned between DCM (0.5 mL) and 
water (0.5 mL) and the organic phase was separated. The aqueous layer was extracted 
with DCM (0.5 mL) and the combined organic extracts were washed with brine (1 
mL), dried over anhydrous MgSO4 and concentrated under reduced pressure. Flash 
column chromatography (silica gel, 20% Et2O in hexanes) provided aldehyde 37 (15.7 
mg, 86%) as a yellow oil: [α]D
20 -29.8 (c 1.00, CHCl3); IR (neat) 2954, 2929, 2857, 
2719, 1728, 1618, 1472, 1362, 1279, 1255, 1095, 994, 838, 777, 677 cm
-1; 
1H NMR 
(400 MHz, CDCl3) δ (ppm) 0.03 (s, 3H), 0.08 (s, 3H), 0.88 (s, 9H), 1.83 (d, J = 0.8 
Hz, 3H), 2.47 (ddd, J = 2.0, 4.4, 16.0 Hz, 1H), 2.71 (ddd, J = 2.8, 8.0, 16.0 Hz, 1H), 
4.72 (dd, J = 4.0, 8.0 Hz, 1H), 6.37 (d, J = 1.2 Hz, 1H), 9.76 (t, J = 2.4 Hz, 1H); 
13C 
NMR (100 MHz, CDCl3) δ (ppm) -5.3, -4.9, 18.1, 19.7, 25.6, 49.7, 72.6, 78.9, 148.8, 
200.5; HRMS (CI) calcd for C12H23IO2Si [M]
+ m/z 354.0512, found m/z 354.0546. 
243
O
O
B
Cl
Cl
 
2-(Dichloromethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (243) 
  To a stirred solution of dichloromethane (351) (3.73 mL, 55.0 mmol) in THF 
(100 mL) at -100 °C was added dropwise a solution of n-BuLi (31.3 mL, 1.6M in 
hexane, 50.0 mmol) over a period of 40 min and the resulting suspension was stirred 
for an additional 30 min. Trimethyl borate (6.25 mL, 55.0 mmol) was added in one 
portion, and after being stirred for 30 min, the reaction mixture was hydrolyzed with  
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5N HCl (10 mL). The mixture was allowed to warm to room temperature and the 
organic layer was separated. The aqueous layer was extracted with Et2O (2 x 25 mL) 
and the combined organic phases were concentrated under reduced pressure to afford 
crude dichloromethylboronic acid (353)  as a viscous reddish-brown oil. The crude 
product was dissolved in benzene (110 mL) and pinacol (354) (6.50 g, 55.0 mmol) 
was added in one portion. The biphasic mixture was heated at reflux under an argon 
atmosphere for 48 h, utilizing a Dean-Stark trap to remove water, and was then cooled 
to room temperature. The homogeneous yellow solution was fractionally distilled to 
afford dichloromethylboronate 243 (9.5 g, 90%) as a colorless oil: bp 103 °C/30 mm 
Hg; IR (neat) 2982, 2935, 1471, 1408, 1363, 1274, 1214, 1169, 1137, 1111, 1007, 
968, 901, 846, 823, 739, 672, 650, 576 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 
1.35 (s, 12H), 5.37 (s, 1H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 24.5, 85.8. 
I
OTBS
B
O
O
355  
tert-Butyl((S,1E,5E)-1-iodo-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)hexa-1,5-dien-3-yloxy)dimethylsilane (355) 
  To a suspension of CrCl2 (27.8 mg, 0.226 mmol) in THF (0.28 mL) at room 
temperature  was  added  a  solution  of  aldehyde  37  (8.0  mg,  0.023  mmol)  and 
dichloromethyl  pinacolboronate  (243)  (11.9  mg,  0.056  mmol)  in  THF  (0.06  mL) 
followed by dropwise addition of a solution of LiI (15.2 mg, 0.113 mmol) in THF 
(0.03 mL).  The mixture was kept in the dark and was stirred vigorously for 12 h. The  
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reaction mixture was quenched with ice-cold H2O (1.0 mL) and extracted with Et2O (3 
x 2.0 mL). The organic phase was washed with brine (2.0 mL), dried over anhydrous 
MgSO4  and  filtered.  Removal  of  the  solvent  under  reduced pressure  gave  a  crude 
product  which  was  purified  by  flash  chromatography  (10%  EtOAc  in  hexanes)  to 
furnish boronate 355 (8.5 mg, 79%) as a colorless oil: [α]D
20 -9.6 (c 0.50, CHCl3); IR 
(neat) 2976, 2954, 2928, 2856, 1640, 1363, 1321, 1253, 1146, 1082, 836, 776 cm
-1; 
1H 
NMR (400 MHz, CDCl3) δ (ppm) 0.00 (s, 3H), 0.04 (s, 3H), 0.89 (s, 9H), 1.27 (s, 
12H), 1.79 (s, 3H), 2.29-2.42 (m, 2H), 4.22 (t, J = 6.0 Hz, 1H), 5.47 (d, J = 18.0 Hz, 
1H), 6.20 (s, 1H), 6.53 (dt, J = 6.8, 18.0 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ 
(ppm) -5.1, -4.9, 18.2, 19.6, 24.7, 25.8, 43.2, 77.2, 77.6, 83.0, 149.9, 150.0; HRMS 
(ES) calcd for C19H37BIO3Si [M+H]
+ m/z 479.1571, found m/z 479.1524. 
I
OH
B
O
O
240  
(S,1E,5E)-1-Iodo-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexa-
1,5-dien-3-ol (240) 
  To a stirred solution of boronate 355 (5.7 mg, 0.012 mmol) in THF (0.24 mL) 
at room temperature was added TBAF (14 µL, 1M solution in THF, 0.014 mmol) and 
the resulting solution was stirred at room temperature for 12 h. The reaction mixture 
was diluted with Et2O (0.30 mL) and the organic phase was washed with H2O (0.30 
mL), dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. 
Purification of the crude product by flash chromatography  (20% Et2O in hexanes)  
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afforded alcohol 240 (3.5 mg, 81%) as a colorless oil: [α]D
20 -12.1 (c 0.19, CHCl3); IR 
(neat) 3453 (br), 2977, 2920, 2850, 1640, 1362, 1144, 996, 970, 850; 
1H NMR (400 
MHz, CDCl3) δ (ppm) 1.30 (s, 12H), 1.86 (s, 3H), 2.38-2.51 (m, 2H), 4.30 (br s, 1H), 
5.59 (d, J = 10.0 Hz, 1H), 6.36 (s, 1H), 6.57 (dt, J = 4.0, 10.0 Hz, 1H); 
13C NMR (100 
MHz, CDCl3) δ (ppm) 20.2, 24.8, 42.0, 75.1, 78.8, 83.3, 148.7, 149.0; HRMS (ES) 
calcd for C13H23BIO3 [M+H]
+ m/z 365.0716, found m/z 365.0745. 
H
N
N
O
O
OTIPS
H
N
MeO
O HN O
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356  
(S)-Methyl 1-((S)-2-((S)-2-((3R,4R,5R,6R)-3-((E)-2-Iodovinyl)-1,4-dimethyl-2,9-
dioxa-bicyclo[3.3.1]nonane-6-carboxamido)-3-methylbutanamido)-3-(3-
(triisopropylsilyloxy)phenyl)propanoyl)piperazine-3-carboxylate (356) 
  To a stirred solution of tripeptide 241 (26.5 mg, 0.0753 mmol), carboxylic acid 
242 (50.8 mg, 0.0903 mmol) and HATU (30.0 mg, 0.0790 mmol) in acetonitrile (2.5 
mL) at room temperature was added DIPEA (14.4 µL, 0.0828 mmol) and the resulting 
mixture was stirred for 29 h. The reaction was quenched with pH 7 buffer (2.5 mL) 
and the aqueous phase was extracted with DCM (3 x 3.0 mL). The combined organic 
phases  were  dried  over  anhydrous  MgSO4,  filtered  and  concentrated  in  vacuo.  
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Purification of the residue by flash chromatography (70% EtOAc in hexanes with 1% 
Et3N) afforded methyl ester 356 (57.6 mg, 85%) as a yellow oil: [α]D
20 -22.5 (c 0.40, 
CHCl3); IR (neat) 3298, 3216, 3063, 2944, 2867, 1745, 1639, 1604, 1584, 1547, 1485, 
1443, 1384, 1277, 1235, 1164, 1128, 1004, 882, 844, 781, 734, 687 cm
-1; 
1H NMR 
(700 MHz, CDCl3) δ (ppm) 0.88 (d, J = 7.0 Hz, 3H), 0.92 (d, J = 7.0 Hz, 3H), 0.97 (d, 
J = 7.0 Hz, 3H), 1.10 (d, J = 7.7 Hz, 18H), 1.23-1.29 (m, 5H), 1.44 (s, 3H), 1.45-1.56 
(m, 2H), 1.69 (s, 2H), 1.75-1.85 (m, 2H), 1.94-2.01 (m, 2H), 2.05-2.25 (m, 4H), 2.64-
2.66 (m, 2H), 2.83-2.96 (m, 2H), 3.73 (s, 3H), 4.26 (d, J = 5.6 Hz, 1H), 4.31 (dd, J = 
4.9, 8.4 Hz, 1H), 4.45 (dd, J  = 6.3, 11.2 Hz, 1H), 5.70-5.75 (m, 1H), 6.45-6.48 (m, 
2H), 6.70 (s, 1H), 6.75 (d, J = 8.4 Hz, 1H), 6.79 (d, J = 7.7 Hz, 1H), 7.12 (t, J = 7.7 
Hz, 1H), 7.48 (d, J = 8.4 Hz, 1H); 
13C NMR (175 MHz, CDCl3) δ (ppm) 12.7, 12.8, 
17.6, 18.0, 19.5, 22.8, 30.8, 31.0, 36.1, 38.7, 39.6, 41.9, 49.7, 52.2, 57.7, 58.1, 71.8, 
79.0, 80.4, 95.7, 118.1, 121.4, 122.4, 129.2, 137.9, 145.3, 156.1, 170.1, 171.6, 172.2, 
174.5;  HRMS  (ES)  calcd  for  C41H66N4O8SiI  [M+H]
+  m/z  897.3695,  found  m/z 
897.3726. 
H
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(S)-1-((S)-2-((S)-2-((3R,4R,5R,6R)-3-((E)-2-Iodovinyl)-1,4-dimethyl-2,9-dioxa-
bicyclo[3.3.1]nonane-6-carboxamido)-3-methylbutanamido)-3-(3-
(triisopropylsilyloxy)phenyl)propanoyl)piperazine-3-carboxylic Acid (357) 
  To a stirred solution of methyl ester 356 (3.7 mg, 4.13 µmol) in a mixture of 
THF (0.22 mL) and H2O (0.06 mL) at 0 °C was added LiOH⋅H2O (0.35 mg, 8.25 
µmol) and the resulting mixture was stirred at 0 °C for 1 h. The mixture was diluted 
with EtOAc  (3.9 mL)  and washed  with 1M aqueous NaH2PO4  (2 x  1.0 mL). The 
combined  organic  phases  were  dried  over  anhydrous  Na2SO4,  filtered  and 
concentrated under reduced pressure to give carboxylic acid 357 (3.6 mg, 99%) as a 
colorless viscous oil: IR (neat) 3300-2560 (br), 3061, 2926, 2864, 1750, 1632, 1601, 
1584, 1485, 1443, 1384, 1273, 1231, 1163, 1122, 1007, 879, 836, 779, 732, 685 cm
-1; 
1H NMR (700 MHz, CDCl3) δ (ppm) 0.87 (d, J = 7.0 Hz, 3H), 0.90 (d, J = 7.0 Hz, 
3H), 0.96 (d, J = 7.0 Hz, 3H), 1.10 (d, J = 7.7 Hz, 18H), 1.23-1.29 (m, 5H), 1.42 (s, 
3H), 1.57-1.65 (m, 2H), 1.69-2.09 (m, 6H), 2.12-2.25 (m, 2H), 2.66-2.67 (m, 1H), 
2.89-2.99 (m, 3H), 3.69 (s, 1H), 4.26-4.30 (m, 2H), 4.45 (dd, J = 6.3, 11.2 Hz, 1H), 
5.80 (br s, 1H), 6.47-6.51 (m, 2H), 6.68 (s, 1H), 6.73 (d, J = 8.4 Hz, 2H), 6.79 (d, J = 
7.7 Hz, 1H), 7.11 (t, J = 7.7 Hz, 1H), 7.55 (d, J = 8.4 Hz, 1H); 
13C NMR (175 MHz, 
CDCl3) δ (ppm) 12.7, 12.8, 17.6, 18.0, 19.5, 22.8, 30.8, 32.0, 36.1, 38.6, 39.6, 41.9, 
50.1, 57.6, 58.1, 71.8, 79.0, 80.4, 95.7, 118.1, 121.4, 122.4, 129.3, 137.8, 145.2, 156.0, 
170.7,  172.1,  173.4,  175.0;  HRMS  (ES)  calcd  for  C40H64N4O8SiI  [M+H]
+  m/z 
883.3538, found m/z 883.3541. The carboxylic acid was used in the next step without 
purification.  
 
188 
 
H
N
N
O
O
OTIPS
H
N
O
O HN O
O O
I
I
B O
O
358  
(S)-((S,1E,5E)-1-Iodo-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)hexa-1,5-dien-3-yl) 1-((S)-2-((S)-2-((3R,4R,5R,6R)-3-((E)-2-Iodovinyl)-1,4-
dimethyl-2,9-dioxa-bicyclo[3.3.1]nonane-6-carboxamido)-3-methylbutanamido)-
3-(3-(triisopropylsilyloxy)phenyl)propanoyl)piperazine-3-carboxylate (358) 
To a stirred solution of carboxylic acid 357 (16.2 mg, 18.3 µmol), alcohol 240 (13.4 
mg, 36.7 µmol), EDCI (7.0 mg, 36.7 µmol) and 4-pyrrolidinopyridine (0.3 mg, 36.7 
µmol) in DCM (0.2 mL) at room temperature was added DIPEA (3.2 µL, 18.3 µmol) 
and the resulting mixture was stirred for 23 h. The reaction was quenched with H2O 
(0.2 mL) and the aqueous layer was extracted with DCM (2 x 1.0 mL). The organic 
layer  was  dried  over  anhydrous  MgSO4,  filtered  and  concentrated  under  reduced 
pressure. The residue was purified by flash chromatography (40% Et2O in hexanes to 
20% MeOH in DCM) to give ester 358 (11.2 mg, 50%) as a colorless oil: 
1H NMR 
(700 MHz, CDCl3) δ (ppm) 0.85-0.92 (m, 9H), 1.11 (d, J = 7.0 Hz, 18H), 1.20-1.35 
(m, 5H), 1.31 (s, 12H), 1.40-1.45 (m, 2H), 1.56-1.73 (m, 7H), 1.80-2.00 (m, 5H), 2.01- 
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2.21 (m, 4H), 2.23 (m, 1H), 2.48-2.62 (m, 2H), 2.91-2.99 (m, 1H), 3.60-3.75 (m, 4H), 
4.25-4.50 (m, 3H), 5.35-5.60 (m, 3H), 6.35-6.49 (m, 3H), 6.70-6.85 (m, 2H), 7.10-
7.13 (m, 1H), 7.36-7.40 (m, 1H); 
13C NMR (175 MHz, CDCl3) δ (ppm) 12.7, 14.2, 
17.4, 18.0, 19.5, 19.9, 20.2, 22.7, 23.0, 24.8, 25.6, 27.2, 29.5, 30.8, 31.3, 32.0, 35.9, 
36.1, 38.8, 39.0, 42.0, 50.2, 57.8, 58.3, 70.6, 71.9, 78.8, 80.2, 81.9, 83.3, 95.7, 113.7, 
118.1, 121.1, 122.2, 127.0, 129.2, 129.8, 130.0, 130.1, 137.8, 144.2, 145.3, 146.5, 
146.9,  156.0,  170.1,  170.3,  172.0,  174.4;  HRMS  (ES)  calcd  for  C53H84N4O10SiIB 
[M+H]
+ m/z 1229.4139, found m/z 1229.4077.    
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CHAPTER 6: STUDIES TOWARDS THE SYNTHESIS OF 
THE C26-N42 SPIROLACTAM OF SFA 
 
  Synthesis of the spirolactam portion of SFA bearing seven stereogenic centers, 
six of which are contiguous, presented an especially challenging objective. Our plan 
for this segment involved initial construction of the C31-C37 substructure as a ω-
hydroxy  heptaldehyde  bearing  a  correctly  configured  stereotetrad  corresponding  to 
C33, 34, 35 and 36. The remaining carbons, C38-C41, could be added via several 
routes, only one of which was explored in detail. Final spirolactamization would be 
accomplished from a suitably constituted 5-oxoundecanamide containing the complete 
C31-C41 chain. Based on this blueprint, our first target was therefore heptaldehyde 
253. 
6.1 Synthesis of the C31-C37 Subunit : Aldehyde 253 
  Our initial approach to the C31-C37 subunit 253 of SFA began with synthesis 
of  olefin  372,  as  illustrated  in  Scheme  6.1.  Exposure  of  commercially  available 
propane-1,3-diol  (367)  to  tert-butyldimethylsilyl  chloride  under  basic  conditions 
furnished  monosilyl  ether  368  which  was  subjected  to  Swern  oxidation  to  give 
aldehyde 369. Asymmetric crotylation
1 of 369 yielded anti homoallylic alcohol 370
2 
in excellent diastereomeric ratio (> 20:1) and enantiomeric excess (88%). Treatment 
of 370 with tetra-n-butylammonium fluoride afforded diol 371 which was reacted with 
2,2-dimethoxypropane in the presence of camphorsulfonic acid to provide acetonide  
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372.  However,  exposure  of  372  to  ozone  followed  by  dimethyl  sulfide  failed  to 
produce aldehyde 373 but instead gave a mixture containing several polar compounds. 
This unexpected result is presumably due to polymerization of aldehyde 373 after long 
exposure to dimethyl sulfide during decomposition of the intermediate ozonide.
3 
HO OR O OTBS
NaH, THF;
TBSCl, quant.
DMSO
oxalyl chloride
DCM, -78 ºC; 
Et3N, -78 ºC
96%
(+)-Ipc2BOMe
trans-2-butene
n-BuLi, KOtBu
BF3·OEt2, -78 ºC
66% (d.r. > 20:1)
(ee 88%)
369
367: R = H
368: R = TBS
RO
OH
TBAF,THF
rt, 82%
O O
acetone, 4 A MS
CSA, rt, 70%
MeO OMe
370: R = TBS
371: R = H
O3, DCM, MeOH
-78 ºC;
Me2S, -78 ºC       rt
31 33 31 33 31 35
31 35
O O
H
O
35
31
372 373  
Scheme 6.1 Synthesis of olefin 372 
  In  contrast  to  the  attempted  ozonolysis  of  372  described  above,  reductive 
ozonolytic cleavage of this alkene using sodium borohydride as reducing agent gave 
primary alcohol 374 in good yield. In this manner, reduction of the ozonide generated 
from 372 directly to alcohol 374 avoided polymerization of aldehyde 373. Alcohol 
374 was oxidized under Swern conditions to aldehyde 373, as depicted in Scheme 6.2, 
but subjection of 373 to asymmetric crotylation in the presence of boron trifluoride-
ether  complex  produced  an  uncharacterizable  mixture  with  no  evidence  for  the 
formation of homoallylic alcohol 375. We believe that the acetonide moiety of 373 
coordinates with boron trifluoride resulting in cleavage of this protecting group in the  
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presence of strong nucleophiles such as methoxide anion,
4 and this leads to a complex 
mixture containing little or no 375. This conclusion caused us to devise a new route to 
253 in which 1,3-diol protection as an acetonide was replaced by individual cover of 
the C31 and C33 hydroxyl groups as silyl ethers. 
O3, DCM
MeOH, -78 º C;
NaBH4
-78 ºC       rt, 65%
O O O O
OH
DMSO, oxalyl chloride
DCM, -78 ºC;
Et3N, -78 ºC, 97%
O O
H
O
(+)-Ipc2BOMe
trans-2-butene
n-BuLi, KOtBu
BF3·OEt2, -78 ºC
35 31 35 31
35
31
372 374
373
O O OH
35
31
375  
Scheme 6.2 Synthesis of aldehyde 373 
  Our new route to the C31-C37 portion of SFA is shown in Scheme 6.3 and 
modifies the previous pathway by replacing the acetonide of 372 with a pair of tert-
butyldimethylsilyl ethers. Thus, anti homoallylic alcohol 370 was converted to bissilyl 
ether 376 by treatment with two equivalents of tert-butyldimethylsilyl chloride in the 
presence of imidazole, after which 376 was subjected to reductive ozonolytic cleavage 
to furnish primary alcohol 377. The alcohol was oxidized under Swern conditions to 
aldehyde 378 which upon asymmetric crotylation furnished anti,anti,anti homoallylic 
alcohol 379 in good yield and with high diastereomeric ratio (10:1) at C35,36. The 
assignment of configuration to 379 is based upon the previously described crotylation 
of an aldehyde  similar to 378  in Zampella’s synthesis  of reidispongiolide A.
5 The  
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transition state that explains attack by the crotylating reagent at the re face of 378 is 
shown in Figure 6.1. 
TBSO
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TBSO O
OTBS
TBSO OH
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TBSO OH
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DMF, 78%
O3, DCM
MeOH, -78 º C;
NaBH4
-78 ºC       rt, 65%
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oxalyl chloride
DCM, -78 ºC; 
Et3N, -78 ºC
97%
(+)-Ipc2BOMe
trans-2-butene
n-BuLi, KOtBu
BF3·OEt2, -78 ºC
70% (d.r. = 10:1)
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Scheme 6.3 Synthesis of alcohol 379 
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Fig 6.1 Transition state for asymmetric crotylation of aldehyde 378 
  Attempts  to  protect  alcohol  379  as  its  p-methoxybenzyl  ether  using  p-
methoxybenzyl  acetimidate  in  the  presence  of  triflic  acid  were  unsuccessful.  An 
inseparable mixture of polar compounds was obtained, probably a result of cleavage of 
one  or  both  tert-butyldimethylsilyl  ethers  under  the  strongly  acidic  conditions.  A  
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pathway  around  this  obstacle  was  found  from  p-methoxybenzyl  acetal  381,  a 
compound obtained from diol 380 by reduction with diisobutylaluminum hydride
6-8 as 
shown in Scheme 6.4. Thus, reductive ozonolytic cleavage of olefin 379 furnished diol 
380 which was reacted with p-anisaldehyde dimethyl acetal (219) in the presence of 
pyridinium  p-toluenesulfonate  to  give  acetal  381.  Treatment  of  381  with 
diisobutylaluminum hydride in a mixture of dichloromethane and toluene resulted in 
clean reductive scission of the more sterically accessible C-O bond to afford 382, and 
Swern oxidation of this primary alcohol delivered aldehyde 253. Although this route 
provided usable quantities of 253 for continuing towards our goal of spirolactam 386, 
eleven steps were required from propane-1,3-diol (367) to reach our target. It was 
therefore decided to revisit the protection of alcohol 379 in an attempt to bypass acetal 
381 and its reduction to 382, thereby shortening the pathway to 253. 
TBSO
TBSO O
PMP
TBSO
TBSO OPMB
OH TBSO
TBSO OPMB
O
(219)
381
382
PPTS, DCM, rt
80% (86% brsm)
253
DMSO
oxalyl chloride
DCM, -78 ºC; 
Et3N, -78 ºC
89%
TBSO
TBSO OH
TBSO
TBSO OH
OH
379 380
O3, DCM
MeOH, -78 º C;
NaBH4
-78 ºC        rt, 98%
31 37 34 31 37 34
31 34
O
37
31 37 34 31 37 34
MeO
OMe
OMe
DIBAL-H
DCM-Toluene
-78 ºC        rt, 66%
 
Scheme 6.4 Synthesis of aldehyde 253 (46% yield, 4 steps)  
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After considerable experimentation, it was found that secondary alcohol 379 
could be protected as its p-methoxybenzyl ether 384 with p-methoxybenzyl chloride 
(383)  and  potassium  hydride  in  a  mixture  of  tetrahydrofuran  and  N,N-
dimethylformamide (10:1) (Scheme 6.5). The terminal alkene of 384 was oxidized 
with osmium tetraoxide in the presence of N-methylmorpholine-N-oxide to produce 
diol  385  which  underwent  periodate-mediated  glycol  cleavage  in  a  mixture  of 
methanol  and  water  to  furnish  aldehyde  253.  This  sequence  from  379  was  more 
efficient (56% compared with 46%) and required one less step than that shown in 
Scheme 6.4. 
TBSO
TBSO OPMB
TBSO
TBSO OPMB
O
384
253
TBSO
TBSO OH
379
MeO
Cl
TBSO
TBSO OPMB
385
OH
OH
KH, THF, DMF
83%
(383)
OsO4, NMO
THF, t-BuOH, H2O
0 ºC        rt
quant.
NaIO4
MeOH/H2O
0 ºC        rt
67%
31 37 34 31 37 34
31
37
34
31 37 34
 
Scheme 6.5 Improved route to aldehyde 253 (56% yield, 3 steps) 
6.2  Towards  the  Synthesis  of  C26-N42  Spirolactam  238:  An 
Approach to Spirolactam 386 via Ireland-Claisen Rearrangement 
  In  this  approach  to  spirolactam  386,  our  previously  prepared  aldehyde  253 
provides the starting point as shown in the retrosynthetic Scheme 6.6. Spirolactam 386  
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would be prepared from diol 387 in which the C37 and C38 stereocenters are set in 
place via regio- and stereoselective hydroboration-oxidation
9 of carboxylic acid 251. 
Transition state 388 leading to addition by borane at the si face of the alkene in 251, 
and  therefore  37S  configuration  of  387,  should  be  favored  because  the  preferred 
conformation of 251 places the largest group on the C36 chiral center perpendicular to 
the alkene and the attacking borane approaches anti to this group in order to minimize 
allylic 1,3-strain. An Ireland-Claisen rearrangement
10, 11 of ester 252 would install the 
C37-C41 carbon  framework and  introduce  the C40  stereocenter of  carboxylic acid 
251. Ester 252 would be prepared using a straightforward sequence from aldehyde 253 
(Scheme 6.7). 
TBSO
TBSO OPMB
O
O
NH
O
PMBO OH
253
386
TBSO
TBSO
OPMB
O
O
OPMB TBSO
OH TBSO
O
Ireland-Claisen
rearrangement
252 251
34
33
36
38
40
34 34
41
40
OH
OPMB
OTBS
OH TBSO
387
substrate-controlled
hydroboration-oxidation
34
37
38 41
37
37 38
31
42
31 37
31
39
40
31
31
H
C35
Me
H
Me
C39
H B H
H
388
36
 
Scheme 6.6 An Ireland-Claisen rearrangement and stereoselective hydroboration  
strategy for the synthesis of spirolactam 386  
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  The  first  step  in  this  plan  was  introduction  of  the  terminal  isopropenyl 
appendage  of  252  by  stereoselective  addition  of  an  isopropenyl  nucleophile  to 
aldehyde  253.
12,  13  Thus,  253  was  treated  with  commercially  available 
isopropenylmagnesium bromide  (389)  in  tetrahydrofuran  at  0  °C  to  give  separable 
allylic  alcohols  in  which  the  37R  diastereomer  391  predominated  over  the  37S 
stereoisomer by 5:1 (Table 6.1, entry 1). However, an analogous reaction of aldehyde 
253  with  freshly  prepared  isopropenyllithium  (390)
14  in  diethyl  ether  at  -78  °C 
resulted  in  an  enhanced  diastereomeric  ratio  (10:1,  Table  6.1,  entry  2).  This 
improvement  could  be  due  to  several  factors.  First,  a  lower  reaction  temperature 
increases the population of the lowest energy transition state 392 (Figure 6.1) and 
leads  to  higher  stereoselectivity  of  addition  by  the  nucleophile.  Second, 
tetrahydrofuran  is  a  stronger  Lewis  base  than  diethyl  ether  and  coordinates  more 
strongly with metal ions such as magnesium and lithium; changing the solvent from 
tetrahydrofuran  to  diethyl  ether  therefore  reduces  solvation  of  the  organometallic 
reagent and increases coordination of aldehyde 253 to the metal ion. Lastly, lithium 
ion is more oxyphilic than magnesium and can coordinate more strongly to oxygen 
atoms in 392. All three factors would lead to higher stereoselectivity in addition by 
390 to 253. The assignment of R configuration at C37 of the major diasteromer was 
inferred  from  a  Reetz-chelation  model
15  and  assumes  coordination  of  the 
organometallic reagent  with  the p-methoxybenzyl  ether as  shown  in  Figure 6.2. A 
half-chair  conformation  392  of  253,  which  has  the  C35  alkyl  chain  in  a 
pseudoequatorial  orientation,  is  the  lowest  energy  transition  state  and  nucleophilic  
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attack occurs at the si face of the aldehyde. This generates R configuration at C37 with 
393 emerging in a chair conformation. Attack at the re face of aldehyde 253 would 
result in a less stable product with a twist-boat conformation. 
Table 6.1 Nucleophilic addition to aldehyde 253 
TBSO
TBSO OPMB
O TBSO
TBSO
OPMB
OH
(389)
(390)
253
31 37 34 MgBr
or
Li
31
37
34
39
391  
 
Entry 
 
Conditions  Yield of 391 (%)  d.r. 
 
1 
  389, tetrahydrofuran, 0 °C à rt  81  5:1 
 
2 
  390, diethyl ether, -78 °C  75  10:1 
 
O M
O
H
Me
H PMB
R
O
M
O
H
PMB
R
Me
H
Nu
Nu
R =
H
OTBS
OTBS
37
35
37
35
H
31 34
Nu =
392 393
M = Mg2+ or Li+
 
Fig 6.2 Reetz-chelate model for the addition of 390 to 253 
  With 37R alcohol 391 in hand, ester 389 was prepared by reaction with butyric 
anhydride  (388)  in  the  presence  of  triethylamine  and  4-dimethylaminopyridine,  as 
depicted in Scheme 6.7. By contrast, treatment of alcohol 385 with butyryl chloride in 
the presence of triethylamine led to an uncharacterizable mixture of products.  
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TBSO
TBSO
OPMB
O
O
TBSO
TBSO
OPMB
OH
31
37
34
39 O
O O
Et3N, DMAP, DCM
rt, 98%
31
37
34 39
391 252
(394)
 
Scheme 6.7 Synthesis of butyl ester 252 
  Before investing 252 in a potentially difficult Ireland-Claisen reaction, a model 
study was conducted on a simpler butyrate ester, as shown in Scheme 6.8. For this 
experiment,  aldehyde  369  was  reacted  with  isopropenyllithium  (390)
14  to  produce 
allylic alcohol 395 which was esterified with butyric anhydride (394) in the presence 
of  4-dimethylaminopyridine.  This  afforded  ester  396,  the  precursor  for  our  model 
Ireland-Claisen rearrangement.
9, 16 Butyrate ester 396 was reacted with trimethylsilyl 
chloride,  lithium  diisopropylamide  and  triethylamine  to  give  trimethylsilyl  ketene 
acetal 397 as the rearrangement precursor. After diluting the reaction mixture with 
tetrahydrofuran and heating the solution to reflux, an aqueous ammonium chloride 
workup  of  the  resulting  mixture  followed  by  silica  gel  chromatography  gave 
rearrangement products in the form of carboxylic acid 398 and trimethylsilyl ester 
399. An alternative acidic work up of the reaction mixture with 1:1:10 acetic acid-
water-tetrahydrofuran gave predominantly the hydroxy carboxylic acid 400 in which 
the tert-butyldimethylsilyl ether had been cleaved. Silyl ester 399 was converted to 
398 by a second chromatography on silica gel resulting in an overall yield of 398 of 
97% from 396.  
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O
OH
TBSO
O
O
TBSO
O OTMS
TBSO
TBSO
O
H TBSO
OH
Et2O, -78 ºC
74%
Li
(394)
DMAP, Et3N
rt, DCM
92%
TMSCl, Et3N
LDA, THF, -78 ºC
then diluted with
THF
20 ºC       60 ºC;
silica gel
chromatography
O
OTMS TBSO
69%
28%
369 (±)-395
(±)-398
(±)-399
O
O O
(390)
then diluted with THF
20 ºC        60 ºC;
AcOH/H2O (1:1), 68%
O
OH HO
(±)-400
(±)-396
(±)-397
 
Scheme 6.8 Ireland-Claisen rearrangement of (±)-396 
The preparation of racemic carboxylic acid 398 enabled us to study the regio- 
and stereoselectivity of hydroboration-oxidation of its trisubstituted double bond. In 
the  event,  subjection  of  398  to  hydroboration  followed  by  oxidation  with  sodium 
perborate  gave  an  inseparable  1:1  mixture  of  diols  401  and  402  (Scheme  6.9), 
indicating that the stereogenic center at C2 does not influence hydroboration which 
therefore occurs at both re and si faces of 398. Nevertheless, the mixture of 401 and 
402 proved useful in guiding strategy as it would apply to 387, and oxidation of this 
mixture  with  tetrapropylammonium  perruthenate  in  the  presence  of  N-
methylmorpholine-N-oxide produced lactones 403 and 404. Treatment of the lactone  
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mixture with dimethylaluminum amide
17 yielded hydroxy amides 405 and 406 which 
upon  oxidation  with  Dess-Martin  reagent  in  the  presence  of  sodium  bicarbonate 
furnished separable keto amide 407 and γ,δ-unsaturated lactam 408. The formation of 
lactam 408 results from cyclization of keto amide 409 to hemi-aminal 410 followed by 
dehydration (Scheme 6.10).  
O
OH TBSO
OH TBSO
OH
TBSO
O
O
BH3·THF
THF, -25 ºC;
NaBO3·4H2O
THF/H2O, rt
quant.
TPAP, NMO
4 A MS, DCM
rt, 83%
NH2 TBSO
OH O
Me2AlNH2
DCM, rt,
65%
DMP, NaHCO3
DCM, rt
NH2 TBSO
O O
TBSO
HN
O
33% 46%
+
(±)-401
(±)-398
(±)-405
(±)-407 (±)-408
2
7
OH TBSO
OH
(±)-402
TBSO
O
O
(±)-403
(±)-404
NH2 TBSO
OH O
(±)-406
2
7
2
7
2
7
2
7
2
7
2
7
2
7
2
7
 
Scheme 6.9 Synthesis of 407 and 408  
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N
H
Me
H
OH
O
TBSO
HN
O
(±)-410
NH2 TBSO
OH O
(±)-406
DMP, NaHCO3
DCM, rt
NH2 TBSO
O O
(±)-409
2
7
OTBS 4
5
(±)-408
2
7
2
7
2
7
-H2O
 
Scheme 6.10 Formation of γ,δ-unsaturated lactam 408 from 406 
Our successful Ireland-Claisen rearrangement of 396 to 398 encouraged us to 
apply the same rearrangement strategy to butyrate ester 252. However, exposure of 
252  to  conditions  used  with  396  resulted  in  carboxylic  acid  251  as  only  a  minor 
product  with  α-silyl  ester  411  as  the  predominant  product.  Formation  of  2-
trimethylsilyl butyrate 411 from the enolate of 252 with trimethylsilyl chloride and 
lithium diisopropyl amide is presumably due to steric factors that obstruct O-silylation 
seen with the simpler substrate 396.
18-20 The 40S configuration assigned to 251 results 
from the chair transition state shown in Figure 6.3 where (E)-silyl ketene acetal 412 
becomes bonded at its re face.
9 The approach to spirolactam 386 ended at this point 
due to the low yield of 251 and a paucity of advanced materials.  
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TBSO
TBSO
OPMB
O
O
31
37
34 39
OPMB TBSO
OH TBSO
O
251 10%
TBSO
TBSO
OPMB
O
O
31
37
34 39
TMS
31 37 34 39
40
41
252
411 42%
TMSCl, Et3N
LDA, THF, -78 C;
then diluted with
THF
20 ºC       60 ºC
 
Scheme 6.11 Synthesis of carboxylic acid 251 
O
H
OTMS
R
H
O
H
OH
R
H
OPMB TBSO
OH TBSO
O
251
31 37 34 39
41 37
39 41
37
39 41
412
R =
OPMB TBSO
TBSO
31 34
40
40
40
 
Figure 6.3 An Ireland-Claisen rearrangement of 412 to 251 
  Although this approach to the spirolactam portion of SFA ended prematurely, 
the  synthesis  of  carboxylic  acid  251  in  low  yield  gives  hope  that  Ireland-Claisen 
rearrangement of 252 can offer a viable route to 387 and to spirolactam 386 if the 
efficiency  of  the  process  can  be  improved.  A  variety  of  modifications  and 
improvements have been made to the Ireland-Claisen rearrangement
16,30-31 that would 
be applicable to 252 and these would be examined with respect to changes in the 
solvent system and the trialkylsilyl halide. For example, Nicolaou in his approach to 
the  spirolactam  portion  of  SFA  (Scheme  2.6)  employed  tert-butyldimethylsilyl  
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chloride  in  a  tetrahydrofuran-hexamethylphosphoramide  solvent  pair  to  prepare 
silylketene acetal 55 from butyrate 54 and he then transferred 55 to hot toluene in 
order to complete Ireland-Claisen rearrangement leading to carboxylic acid 56. These 
conditions are significantly different from those used with our butyrate 252 and point 
towards  a protocol  that  ensures  efficient  formation  of  a  silylketene  acetal prior to 
effecting rearrangement. 
  The  problem  revealed  in  the  non-stereoselcetive  hydroboration-oxidation  of 
model substrate 398 is not expected to carry over to 251 where stereocenters (at C35 
and C36) are positioned to direct addition of borane to the desired re face of the C37-
C38  alkene.  In  fact,  precedent  for  good  stereoselectivity  in  the  hydroboration-
oxidation of 251 can be found in Nicolaou’s synthesis of 57 from 58 (Scheme 2.6).
9  
  With revisions to our synthesis plan described above, access to spirolactam 
386 along lines laid out in Scheme 6.6 seems assured. Alcohol 386 would then stand 
ready for its assembly into the full Western substructure of SFA. 
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6.4 Experimental Section 
 
HO OTBS
368  
3-(tert-Butyldimethylsilyloxy)propan-1-ol (368) 
  To a stirred suspension of NaH (21.0 g, 0.526 mol, 60% dispersion on mineral 
oil, washed with hexanes) in THF (1 L) at room temperature was added portionwise 
neat 1,3-propanediol (40.0 g, 0.526 mol) and the resulting gray suspension was stirred 
vigorously while H2 was evolved. After stirring the suspension for 1.5 h, TBSCl (79.2 
g, 0.526 mol) was added portionwise and the resulting mixture turned milky as an 
exothermic  reaction  occured.  The  mixture  was  stirred  for  18  h  and  10%  aqueous 
Na2CO3 (100 mL) was added slowly to quench the reaction. The aqueous phase was 
extracted with Et2O (2 x 100 mL) and the combined organic phases were washed with 
brine (300 mL), dried over anhydrous MgSO4, filtered and concentrated in vacuo to 
provide alcohol 368 (101.0 g, quant.) as a colorless oil: IR (neat) 3355, 2955, 2930, 
2885, 2858, 1472, 1388, 1361, 1256, 1100, 1006, 962, 939, 872, 837, 815, 776, 721, 
662 cm
-1; 
1H (400 MHz, CDCl3) δ (ppm) 0.09 (s, 6H), 0.91 (s, 9H), 1.78-1.80 (m, 2H), 
2.60 (br s, 1H), 3.81-3.86 (m, 4H); 
13C NMR (100 MHz, CDCl3) δ (ppm) -5.5, 18.2, 
25.9, 34.2, 62.5, 63.0. The alcohol was used in the next step without purification. 
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O OTBS
369  
3-(tert-Butyldimethylsilyloxy)propanal (369) 
  To a stirred solution of oxalyl chloride (0.30 mL, 3.41 mmol) in DCM (24 mL) 
at -78 °C was added dropwise DMSO (0.41 mL, 5.78 mmol) and the resulting mixture 
was stirred for 15 min, at which point a solution of alcohol 368 (500 mg, 2.63 mmol) 
in DCM (4.0 mL) was added slowly.  The cloudy mixture was stirred for 10 min and 
Et3N (1.83 mL, 13.13 mmol) was added dropwise. The reaction mixture was stirred 
for 2 h and warmed to 0 °C. H2O (4.0 mL) was added and the aqueous phase was 
extracted with DCM (2 x 4.0 mL). The combined organic phase was washed with 
brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced 
pressure to furnish aldehyde 369 (475 mg, 96%) as a yellow oil: IR (neat) 2956, 2929, 
2857, 2715, 1729, 1472, 1389, 1361, 1256, 1099, 970, 836, 776 cm
-1; 
1H NMR (400 
MHz, CDCl3) δ (ppm) 0.08 (s, 6H), 0.89 (s, 9H), 2.61 (t, J = 6.0 Hz, 2H), 4.00 (t, J = 
6.0 Hz, 2H), 9.81 (s, 1H); 
13C NMR (100 MHz, CDCl3) δ (ppm) -5.5, 18.2, 25.8, 46.6, 
57.4, 202.1. The aldehyde was used in the next step without purification. 
TBSO
OH
370  
(3S,4R)-1-(tert-Butyldimethylsilyloxy)-4-methylhex-5-en-3-ol (370)  
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  To a stirred suspension of potassium tert-butoxide (7.21 g, 64.26 mmol) in dry 
THF (80 mL) at -78 °C was added trans-2-butene (11.1 mL, 123.58 mmol) followed 
by  n-butyllithium  (1.6M  in  hexanes,  43.3  mL,  69.20  mmol).  The  resulting  yellow 
solution was stirred at -45 °C for 0.5 h, then cooled to -78 °C and a solution of (+)-B-
methoxydiisopinocampheylborane (20.33 g, 64.26 mmol) in THF (80 mL) was added. 
The mixture was stirred for 1 h, BF3·OEt2 (8.54 mL, 69.20 mmol) was introduced 
slowly, and the solution was stirred for another 0.5 h. A solution of aldehyde 369 (9.31 
g, 49.43 mmol) in THF (80 mL) was added, the mixture was stirred for 4 h, and the 
reaction was quenched at -78 °C with aqueous NaOH (3N, 80 mL) followed by 30% 
aqueous H2O2 (80 mL). The mixture was warmed slowly to room temperature and 
stirred for 3 h. The aqueous layer was separated and extracted with Et2O (3 x 250 mL) 
and  the  combined  organic  extracts  were  washed  with  brine  (350  mL),  dried  over 
anhydrous MgSO4 and filtered. The filtrate was concentrated in vacuo and the residue 
was purified by flash chromatography (15% EtOAc in hexanes) to afford 370 (7.906 g, 
66%) as a colorless oil: [α]D
21 +10.4 (c 1.00, CHCl3); IR (neat) 3446 (br), 2955, 2928, 
2857, 1472, 1361, 1255, 1092, 1005, 912, 836, 776 cm
-1; 
1H NMR (400 MHz , CDCl3) 
δ (ppm) 0.09 (s, 9H), 0.92 (s, 9H), 1.06 (d, J = 6.8 Hz, 3H), 1.63-1.68 (m, 2H), 2.24-
2.29 (m, 1H), 3.24 (br s, 1H), 3.71-3.72 (m, 1H), 3.80-3.85 (m, 1H), 3.90-3.94 (m, 
1H), 5.07-5.10 (m, 2H), 5.81-5.90 (m, 1H); 
13C NMR (100 MHz, CDCl3) δ (ppm) -
5.5,  15.8,  18.2,  25.9,  35.5,  44.0,  62.8,  75.1,  115.1,  140.7;  HRMS  (CI)  calcd  for 
C13H29O2Si [M+H]
+ m/z 245.1937, found m/z 245.1923.  
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HO
OH
371  
(3S,4R)-4-Methylhex-5-ene-1,3-diol (371) 
  To a stirred solution of TBS ether 370 (6.638 g, 27.18 mmol) in THF (110 mL) 
at room temperature was added TBAF (32.6 mL, 1M solution in THF, 32.6 mmol) and 
the  resulting  mixture  was  stirred  at  room  temperature  for  2  h.  The  reaction  was 
quenched with H2O (50 mL) and the aqueous layer was washed with EtOAc (50 mL), 
dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The 
residue was purified by flash chromatography (50% EtOAc in hexanes) to give diol 
371 (2.892 g, 82%) as a colorless oil: [α]D
20 +2.2 (c 1.00, CHCl3); IR (neat) 3356, 
3075, 2954, 2925, 2867, 2845, 1729, 1640, 1460, 1419, 1375, 1331, 1277, 1127, 1053, 
1000, 959, 913, 879, 837, 683 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 1.03 (d, J = 
7.2 Hz, 3H), 1.61-1.76 (m, 2H), 2.21-2.26 (m, 1H), 2.79 (br s, 1H), 3.09 (br s, 1H), 
3.64-3.67 (m, 1H), 3.78-3.86 (m, 2H), 5.10 (d, J = 6.0 Hz, 1H), 5.14 (s, 1H), 5.71-5.80 
(m, 1H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 15.9, 35.3, 44.6, 61.6, 74.9, 116.4, 
140.2. 
O O
372  
(S)-4-((R)-But-3-en-2-yl)-2,2-dimethyl-1,3-dioxane (372)  
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To a stirred mixture of diol 371 (1.747 g, 13.42 mmol), camphorsulfonic acid 
(623.6 mg, 2.68 mmol) and 4 Å MS (2.0 g) in acetone (130 mL) at room temperature 
was added 2,2-dimethoxypropane (2.5 mL, 20.13 mmol) and the resulting mixture was 
stirred at room temperature for 16 h. The solvent was evaporated and the residue was 
diluted with DCM (50 mL). The organic phase was washed with saturated aqueous 
NaHCO3  (50  mL),  dried  over  anhydrous  MgSO4,  filtered  and  concentrated  under 
reduced  pressure.  The  crude  product  was  purified  by  flash  chromatography  (30% 
EtOAc in hexanes) to give acetonide 372 (1.605 g, 70%) as a colorless oil: IR (neat) 
2960, 2924, 2854, 1739, 1642, 1462, 1379, 1267, 1241, 1198, 1170, 1101, 1004, 971, 
912, 871, 805 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 1.02 (d, J = 6.8 Hz, 3H), 
1.27-1.40 (m, 1H), 1.39 (s, 3H), 1.45 (s, 3H), 1.60-1.72 (m, 1H), 2.21-2.30 (m, 1H), 
3.75 (ddd, J = 2.4, 5.2, 11.6 Hz, 1H), 3.85 (ddd, J = 1.6, 5.2, 11.6 Hz, 1H), 3.96 (dt, J 
= 2.9, 12.0 Hz, 1H), 5.02 (s, 1H), 5.06 (d, J = 5.9 Hz, 1H), 5.82-5.89 (m, 1H); 
13C 
NMR (100 MHz, CDCl3) δ (ppm) 14.8, 19.2, 27.9, 29.9, 42.4, 60.0, 72.2, 98.2, 114.4, 
140.5. 
O O
OH
374  
(R)-2-((S)-2,2-Dimethyl-1,3-dioxan-4-yl)propan-1-ol (374) 
A solution of acetonide 372 (500 mg, 2.937 mmol) in a mixture of DCM (25 
mL) and MeOH (25 mL) was cooled to -78 °C and a steam of ozone was passed 
through the solution until the starting material was consumed as determined by TLC.  
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The reaction mixture was purged with argon to remove excess ozone and was treated 
portionwise at -78 °C with NaBH4 (444 mg, 11.75 mmol). The reaction mixture was 
warmed  slowly  to  room  temperature  for  1  h  and  was  concentrated  in  vacuo.  The 
residue was dissolved in EtOAc (50 mL) and the solution was washed with H2O (30 
mL). The aqueous layer was extracted with EtOAc (30 mL) and the combined organic 
phases were dried over anhydrous Na2SO4, filtered and concentrated. The residue was 
purified by flash chromatography (30% EtOAc in hexanes) to provide alcohol 374 
(329 mg, 65%) as a colorless oil: IR (neat) 3441 (br), 2991, 2961, 2876, 1460, 1428, 
1381, 1271, 1242, 1200, 1171, 1130, 1096, 1033, 994, 970, 899, 873, 850, 759 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 0.86 (d, J = 7.2 Hz, 3H), 1.39 (s, 3H), 1.45-1.52 
(m, 1H), 1.48 (s, 3H), 1.63-1.70 (m, 1H), 1.72-1.80 (m, 1H), 2.96 (br s, 1H), 3.56-3.65 
(m, 2H), 3.78-3.89 (m, 2H), 3.98 (dt, J = 2.8, 12.0 Hz, 1H); 
13C NMR (100 MHz, 
CDCl3) δ (ppm) 12.8, 19.2, 29.5, 29.9, 40.5, 59.9, 67.6, 75.0, 98.4; HRMS (CI) calcd 
for C9H19O3 [M+H]
+ m/z 175.1334, found m/z 175.1334. 
O O
H
O
373  
(S)-2-((S)-2,2-Dimethyl-1,3-dioxan-4-yl)propanal (373) 
To a stirred solution of oxalyl chloride (0.10 mL, 1.12 mmol) in DCM (1.0 
mL) at -78 °C was added dropwise a solution of DMSO (0.10 mL, 1.37 mmol) in 
DCM (1.0 mL) and the resulting mixture was stirred for 10 min, at which point a 
solution of alcohol 374 (150 mg, 0.86 mmol) in DCM (1.0 mL) was added dropwise.  
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After the addition was complete, the solution was stirred for 20 min at -78 °C and 
Et3N (0.37 mL, 2.67 mmol) was added slowly. The solution was allowed to warm to -
20 °C with stirring over 15 min and H2O (3.0 mL) was added. The aqueous phase was 
extracted with DCM (3 x 5.0 mL) and the organic phase was washed with brine (5.0 
mL),  dried  over  anhydrous  Na2SO4,  filtered  and  concentrated.  Purification  of  the 
residue by flash chromatography (40% Et2O in hexanes) afforded aldehyde 373 (144 
mg, 97%) as a colorless oil: [α]D
20 +36.5 (c 1.00, CHCl3); IR (neat) 2992, 2933, 2871, 
2723, 1728, 1460, 1382, 1272, 1242, 1199, 1171, 1094, 1071, 1044, 968, 878, 760 cm
-
1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 1.08 (d, J = 7.2 Hz, 3H), 1.38 (s, 3H), 1.44-
1.53 (m, 1H), 1.48 (s, 3H), 1.68-1.74 (m, 1H), 2.44-2.48 (m, 1H), 3.90 (ddd, J = 1.6, 
5.6, 12.0 Hz, 1H), 4.01 (dt, J = 2.8, 12.0 Hz, 1H), 4.13 (ddd, J = 2.4, 7.2, 11.2 Hz, 
1H), 9.77 (d, J = 2.0 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ (ppm) 9.6, 19.1, 28.7, 
29.7, 51.1, 59.7, 70.1, 98.5, 204.3; HRMS (CI) calcd for C9H16O3 [M]
+ m/z 172.1100, 
found m/z 175.1106. 
TBSO
OTBS
376  
(3R,4S)-4,6-Bis(tert-butyldimethylsilyloxy)-3-methylhex-1-ene (376) 
  To a stirred solution of alcohol 370 (1.00 g, 4.091 mmol) and imidazole (557 
mg, 8.182 mmol) in DMF (8.5 mL) at room temperature was added TBSCl (802 mg, 
5.318 mmol) and the resulting mixture was stirred at room temperature for 11 h. The 
reaction was quenched with H2O (8.5 mL) and extracted with Et2O (3 x 10 mL). The  
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combined  organic  phases  were  washed  with  brine  (20  mL),  dried  over  anhydrous 
MgSO4, filtered and concentrated under reduced pressure. Flash chromatography of 
the crude product gave TBS ether 376 (1.150 g, 78%) as a colorless oil: [α]D
20 -8.7 (c 
1.00, CHCl3); IR (neat) 3076, 2960, 2928, 2857, 1640, 1472, 1463, 1387, 1361, 1255, 
1100, 1044, 1005, 939, 913, 835, 812, 774, 716, 663 cm
-1; 
1H NMR (CDCl3, 400 
MHz) δ (ppm) 0.06 (s, 3H), 0.07 (s, 3H), 0.07 (s, 6H), 0.91 (s, 9H), 0.91 (s, 9H), 1.02 
(d, J = 7.2 Hz, 3H), 1.58-1.62 (m, 2H), 2.31-2.35 (m, 1H), 3.60-3.68 (m, 2H), 3.76-
3.80 (m, 1H), 5.00 (d, J = 4.8 Hz, 1H), 5.03 (s, 1H), 5.75-5.83 (m, 1H); 
13C NMR 
(CDCl3, 100 MHz) δ (ppm) -5.3, -4.5, 14.7, 18.1, 18.3, 25.9, 26.0, 36.3, 43.3, 60.2, 
72.3, 114.4, 140.9; HRMS (CI) calcd for C19H43O2Si2 [M+H]
+ m/z 359.2802, found 
m/z 359.2772. 
TBSO OH
OTBS
377  
(2R,3S)-3,5-Bis(tert-butyldimethylsilyloxy)-2-methylpentan-1-ol (377) 
A solution of alkene 376 (250 mg, 0.697 mmol) in a mixture of DCM (7.0 mL) 
and MeOH (7.0 mL) was cooled to -78 °C and a stream of O3 was bubbled gently 
through the solution until a light purple color persisted, at which point TLC showed 
that all of the starting material was consumed. The stream of O3 was removed and the 
flask was flushed with argon until the solution was colorless. NaBH4 (106 mg, 2.789 
mmol) was added slowly at -78 °C and the mixture was allowed to warm to room 
temperature. The mixture was concentrated and the residue was dissolved in EtOAc  
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(14 mL). The organic phase was washed with H2O (10 mL) and the aqueous layer was 
extracted  with  EtOAc  (10  mL).  The  combined  organic  phase  was  dried  over 
anhydrous  Na2SO4,  filtered  and  concentrated  to  provide  crude  product  which  was 
purified by flash chromatography (10% EtOAc/hexanes) to give alcohol 377 (163 mg, 
65%) as a colorless oil: [α]D
20 -3.1 (c 1.00, CHCl3); IR (neat) 3388 (br), 2956, 2930, 
2885, 2858, 1472, 1463, 1388, 1361, 1256, 1098, 1036, 1006, 939, 836, 812, 775, 665 
cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 0.06 (s, 6H), 0.11 (s, 6H), 0.90 (s, 9H), 
0.91 (s, 9H), 1.03 (d, J = 7.2 Hz, 3H), 1.77-1.82 (m, 3H), 2.67 (br s, 1H), 3.54 (dd, J = 
5.2, 10.8 Hz, 1H), 3.68 (t, J = 6.4 Hz, 2H), 3.79 (dd, J = 4.0, 10.8 Hz, 1H), 3.89-3.93 
(m, 1H); 
13C NMR (100 MHz, CDCl3) δ (ppm) -5.4, -4.7, -4.5, 14.3, 18.0, 18.2, 25.8, 
25.9,  37.6,  38.6,  59.7,  65.2,  74.1;  HRMS  (CI) calcd  for  C18H43O3Si2  [M+H]
+  m/z 
363.2751, found m/z 363.2752. 
TBSO O
OTBS
378  
(2S,3S)-3,5-Bis(tert-butyldimethylsilyloxy)-2-methylpentanal (378) 
  To a stirred solution of oxalyl chloride (1.56 mL, 17.834 mmol) in DCM (35 
mL) at -78 °C was added dropwise a solution of DMSO (2.14 mL, 30.181 mmol) in 
DCM (25 mL) and the resulting mixture was stirred for 15 min, at which point a 
solution of alcohol 377 (4.976 g, 13.719 mmol) in DCM (25 mL) was added slowly. 
The solution was stirred at -78 °C for 20 min and Et3N (9.57 mL, 68.593 mmol) was 
added dropwise. The mixture was stirred for 10 min at -78 °C then was allowed to  
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warm to room temperature. The reaction was quenched with water (60 mL) and the 
aqueous layer was extracted with DCM (2 x 100 mL). The organic layer was washed 
with  brine  (100  mL),  dried  over  anhydrous  Na2SO4,  filtered  and  concentrated  in 
vacuo. The crude product was purified by flash chromatography (5% EtOAc/hexanes) 
to  provide  aldehyde  378  (4.804  g,  97%)  as  a  colorless  oil:  [α]D
20  +17.3  (c  1.00, 
CHCl3); IR (neat) 2955, 2930, 2885, 2858, 2813, 2710, 1727, 1472, 1463, 1388, 1361, 
1256, 1101, 1042, 1006, 939, 837, 812, 776, 712 cm
-1; 
1H NMR (400 MHz, CDCl3) δ 
(ppm) 0.05 (s, 3H), 0.06 (s, 3H), 0.08 (s, 3H), 0.10 (s, 3H), 0.89 (s, 9H), 0.90 (s, 9H), 
1.13 (d, J = 7.0 Hz, 3H), 1.61-1.83 (m, 2H), 2.54-2.61 (m, 1H), 3.69-3.72 (m, 2H), 
4.15-4.19 (m, 1H), 9.75 (d, J = 2.1 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ (ppm)      
-5.4, -4.8, -4.4, 10.2, 18.0, 18.2, 25.8, 25.9, 37.7, 51.6, 59.1, 70.4, 204.8; HRMS (CI) 
calcd for C18H40O3Si2 [M]
+ m/z 360.2516, found m/z 360.2527. 
TBSO
TBSO OH
379  
(3R,4R,5R,6S)-6,8-Bis(tert-butyldimethylsilyloxy)-3,5-dimethyloct-1-en-4-ol (379) 
  To a stirred suspension of potassium tert-butoxide (36.4 mg, 0.324 mmol) in 
dry THF (1.0 mL) at -78 °C was added trans-2-butene (60 µL, 0.624 mmol) followed 
by  n-butyllithium  (1.6M  in  hexanes,  0.22  mL,  0.349  mmol).  The  resulting  yellow 
solution was stirred at -45 °C for 0.5 h, then cooled to -78 °C and a solution of (+)-B-
methoxydiisopinocampheylborane (103 mg, 0.324 mmol) in THF (1.0 mL) was added. 
The  mixture  was  stirred  for  1  h,  BF3·OEt2  (43  µL,  0.349  mmol)  was  introduced  
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slowly, and the solution was stirred for 0.5 h. A solution of aldehyde 378 (90 g, 0.250 
mmol) in THF (1.0 mL) was added, the mixture was stirred for 4 h, and the reaction 
was quenched at -78 °C with aqueous NaOH (3 N, 1.0 mL) followed by 30% aqueous 
H2O2 (1.0 mL). The mixture was warmed slowly to room temperature and stirred for 3 
h. The aqueous layer was separated and extracted with Et2O (3 x 3.0 mL) and the 
combined organic extracts were washed with brine (5.0 mL), dried over anhydrous 
MgSO4  and  filtered.  The  filtrate  was  concentrated  in  vacuo  and  the  residue  was 
purified by flash chromatography (20% Et2O in hexanes) to afford alcohol 379 (73 
mg, 70%) as a colorless oil: [α]D
20 -4.7 (c 1.00, CHCl3); IR (neat) 3501 (br), 3077, 
2956, 2885, 2858, 1639, 1472, 1463, 1388, 1361, 1255, 1104, 1048, 1004, 976, 939, 
911, 840, 774, 714, 664 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 0.07 (s, 3H), 0.08 
(s, 3H), 0.12 (s, 6H), 0.92 (s, 18H), 0.95 (d, J = 7.2 Hz, 3H), 1.05 (d, J = 7.2 Hz, 3H), 
1.75-1.78 (m, 1H), 1.85-1.90 (m, 2H), 2.29-2.38 (m, 1H), 3.49 (s, 1H), 3.60-3.72 (m, 
3H), 4.01-4.04 (m, 1H), 5.09-5.16 (m, 2H), 5.88-5.97 (m, 1H); 
13C NMR (100 MHz, 
CDCl3) δ (ppm) -5.3, -4.7, -4.5, -4.4, 10.9, 16.6, 18.0, 18.2, 25.9, 36.3, 37.5, 41.2, 
59.7,  74.4,  75.4,  114.4,  142.3;  HRMS  (ES)  calcd  for  C22H49O3Si2  [M+H]
+  m/z 
417.3220, found m/z 417.3216. 
TBSO
TBSO OH
OH
380  
(2R,3R,4R,5S)-5,7-Bis(tert-butyldimethylsilyloxy)-2,4-dimethylheptane-1,3-diol 
(380)  
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  A solution of alkene 379 (1.847 g, 4.432 mmol) in DCM (22 mL) and MeOH 
(22 mL) was cooled to -78 °C and a stream of O3 was bubbled gently through the 
solution until a light purple color persisted, at which point TLC showed that all of the 
starting material was consumed. The stream of O3 was removed and the flask was 
flushed with argon until the solution was colorless. NaBH4 (503 mg, 13.297 mmol) 
was  then  added  slowly  at  -78  °C  and  the  mixture  was  allowed  to  warm  to  room 
temperature.  The  mixture  was  concentrated  and  EtOAc  (40  mL)  was  added.  The 
organic phase was washed with H2O (30 mL) and the aqueous phase was extracted 
with  EtOAc  (30  mL).  The  combined  organic  phases  were  dried  over  anhydrous 
Na2SO4, filtered and concentrated to provide the crude product which was purified by 
flash chromatography (10% EtOAc/hexanes) to give  diol 380 (1.838 g, 98%) as  a 
colorless oil: IR (neat) 3439 (br), 2956, 2930, 2885, 2858, 1472, 1420, 1387, 1361, 
1337, 1255, 1102, 1004, 976, 939, 836, 775, 715, 681, 664 cm
-1; 
1H NMR (400 MHz, 
CDCl3) δ (ppm) 0.06 (s, 3H), 0.07 (s, 3H), 0.14 (s, 6H), 0.75 (d, J = 6.8 Hz, 3H), 0.91 
(s, 9H), 0.92 (s, 9H), 1.07 (d, J = 7.2 Hz, 3H), 1.66-1.73 (m, 1H), 1.89-1.93 (m, 3H), 
3.56-3.74 (m, 5H), 3.94 (d, J = 9.6 Hz, 1H), 4.03-4.06 (m, 1H), 4.28 (s, 1H); 
13C NMR 
(100 MHz, CDCl3) δ (ppm) -5.5, -5.4, -4.8, -4.4, 11.5, 13.3, 17.9, 18.2, 25.8, 25.9, 
35.8, 37.3, 37.9, 59.6, 69.2, 76.6, 77.2; HRMS (ES) calcd for C21H49O4Si2 [M+H]
+ m/z 
421.3169, found m/z 421.3157.  
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TBSO
TBSO O
PMP
O
381  
(4R,5R)-4-((2R,3S)-3,5-Bis(tert-butyldimethylsilyloxy)pentan-2-yl)-2-(4-
methoxyphenyl)-5-methyl-1,3-dioxane (381) 
  To a stirred solution of diol 380 (479 mg, 1.137 mmol) and PPTS (29 mg, 
0.114  mmol)  in  DCM  (4.5  mL)  at  room  temperature  was  added  p-anisaldehyde 
dimethylacetal (0.29 mL, 1.706 mmol) and the reaction mixture was stirred for 5 h. 
The reaction was quenched with saturated aqueous NaHCO3 (4.5 mL) and the aqueous 
layer was extracted with DCM (3 x 6.0 mL). The organic phase was washed with 
brine, dried over anhydrous MgSO4, filtered and concentrated. The crude product was 
purified by flash chromatography (10% EtOAc/hexanes) to afford acetal 381 (394 mg, 
80%, 86% brms) as a pale yellow oil: [α]D
20 +21.4 (c 1.00, CHCl3); IR (neat) 2955, 
2929, 2883, 2856, 1616, 1519, 1470, 1463, 1389, 1360, 1302, 1251, 1171, 1121, 1108, 
1087, 1039, 1005, 969, 938, 835, 774, 663 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 
0.04 (s, 6H), 0.05 (s, 3H), 0.06 (s, 3H), 0.75 (d, J = 6.8 Hz, 3H), 0.90 (s, 9H), 0.93 (s, 
9H), 0.97 (d, J = 6.8 Hz, 3H), 1.77-1.80 (m, 2H), 1.86-1.90 (m, 1H), 2.03-2.05 (m, 
1H), 3.45-3.49 (m, 1H), 3.64-3.78 (m, 3H), 3.82 (s, 3H), 3.88-3.90 (m, 1H), 4.10-4.14 
(m, 1H), 5.42 (s, 1H), 6.89 (d, J = 8.4 Hz, 2H), 7.41 (d, J = 8.4 Hz, 2H); 
13C NMR 
(100 MHz, CDCl3) δ (ppm) -5.3, -5.2, -4.8, -4.1, 8.8, 12.3, 18.1, 18.3, 26.0, 30.3, 36.6,  
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39.3, 55.3, 59.0, 70.9, 73.4, 82.1, 100.8, 113.5, 127.4, 131.7, 159.7; HRMS (ES) calcd 
for C29H54O5NaSi2 [M+Na]
+ m/z 561.3408, found m/z 561.3387. 
TBSO
TBSO OPMB
OH
382  
(2R,3R,4R,5S)-3-(4-Methoxybenzyloxy)-5,7-bis(tert-butyldimethylsilyloxy)-2,4-
dimethylheptan-1-ol (382) 
Method A. To a stirred solution of acetal 381 (440 mg, 0.817 mmol) in DCM 
(4.0  mL)  at  -78  °C  was  added  dropwise  a  solution  of  DIBAL-H  (1M  solution  in 
hexanes, 2.45 mL, 2.45 mmol) and the resulting mixture was stirred at -78 °C for 45 
min, then was allowed to warm to room temperature over 1.5 h. The reaction mixture 
was  quenched  with  saturated  aqueous potassium  sodium  tartrate  (13  mL),  the two 
phases were separated and the aqueous phase was extracted with Et2O (2 x 20 mL). 
The combined organic layers were washed with brine (30 mL), dried over anhydrous 
Na2SO4, filtered and concentrated in vacuo. The crude product was purified by flash 
chromatography (20% EtOAc in hexanes) to provide alcohol 382 (231 mg, 52%) as a 
pale yellow oil. 
Method B. To  a stirred solution  of acetal 381 (250.4 mg,  0.465 mmol)  in 
DCM (4.6 mL) at –78 °C was added a solution of DIBAL-H (0.30 mL, 1.626 mmol) 
in toluene (1.6 mL) and the resulting mixture was stirred at –78 °C for 5 min, then was 
allowed to warm to room temperature over 45 min. The reaction was quenched with 
MeOH (0.5 mL), and the mixture was diluted with DCM (3.0 mL) and poured into  
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saturated aqueous potassium sodium tartrate (7.0 mL). The two phases were stirred 
vigorously  and  the  aqueous  phase  was  extracted  with  DCM  (3  x  10.0  mL).  The 
combined organic layers were washed with brine (15.0 mL), dried over anhydrous 
Na2SO4, filtered and concentrated. Purification of the residue by flash chromatography 
(20% Et2O in hexanes) furnished alcohol 382 (159.7 mg, 66%) as a colorless  oil: 
[α]D
20 -15.9 (c 1.00, CHCl3); IR (neat) 3454, 2955, 2929, 2857, 1614, 1515, 1471, 
1388, 1360, 1302, 1251, 1173, 1090, 1039, 1005, 940, 835, 774 cm
-1; 
1H NMR (400 
MHz, CDCl3) δ (ppm) 0.07 (s, 6H), 0.10 (s, 6H), 0.92 (s, 9H), 0.93 (s, 9H), 2.13 (d, J 
= 6.8 Hz, 3H), 1.11 (d, J = 7.2 Hz, 3H), 1.62-1.68 (m, 2H), 1.91 (br s, 1H), 1.96-2.01 
(m, 1H), 2.82-2.85 (m, 1H), 3.38-3.41 (m, 1H), 3.60-3.74 (m, 3H), 3.83 (s, 3H), 3.83-
3.92 (m, 2H), 4.53-4.62 (AB quartet, 2H), 6.90 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.4 
Hz, 2H); 
13C NMR (100 MHz, CDCl3) δ (ppm) -5.4, -4.4, -4.2, 10.2, 15.7, 18.1, 18.2, 
25.8, 25.9, 35.4, 37.3, 42.7, 55.3, 59.5, 65.3, 70.3, 75.4, 86.6, 113.9, 129.4, 130.5, 
159.3; HRMS (ES) calcd for C29H57O5Si2 [M+H]
+ m/z 541.3745, found m/z 541.3749. 
TBSO
TBSO OPMB
O
253  
(2S,3S,4R,5S)-3-(4-Methoxybenzyloxy)-5,7-bis(tert-butyldimethylsilyloxy)-2,4-
dimethylheptanal (253) 
  Method A. To a stirred solution of oxalyl chloride (8.4 µL, 0.096 mmol) in 
DCM (0.3 mL) at -78 °C was added dropwise a solution of DMSO (11.6 µL, 0.163 
mmol) in DCM (0.2 mL) and the resulting mixture was stirred for 10 min, at which  
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point a solution of alcohol 382 (40 mg, 0.074 mmol) in DCM (0.2 mL) was added 
slowly. The reaction mixture was stirred at -78 °C for 20 min and Et3N (52 µL, 0.370 
mmol) was added dropwise. The mixture was stirred at -78 °C for 10 min then was 
warmed to room temperature. The reaction was quenched with water (1.0 mL) and the 
aqueous layer was extracted with DCM (2 x 2.0 mL). The organic layer was washed 
with brine (2.0 mL), dried over anhydrous Na2SO4, filtered and concentrated under 
reduced  pressure.  The  crude  product  was  purified  by  flash  chromatography  (10% 
EtOAc in hexanes) to give aldehyde 253 (35.6 mg, 89%) as a colorless oil.  
  Method B. To a solution of diol 385 (656.1 mg, 1.149 mmol) in a mixture of 
THF (10.5 mL) and H2O (1.0 mL) at room temperature was added NaIO4 (737.4 mg, 
3.447 mmol) and the resulting suspension was stirred for 45 min. The mixture was 
partitioned  between  Et2O  (10  mL)  and  H2O  (10  mL)  and  the  aqueous  phase  was 
extracted  with  Et2O  (15  mL).  The  combined  organic  extracts  were  dried  over 
anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was purified 
by flash chromatography (5% Et2O in hexanes) to give aldehyde 253 (413.5 mg, 67%) 
as a yellow oil: [α]D
20 -20.9 (c 1.00, CHCl3); IR (neat) 2955, 2930, 2884, 2857, 2720, 
1724, 1614, 1587, 1515, 1472, 1388, 1360, 1302, 1251, 1173, 1089, 1039, 1005, 940, 
836, 775; 
1H NMR (400 MHz, CDCl3) δ (ppm) 0.07 (s, 12H), 0.91 (s, 18H), 1.05 (d, J 
= 6.8 Hz, 3H), 1.16 (d, J = 6.8 Hz, 3H), 1.64-1.69 (m, 2H), 1.93-1.96 (m, 1H), 2.71 (br 
s, 1H), 3.58-3.73 (m, 3H), 3.82 (s, 3H), 3.97 (br s, 1H), 4.50 (A of AB quartet, J = 
10.4 Hz, 1H), 4.57 (B of AB quartet, J = 10.4 Hz, 1H), 6.89 (d, J = 8.4 Hz, 2H), 7.26 
(d, J = 8.4 Hz, 2H), 9.82 (s, 1H); 
13C NMR (100 MHz, CDCl3) δ (ppm) -5.4, -4.5, - 
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4.3, 10.0, 11.9, 18.1, 18.2, 25.9, 35.6, 42.8, 49.5, 55.3, 59.5, 70.2, 74.4, 82.6, 113.8, 
129.2,  130.4,  159.2,  204.5;  HRMS  (ES)  calcd  for  C29H54O5NaSi2  [M+Na]
+  m/z 
561.3408, found m/z 561.3403. 
TBSO
TBSO OPMB
384  
1-(((3R,4R,5R,6S)-6,8-Bis(tert-butyldimethylsilyloxy)-3,5-dimethyloct-1-en-4-
yloxy)methyl)-4-methoxybenzene (384) 
  To a stirred suspension of KH (36.6 mg, 0.912 mmol) in THF (0.50 mL) at 0 
°C was added a solution of alcohol 379 (200.0 mg, 0.480 mmol) in THF (0.70 mL) 
and the mixture was allowed to warm to room temperature with stirring over 1 h. 
DMF (0.11 mL) and PMBCl (71.6 µL, 0.528 mmol) were added and the resulting 
mixture was stirred at room temperature for 12 h. The mixture was cooled to 0 °C and 
the  reaction  was  quenched  with  saturated  aqueous  NH4Cl  (1.0  mL).  The  aqueous 
phase was extracted with Et2O (3 x 2.0 mL) and the organic phase was dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. Purification of the residue by 
flash chromatography (5% EtOAc in hexanes) afforded ether 384 (214.9 mg, 83%) as 
a colorless oil: [α]D
28  -17.2 (c 1.00, CHCl3); IR (neat) 3080, 2956, 2929, 2857, 1613, 
1514, 1471, 1250, 1172, 1088, 1041, 1005, 940, 835, 774, 665 cm
-1; 
1H NMR (700 
MHz, CDCl3) δ 0.025 (s, 3H), 0.046 (s, 3H), 0.083 (s, 6H), 0.89 (s, 9H), 0.93 (s, 9H), 
1.02 (d, J = 7.0 Hz, 3H), 1.13 (d, J = 7.0 Hz, 3H), 1.51-1.63 (m, 2H), 1.88-1.89 (m, 
1H), 2.46-2.52 (m, 1H), 3.13 (dd, J = 2.8, 7.7 Hz, 1H), 3.66-3.68 (m, 1H), 3.71-3.73  
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(m, 1H), 3.83 (s, 3H), 3.94-3.95 (m, 1H), 4.52-4.57 (m, 2H), 5.07-5.11 (m, 2H), 5.94-
5.98 (m, 1H), 6.90 (d, J = 8.4 Hz, 2H), 7.32 (d, J = 8.4 Hz, 2H); 
13C NMR (175 MHz, 
CDCl3) δ (ppm) -5.3, -4.7, -4.1, 10.0, 18.1, 18.3, 25.9, 34.6, 41.0, 42.5, 55.3, 60.0, 
68.8,  74.9,  85.5,  113.7,  115.1,  129.2,  131.2,  140.5,  159.0;  HRMS  (CI)  calcd  for 
C30H57O4NaSi2 [M+H]
+ m/z 537.3795, found m/z 537.3783. 
TBSO
TBSO OPMB
OH
OH
385  
(3R,4R,5R,6S)-4-(4-Methoxybenzyloxy)-6,8-bis(tert-butyldimethylsilyloxy)-3,5-
dimethyloctane-1,2-diol (385) 
  To a stirred solution of olefin 384 (200 mg, 0.373 mmol) and NMO (87.3 mg, 
0.745 mmol) in a mixture of THF (1.70 mL), t-BuOH (1.70 mL) and H2O (0.34 mL) 
at 0 °C was added OsO4 (0.37 mL, 0.05M solution in t-BuOH, 0.0186 mmol) and the 
resulting mixture was allowed to warm to room temperature with and was stirred for 
22  h.  The  reaction  was  quenched  with  saturated  aqueous  Na2SO3  (3.0  mL)  and 
extracted with EtOAc (3 x 5.0 mL). The combined organic phases were dried over 
anhydrous MgSO4, filtered and concentrated under reduced pressure. Purification of 
the  residue  by  flash  chromatography  (20%  EtOAc  in  hexanes)  afforded  diol  385 
(217.8 mg, quant.) as a colorless oil: IR (neat) 3428, 2955, 2929, 2857, 1614, 1587, 
1515, 1471, 1388, 1361, 1302, 1251, 1173, 1087, 1040, 1006, 940, 836, 775, 665 cm
-
1; HRMS (CI) calcd for C30H59O6Si2 [M+H]
+ m/z 571.3850, found m/z 571.3859. 
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TBSO
TBSO
OPMB
OH
391  
(3R,4R,5R,6R,7S)-5-(4-Methoxybenzyloxy)-7,9-bis(tert-butyldimethylsilyloxy)-
2,4,6-trimethylnon-1-en-3-ol (391) 
  Method A. To a stirred solution of aldehyde 253 (10 mg, 18.6 µmol) in THF 
(0.5 mL) at 0 °C was added dropwise a solution of isopropenylmagnesium bromide 
(0.45 µL, 0.5M solution in THF, 22.3 µmol) and the resulting solution was stirred at 0 
°C for 1.5 h, then was warmed to room temperature over 3 h. The reaction mixture 
was quenched with H2O (1.0 mL) and the aqueous phase was extracted with Et2O (3 x 
5.0 mL). The combined organic phases were washed with saturated aqueous NaHCO3 
(2.5  mL)  and  brine,  then  were  dried  over  anhydrous  Na2SO4,  filtered,  and 
concentrated. Purification of the crude product by flash chromatography (10% EtOAc 
in hexanes) provided alcohol 391 (8.7 mg, 81%, d.r. 5:1) as a yellow oil. 
Method B. Isopropenyllithium (0.5M solution in Et2O, 1.0 mL) was prepared 
in the following manner. To a stirred solution of t-BuLi (1.7M in pentane, 0.59 mL, 
1.0 mmol) in Et2O (0.36 mL) at -78 °C was added dropwise 2-bromopropene (44.4 
µL, 0.5 mmol) and the resulting mixture was stirred at -78 °C for 35 min, then 0 °C for 
5 min.  
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To a stirred solution of aldehyde 253 (97.0 mg, 0.180 mmol) in Et2O (0.90 
mL) at -78 °C was added isopropenyllithium prepared above (0.5M solution in Et2O, 
0.45 mL, 0.225 mmol) and the resulting mixture was stirred at -78 °C for 1.5 h, then 
was warmed to room temperature over 15 min. The reaction mixture was diluted with 
Et2O (1.0 mL) and washed with H2O (1.0 mL). The aqueous phase was extracted with 
Et2O  (2  x  1.5  mL)  and  the  combined  organic  phases  were  dried  over  anhydrous 
Na2SO4,  filtered,  and  concentrated.  Purification  of  the  crude  product  by  flash 
chromatography (10% EtOAc in hexanes) afforded alcohol 391 (78.8 mg, 75%, d.r. 
10:1) as a colorless oil: [α]D
28 -19.8 (c 1.00, CHCl3); IR (neat) 3489, 2955, 2929, 
2884, 2857, 1614, 1515, 1471, 1388, 1360, 1302, 1251, 1174, 1088, 1039, 1005, 940, 
900, 835, 775 cm
-1; 
1H NMR (700 MHz, CDCl3) δ (ppm) 0.06 (s, 3H), 0.07 (s, 3H), 
0.08 (s, 3H), 0.09 (s, 3H), 0.91 (s, 9H), 0.92 (s, 9H), 1.00 (d, J = 7.7 Hz, 3H), 1.12 (d, 
J = 7.0 Hz, 3H), 1.45-1.51 (m, 1H), 1.58-1.65 (m, 1H), 1.71 (s, 3H), 1.86-1.89 (m, 
1H), 2.16-2.19 (m, 1H), 3.40 (dd, J = 2.8, 9.1 Hz, 1H), 3.67-3.69 (m, 1H), 3.73-3.75 
(m, 1H), 3.83 (s, 3H), 3.84 (s, 1H), 3.92-3.94 (m, 1H), 4.46 (s, 1H), 4.60 (AB quartet, 
2H), 4.95 (s, 1H), 5.12 (s, 1H), 6.90 (d, J = 9.1 Hz, 2H), 7.30 (d, J = 9.1 Hz, 2H); 
13C 
NMR (175 MHz, CDCl3) δ (ppm) -5.3, -5.2, -4.6, -4.0, 10.6, 11.3, 18.1, 18.4, 20.3, 
25.9, 26.0, 34.6, 36.1, 42.4, 55.3, 59.9, 68.9, 73.1, 76.3, 87.6, 110.5, 113.9, 129.4, 
130.2, 145.0, 159.3; HRMS (ES) calcd for C32H61O5Si2 [M+H]
+ m/z 581.4058, found 
m/z 581.4033.  
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TBSO
TBSO
OPMB
O
O
252  
(3R,4S,5R,6R,7S)-5-(4-Methoxybenzyloxy)-7,9-bis(tert-butyldimethylsilyloxy)-
2,4,6-trimethylnon-1-en-3-yl Butyrate (252) 
  To a stirred solution of alcohol 391 (78.0 mg, 0.134 mmol) and DMAP (32.8 
mg,  0.269  mmol)  in  DCM  (6.7  mL)  at  room  temperature  was  added  n-butyric 
anhydride  (44  µL,  0.269  mmol)  followed  by  Et3N  (94  µL,  0.671  mmol)  and  the 
resulting mixture was stirred for 27 h, at which point saturated aqueous NaHCO3 (6.0 
mL) was added. The aqueous layer was extracted with DCM (3 x 6.0 mL) and the 
combined  organic  extract  was  dried  over  anhydrous  Na2SO4,  filtered,  and 
concentrated. Purification of the crude product by flash chromatography (10% Et2O in 
hexanes)  gave  ester  252  (85.3  mg,  98%)  as  a  colorless  oil:  [α]D
24  -10.7  (c  1.00, 
CHCl3); IR (neat) 2956, 2930, 2857, 1738, 1614, 1515, 1471, 1386, 1360, 1303, 1251, 
1180, 1088, 1040, 1005, 940, 836, 774, 665 cm
-1; 
1H NMR (700 MHz, CDCl3) δ 
(ppm) 0.07 (s, 3H), 0.08 (s, 3H), 0.12 (s, 3H), 0.13 (s, 3H), 0.88 (d, J = 4.2 Hz, 3H), 
0.90 (s, 9H), 0.91 (d, J = 7.0 Hz, 3H), 0.93 (s, 9H), 0.99 (t, J = 7.0 Hz, 3H), 1.68-1.77 
(m, 3H), 1.74 (s, 3H), 1.85-1.91 (m, 2H), 1.92-1.95 (m, 1H), 2.35 (t, J = 7.0 Hz, 2H), 
3.50 (d, J = 8.4 Hz, 1H), 3.70-3.79 (m, 2H), 3.82 (s, 3H), 3.97-4.00 (m, 1H), 4.29 (d, J 
= 9.1 Hz, 1H), 4.51 (d, J = 9.1 Hz, 1H), 4.83 (s, 1H), 4.93 (s, 1H), 5.54 (s, 1H), 6.88 
(d, J = 8.4 Hz, 2H), 7.34 (d, J = 8.4 Hz, 2H); 
13C NMR (175 MHz, CDCl3) δ (ppm)      
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-5.3, -4.2, -3.8, 8.6, 10.4, 13.9, 18.3, 18.5, 20.1, 26.0, 26.1, 36.4, 36.5, 37.4, 41.4, 55.3, 
59.2, 72.3, 74.0, 75.6, 80.4, 110.8, 113.7, 129.7, 130.9, 143.0, 159.1, 172.8; HRMS 
(ES) calcd for C36H67O6Si2 [M+H]
+ m/z 651.4476, found m/z  651.4455. 
TBSO
OH
(±)-395  
5-(tert-Butyldimethylsilyloxy)-2-methylpent-1-en-3-ol (395) 
Isopropenyllithium  (0.5M  solution  in  Et2O)  was  prepared  in  the  following 
manner. To a stirred solution of t-BuLi (1.8M in pentane, 11.1 mL, 20 mmol) in Et2O 
(8.0 mL) at -78 °C was added dropwise 2-bromopropene (0.90 mL, 10 mmol) and the 
resulting mixture was stirred at -78 °C for 35 min. 
To a stirred solution of aldehyde 369 (1.497 g, 7.95 mmol) in Et2O (40.0 mL) 
at -78 °C was added isopropenyllithium prepared above (0.5M solution in Et2O, 20 
mL, 10 mmol) and the resulting mixture was stirred at -78 °C for 1.5 h, then was 
warmed to room temperature for 15 min. The reaction mixture was diluted with Et2O 
(30 mL) and washed with H2O (50 mL). The aqueous phase was extracted with Et2O 
(2 x 50 mL) and the combined organic phases were dried over anhydrous Na2SO4, 
filtered, and concentrated. Purification of the crude product by flash chromatography 
(10% EtOAc in hexanes) afforded alcohol 395 (1.352 g, 74%) as a colorless oil: IR 
(neat) 3428 (br), 3074, 2954, 2929, 2858, 1651, 1472, 1389, 1361, 1256, 1100, 1006, 
939, 899, 835, 812, 776, 732, 665 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 0.10 (s,  
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6H), 0.93 (s, 9H), 1.75 (s, 3H), 1.76-1.82 (m, 2H), 3.35 (d, J = 3.2 Hz, 1H), 3.79-3.85 
(m, 1H), 3.87-3.92 (m, 1H), 4.27-4.30 (m, 1H), 4.87 (s, 1H), 5.05 (s, 1H); 
13C NMR 
(175 MHz, CDCl3) δ (ppm) -5.5, 18.2, 18.5, 25.9, 36.6, 62.3, 75.3, 110.4, 147.0. 
TBSO
O
O
(±)-396  
5-(tert-Butyldimethylsilyloxy)-2-methylpent-1-en-3-yl Butyrate (396) 
  To a stirred solution of alcohol 395 (281 mg, 1.22 mmol) and DMAP (297 mg, 
2.43 mmol) in DCM (2.4 mL) at room temperature was added n-butyric anhydride 
(0.40  mL,  2.43  mmol)  followed  by  Et3N  (0.85  mL,  6.09  mmol)  and  the  resulting 
mixture was stirred for 12 h, at which point saturated aqueous NaHCO3 (3 mL) was 
added. The aqueous layer was extracted with DCM (3 x 5 mL) and the organic layer 
was dried over anhydrous Na2SO4, filtered, and concentrated. Purification of the crude 
product by flash chromatography (5% EtOAc in hexanes) gave ester 396 (335 mg, 
92%) as a colorless oil: IR (neat) 3080, 2958, 2930, 2858, 1741, 1656, 1472, 1362, 
1256, 1179, 1101, 954, 903, 836, 776, 665 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 
0.05 (s, 6H), 0.91 (s, 9H), 0.97 (t, J = 7.2 Hz, 3H), 1.65-1.71 (m, 2H), 1.75 (s, 3H), 
1.84-1.90 (m, 2H), 2.31 (t, J = 7.6 Hz, 2H), 3.64 (t, J = 6.8 Hz, 2H), 4.89 (s, 1H), 4.97 
(s, 1H), 5.29-5.45 (m, 1H); 
13C NMR (175 MHz, CDCl3) δ (ppm) -5.4, 13.8, 18.2, 
18.3, 18.5, 25.9, 36.1, 36.5, 59.3, 74.1, 112.3, 143.5, 172.8.  
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O
OH TBSO
(±)-398                 
O
OTMS TBSO
(±)-399  
(E)-7-(tert-Butyldimethylsilyloxy)-2-ethyl-4-methylhept-4-enoic  Acid  (398)  and 
(E)-Trimethylsilyl  7-(tert-Butyldimethylsilyloxy)-2-ethyl-4-methylhept-4-enoate 
(399) 
  To a stirred solution of ester 396 (1.265 g, 4.21 mmol) in THF (2.8 mL) at -78 
°C  was  added  a  freshly  prepared  mixture  (1:1  v/v)  of  trimethylsilyl  chloride-
triethylamine (5.4 mL), followed by cooled (-30 °C) LDA (5.9 mL, 1.0M solution in 
THF,  5.90  mmol).  The  reaction  mixture  was  stirred  at  -78  °C  for  2  h,  then  was 
warmed  to  room  temperature  for  30  min  and  diluted  with  THF  (10.5  mL).  The 
solution was heated at reflux with stirring for 2 h, then was cooled and diluted with 
ether (10 mL). The reaction was quenched with saturated aqueous NH4Cl (15 mL), the 
aqueous layer was extracted with Et2O (3 x 20 mL) and the combined organic phases 
were  washed  with  H2O  (30  mL),  dried  over  anhydrous  Na2SO4,  filtered,  and 
concentrated. Purification of the crude product by flash chromatography (10% EtOAc 
in hexane) provided carboxylic acid 398 (875 mg, 69%) as a colorless oil along with 
TMS ester 399 (431 mg, 28%) as a colorless oil.  
398: IR (neat) 3300-2500 (br), 2958, 2930, 2858, 1708, 1463, 1255, 1101, 938, 
836, 775, 665 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 0.07 (s, 6H), 0.91 (s, 9H), 
0.96 (t, J = 7.6 Hz, 3H), 1.53-1.61 (m, 2H), 1.64 (s, 3H), 2.14-2.19 (m, 1H), 2.22-2.27  
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(m, 2H), 2.33-2.38 (m, 1H), 2.45-2.53 (m, 1H), 3.59 (t, J = 7.2 Hz, 2H), 5.21 (t, J = 
6.8 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ (ppm) -5.3, 11.7, 15.9, 18.3, 24.7, 25.9, 
31.9, 42.0, 45.5, 62.9, 123.2, 133.9, 182.0.  
399: 
1H NMR (400 MHz, CDCl3) δ (ppm) 0.07 (s, 6H), 0.14 (s, 9H), 0.91 (s, 
9H), 1.04 (t, J = 7.6 Hz, 3H), 1.50-1.58 (m, 1H), 1.61 (s, 3H), 1.72-1.78 (m, 2H), 2.15 
(d, J = 14.0 Hz, 1H), 2.24 (m, 2H), 2.85 (d, J = 14.0 Hz, 1H), 3.60 (t, J = 7.2 Hz, 2H), 
5.17-5.21 (m, 1H); 
13C NMR (100 MHz, CDCl3) δ (ppm) -5.3,       -2.5, 11.3, 16.5, 
18.3, 24.3, 26.0, 31.9, 40.9, 43.0, 62.9, 123.9, 135.1, 184.1. 
O
OH HO
(±)-400  
(E)-2-Ethyl-7-hydroxy-4-methylhept-4-enoic Acid (400) 
  To a stirred solution of ester 396 (230 mg, 0.765 mmol) in THF (0.29 mL) at -
78  °C  was  added  a  freshly  prepared  mixture  (1:1  v/v)  of  trimethylsilyl  chloride-
triethylamine (1.16 mL), followed by a cooled (-30 °C) solution of LDA (1.1 mL, 
1.0M solution in THF, 1.1 mmol). The reaction mixture was stirred at -78 °C for 2 h, 
then was warmed to room temperature for 30 min and diluted with THF (3.0 mL). The 
solution was heated at reflux with stirring for 2 h. The reaction was quenched with a  
mixture (1:1) of AcOH and H2O (2.5 mL) and the resulting mixture was stirred for 4 h 
and extracted with Et2O (3 x 5.0 mL). The organic phase was washed with H2O (5.0  
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mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. Purification of 
the residue by flash chromatography (10% EtOAc in hexane) afforded carboxylic acid 
400 (96.6 mg, 68%) as a colorless oil: 
1H NMR (700 MHz, CDCl3) δ (ppm) 0.97 (t, J 
= 7.0 Hz, 3H), 1.51-1.55 (m, 1H), 1.65-1.70 (m, 1H), 1.68 (s, 3H), 2.20-2.28 (m, 2H), 
2.30-2.36 (m, 2H), 2.50-2.55 (m, 1H), 3.60-3.68 (m, 2H), 5.22 (t, J = 7.0 Hz, 1H); 
13C 
NMR  (175  MHz,  CDCl3)  δ  (ppm)  12.0,  16.1,  25.3,  31.2,  42.8,  46.4,  62.2,  122.6, 
136.1, 180.8. 
OH TBSO
OH
(±)-401                  
OH TBSO
OH
(±)-402  
(2S,4S,5R)-7-(tert-Butyldimethylsilyloxy)-2-ethyl-4-methylheptane-1,5-diol (401) 
and (2S,4R,5S)-7-(tert-Butyldimethylsilyloxy)-2-ethyl-4-methylheptane-1,5-diol 
(402) 
To a stirred solution of carboxylic acid 398 (100 mg, 0.333 mmol) in THF (0.3 
mL) at -25 °C was added BH3⋅THF (1.7 mL, 1M solution in THF, 1.7 mmol) and the 
resulting mixture was stirred at that temperature for 2 h. The reaction was quenched 
with saturated aqueous NH4Cl (0.17 mL) at -25 °C and a mixture of THF (1.7 mL) and 
H2O (1.7 mL) was added followed by NaBO3⋅4H2O (1.54 g). The mixture was stirred 
for 12 h and extracted with EtOAc (3 x 3 mL) and the combined organic extracts were 
dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by 
flash chromatography (30% EtOAc in hexane) to give an inseparable ∼1:1 mixture of  
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diols 401 and 402 (112 mg, quant.) as a colorless oil: IR (neat) 3423 (br), 3224 (br), 
2929, 2875, 1712, 1463, 1336, 1255, 1094, 836, 776, 665 cm
-1; 
1H NMR (400 MHz, 
CDCl3) δ (ppm) 0.10 (s, 6H), 0.88-0.92 (m, 6H), 0.92 (s, 9H), 1.20-1.71 (m, 8H), 
3.55-3.89 (m, 4H), 3.92-3.99 (m, 1H). 
TBSO
O
O
(±)-403                     
TBSO
O
O
(±)-404  
(3S,5S,6R)-6-(2-(tert-Butyldimethylsilyloxy)ethyl)-3-ethyl-5-methyl-
tetrahydropyran-2-one (403) and (3S,5R,6S)-6-(2-(tert-Butyldimethylsilyloxy) 
ethyl)-3-ethyl-5-methyl-tetrahydropyran-2-one (404) 
  To a stirred mixture of diols 401 and 402 (14.0 mg, 0.060 mmol), NMO (32.3 
mg, 0.276 mmol) and 4 Å MS in DCM (0.92 mL) at room temperature was added 
TPAP  (1.6  mg,  0.0046  mmol)  and  the  resulting  mixture  was  stirred  for  1  h.  The 
reaction  mixture  was  filtered  through  a  short  silica  column  and  the  filtrate  was 
evaporated.  The  residue  was  purified  by  flash  chromatography  (10%  EtOAc  in 
hexane) to afford an inseparable ∼1:1 mixture of lactones 403 and 404 (11.5 mg, 83%) 
as a brown oil: IR (neat) 2958, 2930, 2880, 2858, 1737, 1463, 1385, 1361, 1256, 1190, 
1163, 1091, 1006, 939, 836, 812, 777, 665 cm
-1; 
1H NMR (400 MHz, CDCl3) δ (ppm) 
0.07 and 0.08 (s, 6H), 0.91 (s, 9H), 096-1.05 (m, 6H), 1.41-1.51 (m, 1H), 1.59-1.70 
(m, 3H), 1.71-2.01 (m, 3H), 2.35-2.46 (m, 1H), 3.78-3.85 (m, 2H), 4.03-4.11 (m, 1H);  
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13C NMR (100 MHz, CDCl3) δ (ppm) -5.3, 11.0 and 11.6, 17.5 and 18.0, 18.3, 23.9 
and 24.8, 25.9, 29.7, 31.6, 32.6, 33.5, 34.2, 36.4, 36.8, 39.0, 42.2, 58.7 and 58.8, 79.9 
and 83.5, 173.8 and 175.8. 
NH2 TBSO
OH O
(±)-405                
NH2 TBSO
OH O
(±)-406  
(2S,4S,5R)-7-(tert-Butyldimethylsilyloxy)-2-ethyl-5-hydroxy-4-
methylheptanamide (405) and (2S,4R,5S)-7-(tert-Butyldimethylsilyloxy)-2-ethyl-
5-hydroxy-4-methylheptanamide (406) 
  To a stirred solution of lactones 403 and 404 (46.6 mg, 0.155 mmol) in DCM 
(6.5 mL) at room temperature was added freshly prepared Me2AlNH2 (1.6 mL, 1.2M 
solution  in  DCM,  1.86  mmol)  and  the  cloudy  mixture  was  stirred  for  3.5  h.  The 
mixture was diluted with DCM (3 mL) and the reaction was quenched with saturated 
aqueous NH4Cl (6 mL) followed by saturated aqueous sodium potassium tartrate (5 
mL). The mixture was stirred for 1 h and the aqueous layer was extracted with DCM 
(2 x 10 mL). The combined organic phase was washed with brine (15 mL), dried over 
anhydrous NaSO4, filtered and concentrated under reduced pressure. Purification of 
the crude product by flash chromatography (50% EtOAc in hexanes with 1% Et3N) 
furnished an inseparable ∼1:1 mixture of amides 405 and 406 (30.5 mg, 65%) as a 
colorless oil: IR (neat) 3350 (br), 3200, 2957, 2929, 2857, 1666, 1463, 1416, 1387, 
1361, 1299, 1255, 1090, 1006, 939, 836, 812, 777, 665 cm
-1; 
1H NMR (400 MHz,  
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CDCl3) δ (ppm) 0.09 (s, 6H), 0.82-0.95 (m, 6H), 0.91 (s, 9H), 1.45-1.68 (m, 6H), 
1.85-1.96 (m, 1H), 2.19-2.48 (m, 1H), 3.61-3.67 (m, 1H), 3.79-3.82 (m, 1H), 3.89-
3.95 (m, 1H), 5.68 (br s, 1H), 5.96 (br s, 1H); 
13C NMR (100 MHz, CDCl3) δ (ppm) -
5.5, 11.9, 15.9 and 16.3, 18.1, 25.9, 27.1, 34.9 and 35.0, 36.8 and 37.2, 46.3 and 46.7, 
63.3, 76.7 and 77.0, 178.5 and 179.2. 
NH2 TBSO
O O
(±)-407                 
TBSO
HN
O
(±)-408  
(2S,4S)-7-(tert-Butyldimethylsilyloxy)-2-ethyl-4-methyl-5-oxoheptanamide (407) 
and  (S)-6-(2-(tert-Butyldimethylsilyloxy)ethyl)-3-ethyl-5-methyl-3,4-
dihydropyridin-2(1H)-one (408) 
To  a  stirred  mixture  of  amides  405  and  406  (10.4  mg,  0.0328  mmol)  and 
NaHCO3 (8.3 mg, 0.0983 mmol) in DCM at 0 °C was added Dess-Martin periodinane 
(20.8  mg,  0.0491  mmol)  and  the  resulting  mixture  was  allowed  to  warm to  room 
temperature over 2 h. The reaction was quenched with saturated aqueous Na2S2O3 (1 
mL) and NaHCO3 (1 mL). The aqueous phase was extracted with DCM (3 x 2 mL) 
and the  organic  layer was  dried  over  anhydrous Na2SO4,  filtered  and  concentrated 
under reduced pressure. Purification of the crude product by flash chromatography 
(50% EtOAc in hexane) gave amide 407 (4.8 mg, 46%) as a colorless oil and lactam 
408 (3.2 mg, 33%) as a colorless oil.   
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407: 
1H NMR (400 MHz, CDCl3) δ (ppm) 0.09 (s, 6H), 0.95-0.99 (m, 3H), 
0.92 (s, 9H), 1.11 (d, J = 7.2 Hz, 3H), 1.40-1.70 (m, 4H), 1.80-2.10 (m, 2H), 2.20-2.35 
(m, 1H), 2.65-2.75 (m, 1H), 3.89-3.96 (m, 1H), 3.97-4.02 (m, 1H), 5.73 (br s, 1H), 
5.92 (br s, 1H); 
13C NMR (100 MHz, CDCl3) δ (ppm) -5.3, 12.0, 17.5, 22.7, 29.7, 
32.0, 35.2, 43.5, 44.2, 45.9, 58.7, 178.0, 213.5.  
408: 
1H NMR (400 MHz, CDCl3) δ (ppm) 0.08 (s, 6H), 0.92 (s, 9H), 0.99 (t, J 
= 7.2 Hz, 3H), 1.40-1.51 (m, 2H), 1.72 (s, 3H), 1.72-180 (m, 1H), 2.01-2.11 (m, 1H), 
2.23-2.35 (m, 3H), 3.72-3.75 (m, 2H), 7.15 (br s, 1H); 
13C NMR (100 MHz, CDCl3) δ 
(ppm) -5.5, 11.5, 17.3, 18.2, 22.7, 25.9, 32.3, 32.4, 41.1, 62.1, 108.1, 128.1, 173.1. 
OPMB TBSO
OH TBSO
O
251       
TBSO
TBSO
OPMB
O
O
TMS
411  
(2S,6R,7R,8R,9S,E)-7-(4-Methoxybenzyloxy)-9,11-bis(tert-butyldimethylsilyloxy)-
2-ethyl-4,6,8-trimethylundec-4-enoic Acid (251) and (3R,4S,5R,6R,7S)-5-(4-
Methoxybenzyloxy)-7,9-bis(tert-butyldimethylsilyloxy)-2,4,6-trimethylnon-1-en-3-
yl 2-(Trimethylsilyl)butanoate (411) 
  To a stirred solution of ester 252 (84.0 mg, 0.129 mmol) in THF (0.05 mL) at  
-78 °C was added a freshly prepared  mixture (1:1 v/v) of trimethylsilyl chloride-
triethylamine (0.20 mL), followed by a cooled (-30 °C) solution of LDA (0.18 mL, 
1.0M solution in THF, 0.18 mmol). The reaction mixture was stirred at -78 °C for 2 h,  
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then was warmed to room temperature for 30 min and diluted with THF (1.0 mL). The 
solution was heated at reflux with stirring for 4 h, then was cooled and diluted with 
Et2O (2.0 mL). A mixture of H2O (0.25 mL) and AcOH (0.25 mL) was added and the 
resulting mixture was stirred overnight and extracted with Et2O (3 x 3.0 mL). The 
combined  organic  phase  was  washed  with  H2O  (2.0  mL),  dried  over  anhydrous 
Na2SO4, filtered, and concentrated in vacuo. Purification of the crude product by flash 
chromatography (5% EtoAc in hexane) provided carboxylic acid 251 (8.3 mg, 10%) as 
a colorless oil and ester 411 (35.4 mg, 42%) as a colorless oil.  
251: [α]D
27 -11.6 (c 0.95, CHCl3); IR (neat) 3200-2500 (br), 2956, 2929, 2857, 
1708, 1612, 1514, 1463, 1387, 1361, 1252, 1171, 1090, 1005, 940, 836, 775 cm
-1; 
1H 
NMR (700 MHz, CDCl3) δ (ppm) -0.02 (s, 3H), 0.02 (s, 3H), 0.08 (s, 3H), 0.09 (s, 
3H), 0.88 (s, 9H), 0.89-0.91 (m, 6H), 0.94 (s, 9H), 1.00 (d, J = 7.0 Hz, 3H), 1.49-1.55 
(m, 2H), 1.55-1.63 (m, 2H), 1.65 (s, 3H), 1.78-1.81 (m, 1H), 2.10-2.15 (m, 1H), 2.30-
2.33 (m, 1H), 2.5 (br s, 1H), 2.57-2.63 (m, 1H), 3.09-3.12 (m, 1H), 3.60-3.70 (m, 1H), 
3.70-3.78 (m, 2H), 3.82 (s, 3H), 4.52 (AB quartet, 2H), 5.40 (d, J = 7.7 Hz, 1H), 6.90 
(d, J = 7.0 Hz, 2H), 7.30 (d, J = 7.0 Hz, 2H); 
13C NMR (175 MHz, CDCl3) δ (ppm) -
5.2, -4.9, -4.4, 10.1, 12.0, 16.0, 18.1, 18.5, 25.4, 25.9, 34.8, 35.7, 42.8, 42.9, 43.0, 
55.3, 60.4, 69.5, 74.8, 85.2, 113.6, 129.1, 129.3, 131.3, 131.9, 159.0, 181.0; HRMS 
(ES) calcd for C32H67O6Si2 [M+H]
+ m/z 651.4476, found m/z 651.4483.  
  411: IR (neat) 2956, 2921, 2857, 1716, 1656, 1614, 1587, 1515, 1471, 1387, 
1360, 1344, 1303, 1251, 1223, 1173, 1089, 1038, 1006, 967, 945, 836, 775, 663 cm
-1;  
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1H NMR (700 MHz, CDCl3) δ (ppm) 0.06 (s, 3H), 0.07 (s, 3H), 0.11 (s, 3H), 0.12 (s, 
3H), 0.14 (s, 9H), 0.88 (d, J = 4.2 Hz, 3H), 0.91 (s, 9H), 0.91 (d, J = 7.0 Hz, 3H), 0.93 
(s, 9H), 0.99 (t, J = 7.0 Hz, 3H), 1.50-1.56 (m, 1H), 1.62-1.69 (m, 2H), 1.78 (s, 3H), 
1.85-1.91 (m, 3H), 1.98-2.02 (m, 1H), 3.36 (d, J = 7.7 Hz, 1H), 3.70-3.79 (m, 2H), 
3.82 (s, 3H), 3.97-4.00 (m, 1H), 4.39 (d, J = 9.8 Hz, 1H), 4.48 (d, J = 9.8 Hz, 1H), 
4.95 (s, 1H), 4.97 (s, 1H), 5.57 (d, J = 4.9 Hz, 1H), 6.89 (d, J = 8.4 Hz, 2H), 7.35 (d, J 
= 8.4 Hz, 2H); 
13C NMR (175 MHz, CDCl3) δ (ppm) -5.4, -4.2, -4.0, -2.1, 7.9, 10.7, 
15.4, 18.2, 19.8, 20.4, 26.0, 26.1, 36.0, 37.7, 39.9, 41.1, 55.3, 59.5, 72.5, 73.0, 76.4, 
80.4,  112.8,  113.7,  129.6,  130.9,  143.1,  159.0,  174.7;  HRMS  (ES)  calcd  for 
C39H75O6Si3 [M+H]
+ m/z 723.4872, found m/z 723.4843.    
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CHAPTER 7: CONCLUSION 
 
The studies described in this dissertation outline a conceptually novel approach 
to  sanglifehrin  A.  The  key  features  in  our  approach  are  a  Masamune  anti-aldol 
reaction to set in place the C14-C15 configuration of iodo acid 242, an asymmetric 
catalytic phase-transfer method to introduce an α-amino function in the synthesis of L-
m-tyrosine derivative 331 and a double asymmetric crotylation to assemble an array of 
alternating oxygen and methyl functionalities along the C33-C36 backbone. Although 
an attempt to close vinyl boronate 358 to macrolactone 239 using Suzuki-Miyaura 
cross coupling was unsuccessful, modification of the reaction conditions hold promise 
for the completion of this subunit of sanglifehrin A. A model study with 396 in which 
Ireland-Claisen rearrangement was shown to yield 398 could not be extrapolated to 
butyrate 252 efficiently. This leaves in question our planned route to spirolactam 386 
and an eventual total synthesis of SFA along lines laid out in Scheme 3.1. Further 
studies will be needed before a plausible synthesis of this complex structure can be 
charted. 
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